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The ERK pathway, a ubiquitously expressed signal transduction module that 
mediates cellular responses to a variety of stimuli, is activated in gonadotropes 
following stimulation with the hypothalamic decapeptide GnRH.  Several lines of 
evidence suggest that ERK signaling is important for gonadotrope function; however, 
little is known regarding the role of ERK signaling in these cells in vivo.  The studies 
described here address aspects of the functional organization and requirement for ERK 
signaling in differentiated gonadotropes and the role of  ERK activity within the 
reproductive axis in vivo. 
 ERK 2 associated partially and constitutively with low buoyant density 
membranes (membrane rafts) following fractionation of both T3-1 gonadotrope cells 
and murine pituitaries.  Following treatment with GnRH agonist, activated ERKs were 
recovered in association with low-density membranes.   ERK2 coimmunoprecipitated 
with the GnRHR from these fractions suggesting that coupling of the GnRHR to the 
ERK signaling pathway may involve the formation of signaling complexes associated 
with membrane rafts. 
 To examine the requirement for ERK signaling within gonadotropes in vivo, a 
mouse model with a pituitary-targeted ablation of ERK1 and ERK2 was generated.  
ERK deficient male mice were fertile while females demonstrated anovulatory 
infertility associated with a deficiency of luteinizing hormone (LH).  The mechanism 
 underlying this gender-specific phenotype was linked to impaired transcriptional 
upregulation of the ERK-dependent transcription factor Egr-1 which is required for 
LH biosynthesis. 
  Finally, to explore the role of ERK signaling in upregulation of immediate 
early response genes in the gonadotrope, we examined expression of the orphan 
nuclear receptor Nur77.  Our results establish Nur77 as an ERK-dependent, GnRH-
responsive immediate early gene in the gonadotrope.   Analysis of the signaling 
activities required for Nur77 upregulation led to the unexpected finding that c-Raf 
kinase is not required for GnRH-induced activation of the ERK pathway.  Mice with a 
pituitary-targeted conditional ablation of c-Raf were viable and fertile.  Transcriptional 
upregulation of Nur77 was unimpaired in gonadotropes from these mice, while being 
blocked in gonadotropes from mice with pituitary disruption of ERK1 and 2.   
These results confirm the requirement for ERK signaling for gonadotrope 
function, and shed new light on the organization of this pathway in the gonadotrope as 
well as its role in the sexually dimorphic regulation of reproductive function. 
 iii 
BIOGRAPHICAL SKETCH 
 
Stuart Bliss was born in 1964 in Ithaca, New York.  His secondary education 
took place in both the mid-Hudson Valley in New York, and Brussels, Belgium.  He 
attended Bates College in Lewiston, Maine from 1982 through 1984, and after a brief 
hiatus from higher education, completed a BA degree from the State University of 
New York at Albany in 1988 with majors in philosophy and music.  He then 
completed a post-baccalaureate premedical basic science curriculum at the same 
University from 1990 through 1991, and entered the College of Veterinary Medicine 
at Cornell University in 1992.  He earned the DVM degree from Cornell in 1996.  
From 1996 through 2001 he completed a one-year rotating clinical internship at the 
College of Veterinary Medicine at North Carolina State University, three years of 
residency training in small animal surgery at the College of Veterinary Medicine at 
Cornell University, and a one-year fellowship in small animal clinical orthopedics, 
also at Cornell.  Stuart earned board certification from the American College of 
Veterinary Surgeons in 2003.   
In 2001 Stuart matriculated in the Program in Comparative Medicine at 
Cornell University, joining the laboratory of Dr. Mark Roberson in early 2002.   
  
 
 
 
 
 
 
 
 iv 
ACKNOWLEDGMENTS 
 
 Many thanks to Dr. Mark Roberson for his patience and mentorship during the 
period over which this work was performed.  Also thanks to the members of my 
Graduate Committee: Drs. David Holowka, Lee Kraus, and Bud Tennant, for their 
time and attention to this work.   
 The contributions of numerous other individuals are also gratefully 
acknowledged:  Dr. Amy Navratil and Jian Jun Xie helped with many aspects of this 
work.  Dr. Tim O’Brien and members of his laboratory, in particular Ian Welsh, 
provided many insightful discussions, and invaluable assistance with the gene 
profiling experiments.  Dr. Ned Place provided helpful and critical review of the data 
presented in Chapter 3.  Patricia Fisher provided special expertise with 
immunocytochemical and immunoflourescence techniques and microscopy.  Thanks 
also to Dr. Micheal Kotlikoff for mice and reagents.  Special thanks to Drs. Mark 
Rishniw, Joe Wakshlag, and Bruce Kornreich for cells, reagents, and perspective.  The 
assistance of Kathy Mott and other members of the CARE staff with all aspects of 
animal care is also greatly appreciated.  I would also like to recognize members of the 
Department of Clinical Sciences for support and opportunities during the past several 
years. 
 
 
 
 
 
 v 
TABLE OF CONTENTS 
 
          Page 
BIOGRAPHICAL SKETCH        iii 
ACKNOWLEDGEMENTS        iv 
TABLE OF CONTENTS        v 
LIST OF FIGURES         viii 
LIST OF ABBREVIATIONS       x 
CHAPTER ONE   REVIEW OF THE LITERATURE    1 
1.  Introduction         2 
2.  The mammalian hypothalamic-pituitary-gondal (HPG) axis   2 
 2.1  Hypothalamic secretion of GnRH     5 
 2.2  Feedback regulatory mechanisms in the HPG axis   6 
3.  Developmental background of the gonadotrope     8 
 3.1 Basic mechanisms of pituitary morphogenesis    9 
 3.2  Developmental specification and differentiation of the  
       gonadotrope lineage       11 
4.  Molecular basis of the response of the gonadotrope to GnRH   12 
 4.1  Experimental models used in the study of gonadotrope function 12 
 4.2  Structural and functional aspects of the GnRH receptor   13 
 4.3  GnRH-induced signal transduction in the gonadotrope   16 
  4.3.1  Membrane associated signaling events    17 
  4.3.2  Membrane rafts and the GnRH receptor   19 
  4.3.3  Calcium signaling in the gonadotrope    28 
  4.3.4  GnRH-induced MAP kinase activation   29 
 
 vi 
5. The ERK signaling pathway       30 
 5.1  Mechanisms of ERK activation by G-protein coupled receptors 33 
 5.2  Mechanisms of GnRH-induced ERK activation in the gonadotrope 35 
 5.3  Importance of ERK signaling for gonadotrope function   36 
6. Summary and study aims        37 
References          39 
 
CHAPTER TWO    SIGNALING COMPLEXES ASSOCIATED WITH THE  
 TYPE I GnRH RECEPTOR: COLOCALIZATION OF ERK2 AND  
GnRH RECEPTOR WITHIN MEMBRANE RAFTS 
Summary          57 
Introduction          58 
Materials and methods        60 
Results          66 
Discussion          87 
References          93 
 
CHAPTER THREE    ERK SIGNALING IN THE PITUITARY IS REQUIRED 
 FOR FEMALE BUT NOT MALE FERTILITY 
Summary           99 
Introduction                    100 
Materials and methods                  102 
Results                    107 
Discussion                    128 
References                    132 
 
 vii 
CHAPTER FOUR    ERK SIGNALING, BUT NOT C-RAF, IS REQUIRED FOR  
 GONADOTROPIN-RELEASING HORMONE (GNRH) INDUCTION OF  
 NUR77 IN PITUITARY GONADOTROPES 
Summary                   138 
Introduction                   139 
Materials and methods                          140 
Results                   147 
Discussion                   170 
References                   175 
 
CHAPTER FIVE    CONCLUSIONS AND FUTURE DIRECTIONS         
Body                    182 
 
References                   189 
 
 viii 
LIST OF FIGURES 
Page 
 
Figure 2.1 GnRHR co-localizes with GM1 positive membrane domains  
in αT3-1 cells.        68 
Figure 2.2 Validation of GnRHR antiserum.     71 
Figure 2.3  ERK2 associates with detergent-resistant, low-density  
membrane fractions in αT3-1 cells.     74 
Figure 2.4 GnRHa stabilizes the association of ERK2 with detergent- 
resistant, low density membrane domains in αT3-1 cells.    75 
Figure 2.5 In αT3-1 cells, GnRHR and ERK2 associate with low-density 
membrane domains isolated in the absence of detergent.    77 
Figure 2.6 Normalization of cellular cholesterol restores the association of  
ERK2 with low-density membrane domains in αT3-1 cells  
following cholesterol depletion, but this is not sufficient to  
reconstitute cholesterol-dependent ERK inducibility by GnRH.   81 
Figure 2.7 GnRH receptor and ERK2 co-immunoprecipitate from low- 
density membrane fractions in αT3-1 cells.    84 
Figure 2.8 GnRHR and ERK2 co-immunoprecipitate from detergent- 
resistant, low-density membranes in whole mouse pituitaries.   86 
Figure 3.1 Generation and validation of the pituitary-targeted ERK1/2  
double knockout mouse.               109    
Figure 3.2 Assessment of estrous cycle activity in the ERK1/2 DKO mouse.  112 
Figure 3.3 Evaluation of thyroid function in the ERK1/2 DKO mouse.           115 
Figure 3.4 Basal expression of gonadotropin subunit and GnRHR genes  
in the ERK1/2 DKO mouse.                 118 
 ix 
Figure 3.5 Pharmacological superovulation rescues the anovulatory  
phenotype of the ERK1/2 DKO mouse.            120 
Figure 3.6 ERK1/2 DKO of both genders fail to upregulate LH  following 
  gonadectomy.               122 
Figure 3.7 Serum gonadotropin levels do not increase in DKO animals 
of either gender following gonadectomy.           123  
Figure 3.8  ERK-deficient gonadotropes fail to upregulate the immediate  
early gene Egr1 in response to GnRH stimulation.           126 
Figure 4.1 Upregulation of Nur77 in T3-1 and primary pituitary cells  
following stimulation with GnRHa.              149 
Figure 4.2 Nuclear localization of Nur77 in mouse pituitary gonadotropes  
in vivo.                  151 
Figure 4.3 ERK signaling is required, but not sufficient, for GnRH-induced 
transcriptional upregulation of Nur77 in T3-1 cells.         154 
Figure 4.4 Pharmacological analysis of Nur77 upregulation in T3-1 cells.  157 
Figure 4.5 Comparative effects of c-Raf inhibition and c-Raf dominant 
negative overexpression on GnRH- and EGF-induced ERK  
activation in T3-1 and NIH-3T3 cells.           160 
Figure 4.6 Effects of siRNA-mediated c-Raf knockdown on GnRH-induced  
ERK activation in T3-1 cells.              163 
Figure 4.7 Validation of the pituitary-targeted conditional c-Raf knockout 
mouse.                166 
Figure 4.8 GnRHa- or CRH-induced transcriptional upregulation of Nur77  
in primary mixed pituitary cell cultures from mice with  
pituitary-targeted ablation of either c-Raf, or ERK1/2.         169
 x 
  LIST OF ABBREVIATIONS 
 
GnRH Gonadotropin-releasing hormone 
GnRHR Gonadotropin-releasing hormone receptor 
GPCR G protein-coupled receptor 
GPKR G protein-coupled receptor kinase 
MAPK Mitogen-activated protein kinase 
MAPKK Mitogen-activated protein kinase kinase 
MAPKKK  Mitogen-activated protein kinase kinase kinase 
MEK MAP kinase ERK kinase 
MKP MAP kinase phosphatase 
RTK Receptor tyrosine kinase 
ERK Extracellular Signal-regulated kinase 
RSK Ribosomal S6 kinase 
KSR Kinase suppressor of ras 
JNK Jun-n-terminal kinase 
LH Luteinizing hormone 
LHR Luteinizing hormone receptor 
FSH Follicle stimulating hormone 
FSHR Follicle stimulating hormone receptor 
GSU Glycoprotein hormone alpha subunit 
cAMP Cyclic-adenosine monophosphate 
ACTH Adrenocorticotropic hormone 
TRH Thyrotropin-releasing hormone 
TSH Thyroid-stimulating hormone 
BMP Bone morphogenic protein 
 xi 
FGF Fibroblast growth factor 
EGF Epidermal growth factor 
NGF Nerve growth factor 
SF1 Steroidogenic factor 1 
IP3 Inositol triphosphate 
DAG Diacylglycerol 
PLC Phospholipase 
PKA Protein kinase A 
PKC Protein kinase C 
BAR Beta-adrenergic receptor 
VGCC Voltage-gated calcium channel 
IGF Insulin-like growth factor 
DRM Detergent-resistant membranes 
PLAP Placental alkaline phosphatase 
MHC Major histocompatability complex 
TCR T-cell receptor 
MBCD Methyl-beta-cyclodextrin 
FRET Fluorescence resonant energy transfer 
ESR Electron spin resonance 
ER Endoplasmic reticulum 
CD Common docking 
MMP Matrix metalloproteinase 
ADAM Alpha-disintegrin and transmembrane metalloproteinase 
1 
CHAPTER 1 
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1. Introduction: 
In mammals, reproductive competence depends on the coordinated activity of 
an intercommunicating set of endocrine tissues and organs referred to as the 
hypothalamic-pituitary gonadal (HPG) axis.  The gonadotrope cell of the anterior 
pituitary plays a particularly critical role within this system as the intermediary 
between the hypothalamic GnRH signal and the germ cell reservoirs and steroid 
hormone productivity of the gonads.  The mechanisms underlying the response of the 
gonadotrope to hypothalamic GnRH are thus of critical importance to our 
understanding of the molecular basis of reproductive function.   
Expression of the GnRH receptor is a defining characteristic of the 
gonadotrope.  Binding of GnRH to its receptor triggers a complex array of 
intracellular signal transduction events within the gonadotrope; these signaling 
cascades orchestrate the overall physiological response of these cells to GnRH 
stimulation.  The extracellular-signal regulated kinase (ERK) signaling pathway is a 
conserved signal transduction module that is strongly activated in gonadotropes 
following GnRH stimulation.  ERK signaling is generally understood to be important 
for gonadotrope function; however, much remains to be learned regarding the 
mechanisms and consequences of GnRH-induced ERK activation in these cells, 
especially within the intact endocrine milieu of the living animal.   
 
2. The mammalian hypothalamic-pituitary-gonadal (HPG) axis 
In the classical view, the HPG axis is depicted as a tiered and linearly 
organized set of endocrine tissues that is dedicated to the regulation and support of 
reproductive activity (1).  This axis consists of a subset of hypothalamic neurons that 
express the decapeptide hormone gonadotropin-releasing hormone (GnRH), the 
gonadotrope cells of the anterior pituitary, and the gonads.  Activation of this 
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endocrine axis commences with the pulsatile secretion of GnRH from the 
hypothalamus.  GnRH is delivered to the anterior pituitary at high concentration via 
the hypophyseal portal circulation where it binds to GnRH receptors (GnRHR) on the 
surface of gonadotropes triggering the synthesis and secretion of the gonadotropins 
follicle-stimulating hormone (FSH), and luteinizing hormone (LH).  The 
gonadotropins are dimeric glycoprotein hormones composed of distinct  subunits 
paired with a common  subunit ( GSU).  The genes for FSH  and LH , together 
with the GSU and the GnRHR comprise the genetic signature of the differentiated 
gonadotrope.  In the male, LH stimulates production of testosterone and androgen-
binding protein by testicular Leydig cells and Sertoli cells, respectively.  In the female, 
LH stimulates the production of androgens by the thecal cells that surround the 
growing ovarian follicle.  FSH binds to receptors on the surface of ovarian granulosa 
cells stimulating the expression of aromatase enzymes that convert thecal androgens to 
estradiol.  During the terminal stages of follicular growth, LH also drives the 
production of progesterone from the granulosa cells of the preovulatory follicle (2).   
 Several animal models have provided insights into the functional organization 
of the HPG axis.  The hypogonadal (HPG) mouse fails to produce GnRH due to a 
deletion mutation in the gene encoding the GnRH precursor peptide (3).  HPG mice 
never enter puberty and display a persistent hypogonadotropic hypogonadal phenotype 
which is nevertheless able to be rescued by knockin of a functional GnRH gene (4).  
Early studies in sheep showed that surgical ablation of the pituitary stalk 
(hypothalamic-pituitary disconnection, HPD) led to dramatic decreases in pituitary 
secretion of the gonadotropins and secondary hypogonadism (5, 6).  Pulsatile 
administration of GnRH to these animals reestablished appropriate pulsatile 
gonadtropin secretion and fertility while continuous administration of GnRH led to 
virtual cessation of pituitary gonadotropin production (7). 
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In mice, elimination of the gene for either LH , or the LH receptor (LHR), 
leads to infertility in both genders associated with marked decreases in gonadal steroid 
hormone production, along with defective spermatogenesis and late follicular 
developmental arrest (8, 9).  FSH levels are normal in these mice and the hypogonadal 
phenotype is able to be rescued by exogenous LH.  In contrast, female mice lacking 
the gene for FSH  are infertile due to a defect in ovarian follicular maturation; 
however, males remain fertile, despite decreased testicular size and sperm production 
(10).  Similarly, the phenotype of female mice lacking the FSH receptor (FSHR) is 
similar to that of the FSH -deficient animal (infertility due to follicular developmental 
arrest) (11, 12).  However, in males, loss of the FSHR leads to a greater impairment of 
gonadal function than in FSH  nulls, with significant decreases in Leydig cell 
numbers and levels of circulating testosterone (13).  It has been suggested that the 
more severe phenotype displayed by FSHR deficient animals as compared with those 
lacking FSH itself, is indicative of constitutive and physiologically important ligand-
independent activity of gonadal FSHR populations (13). 
In addition to information gained from animal models, many naturally-
occuring human diseases provide insight into the HPG axis function.  Kallmann 
Syndrome (KS) is a form of hypogonadotropic hypogonadism that results from a 
failure of migration of GnRH neurons from the olfactory epithelium to the 
hypothalamus during development and the consequent lack of hypothalamic GnRH 
production (14).  Individuals with KS typically are anosmic (deficient in the sense of 
smell) due to hypoplasia or aplasia of the olfactory tracts and in addition may display a 
variety of developmental abnormalities including dental or renal agenesis, palate 
defects, digit malformations and hearing loss (15).   Several specific mutations have 
been identified that collectively account for approximately 30% of reported cases of 
KS.  The most severe form of the disease (KAL1) is an X chromosome-linked 
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condition associated with a loss-of-function mutation in the KAL1 gene that encodes 
the protein anosmin-1 (14, 16).  Anosmin-1 is a secreted multidomain glycoprotein 
that is thought to guide developing axonal projections during morphogenesis of the 
olfactory system in part through stabilization of growth factor-receptor complexes, 
especially complexes between fibroblast growth factors (FGFs) and their receptors 
(FGFRs) (17, 18).  Since olfactory axonal tracts function as a pathway along which 
nascent GnRH neurons migrate from their origin in the olfactory epithelium to the 
hypothalamus, disturbances in the development of the olfactory system may interfere 
with the ability of GnRH neurons to populate the hypothalamus.  This leads to GnRH 
deficiency and hypogonadotropic hypogonadism.  Loss-of-function mutations in 
FGFR1 have also been associated with an autosomal dominant form of KS (KAL2); 
however this form of the disease is incompletely penetrant, indicating a more complex 
and probably oligogenic basis (19, 20). 
Mutations in the gene encoding the human GnRHR have been discovered that 
lead to hypogonadotropic hypogonadism of variable severity (21).  It has been shown 
that some mutations of the GnRHR lead to misfolding and abnormal intracellular 
trafficking of the newly synthesized protein that results in failure of receptor 
expression (22).  This is discussed in more detail in section 4.1 below.  Inactivating 
mutations in the genes for LH  and FSH  as well as their receptors have also been 
reported.  These mutations are generally associated with hypogonadal phenotypes, and 
given their adverse effects on reproductive function, are understandably rare (21).    
 
2.1 Hypothalamic secretion of GnRH 
 The release of GnRH from the hypothalamus is inherently pulsatile, and this 
pulsatility is required for appropriate gonadotropin production by the pituitary (23).  
Both the amplitude and frequency of GnRH pulses are tightly regulated and, in the 
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female, vary dramatically over the course of the reproductive cycle (23).  Rapid GnRH 
pulsatility has been shown to promote synthesis and secretion of LH, while slower 
GnRH pulsatility favors production and release of FSH (24).   The corresponding 
oscillations in plasma levels of the gonadotropins may further reflect the shorter 
circulatory half-life of LH as compared to FSH. 
The importance of GnRH pulsatility was first demonstrated in 1978 in 
experiments in Rhesus monkeys with surgically created lesions of the basomedial 
hypothalamus that eliminated the GnRH neurons (25).   Continuous administration of 
exogenous GnRH to these animals led to decreased production of gonadotropins and 
hypogonadism, while pulsed administration of GnRH at hourly intervals restored 
gonadal function and reproductive cyclicity (26).  The suppression of pituitary 
responsiveness to GnRH following continuous exposure is now known to be caused 
by downregulation of GnRHR‟s at the level of the gonadotrope, although the precise 
mechanism by which this downregulation occurs remains unclear.  Downregulation of 
GnRHR‟s by continuous GnRH exposure forms the basis for the clinical use of long-
acting GnRH analogs that are prescribed during infertility treatments (27).   
  
2.2 Feedback regulatory mechanisms in the HPG axis 
The HPG axis is subject to both positive and negative feedback regulation at 
several levels.  At the level of the hypothalamus, early recognition of the pulsatile 
nature of GnRH secretion led to the notion of a central “pulse generator”, the inherent 
oscillatory activity of which controls the secretory rhythm of GnRH neurons (28).  
Anatomically, this pulse generator is located predominantly within the anteroventral 
paraventricular nucleus (AVPV) of the hypothalamus.  Interestingly, studies from 
dispersed hypothalamic neurons in primary culture suggest that pulsatile secretion of 
GnRH may be an inherent property of the neurons themselves (29).  Moreover, 
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populations of GnRH neurons may be capable of broad scale synchronization of 
GnRH pulsatility, and this synchronization does not appear to require direct 
intercellular contact (30).  GnRH neurons express the GnRHR, which couples to 
different intracellular heterotrimeric G-proteins in a manner dependent on ligand dose 
(31).  These observations have led to a simplified model in which low doses of GnRH 
may exert positive autocrine and paracrine feedback effects on neuronal GnRH 
secretion through GnRHR-G s-induced increases in intracellular cyclic adenosine-
monophosphate (cAMP) levels.  The resulting increase in GnRH secretion 
subsequently propels dramatic further positive feedback effects by driving GnRHR-
G q/11-induced increases in intracellular calcium.  However, once the concentration of 
extracellular GnRH reaches a sufficiently high (threshold) level, GnRHR-G i-
mediated signaling pathways are preferentially activated, leading to negative feedback 
suppression of secretory activity (32). 
Regardless of the extent to which oscillatory release of GnRH is an inherent 
property of the GnRH neurons, it is clear that the hypothalamic pulse generator is 
modulated by a multitude of inputs, in particular androgens and estrogens (33).  In the 
male, testosterone exerts negative feedback effects primarily on the release of GnRH 
from the hypothalamus (34).  A minor negative feedback effect may also be exerted at 
the level of the gonadotrope (34).  In the female, the feedback effects of gonadal 
steroids on HPG function are more complex and depend on the stage of the 
reproductive cycle.  During the follicular phase, estrogen downregulates both the pulse 
frequency and pulse amplitude of GnRH release from the hypothalamus, through a 
direct inhibitory effect on GnRH neurons (35).  This leads primarily to suppression of 
LH production by the gonadotrope (36).  During this phase estrogen also 
downregulates LH production through direct effects on the gonadotrope.  However, 
during the preovulatory period, the effects of estrogen on both the hypothalamus and 
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the pituitary become positive (37).  This positive effect of estrogen on GnRH 
production is indirect, mediated by afferent estrogen-sensitive neurons of the AVPV 
that synapse on the GnRH neurons (35).  This leads to rapid and significant increases 
in hypothalamic GnRH secretion culminating in the massive preovulatory release of 
LH from the pituitary (LH surge) that is the definitive trigger of ovulation.    
The predominant negative inhibitory effects of gonadal steroids on 
hypothalamic GnRH production provide a useful means for manipulation of the 
hypothalamic-pituitary system in experimental animals.  For example, removal of the 
gonads upregulates GnRH production by the hypothalamus due to the disinhibitory 
effects of decreased gonadal steroid levels (38, 39).  Gonadectomy thus subjects the 
gonadotrope to a physiologically appropriate pulsatile GnRH hyperstimulation in vivo, 
an effect that is impossible to recapitulate within a cell culture system.  This strategy 
was employed in the studies described in Chapter 3 of this dissertation.  
 
3. Developmental background of the gonadotrope  
 The anterior lobe of the pituitary is composed of five discrete hormone 
producing cell types; in addition to the gonadotrope, the corticotrope, thyrotrope, 
somatotrope, and lactotrope cells respond to distinct hypothalamic releasing factors 
and produce adrenocorticotrophic hormone (ACTH), thyroid-stimulating hormone 
(TSH), growth hormone (GH), and prolactin (PRL), respectively.  During 
embyrogenesis, these hormone-producing cell lineages develop from a common 
pituitary primordium in a highly regulated spatial and temporal progression.  The 
distinct phenotypes expressed by these cells vis-a-vis their hormone production has 
made the pituitary a useful model system in which to study basic mechanisms of 
cellular differentiation and organogenesis in vivo.  A comprehensive review of 
pituitary development is beyond the scope of this dissertation; however, several basic 
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concepts related to the development of pituitary cell types are integral to the 
hypotheses and experimental approaches described below in chapters 3 and 4, and are 
therefore outlined here in brief.  Pituitary development is reviewed in detail in ref. 
(40). 
 
 3.1 Basic mechanisms underlying pituitary morphogenesis 
 The pituitary is an ectodermal derivative that arises from the most anterior 
portion of the cranial placodes at the midline region of the neural plate.  Expansion 
and bending of the forebrain structures early in development repositions this placodal 
ectoderm to the roof of the oral cavity.  At e8.5 in the mouse, this ectodermal region 
undergoes a dorsal invagination to form Rathke‟s pouch, the anatomical precursor of 
the anterior and intermediate lobes of the pituitary.  The ectodermal region destined to 
undergo invagination is marked by a lack of expression of the morphogen sonic 
hedgehog (shh) which is otherwise expressed throughout the surrounding ectoderm.  
Simultaneously, a ventral outgrowth of the overlying diencephalon occurs (the 
infundibulum) which is destined to become the posterior pituitary.  Expression of bone 
morphogenic protein 4 (BMP4) by the adjacent overlying region of diencephalon has 
been shown to be a critical inductive stimulus for the initial invagination of Rathke‟s 
pouch, and close contact between Rathke‟s pouch and the infundibulum is necessary 
for subsequent morphogenesis of the gland.  
Shortly after the appearance of Rathke‟s pouch, diencephalic expression of 
members of the fibroblast growth factor (Fgf) family, specifically Fgf‟s 8, 10, and 18 
commences, while diencephalic production of BMP4 subsides.  Concurrently, BMP2 
begins to be expressed at the boundary region between Rathke‟s pouch and the 
surrounding oral ectoderm.  The LIM homeodomain transcription factors Lhx3, Lhx4, 
and Isl1 are also expressed within the pouch at this time where they function to 
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maintain pouch cells in an undifferentiated state while contributing to the ensuing 
proliferative expansion of the pituitary primordium and final separation of the pouch 
from the oral ectoderm.  These dorso-ventral gradients of diencephalic Fgf signals, 
combined with shh and BMP2 from the oral ectoderm and adjacent pouch region, 
provide important morphogenic cues that guide expansion and shaping of the gland.  
FGF8 is of particular importance in this process.  Experiments using explants of 
Rathke‟s pouch in primary culture indicate that Fgf8 alone is able to recapitulate the 
effects of the entire diencephalic infundibular region with respect to maintenance of 
Lhx expression, repression of Isl1 expression, and pouch cell proliferation (41).  It 
thus stands to reason that the intracellular signal transduction cascades that mediate 
the cellular effects of Fgf‟s are critical to the process of early pituitary morphogenesis. 
 Proliferative expansion of the pituitary primordium and sequential appearance 
of lineage-committed cell types of the anterior portion of the gland occurs from e9.5 
through approximately e13.5.  These processes are dependent upon tightly regulated 
spatiotemporal expression of numerous transcription factors (42).  The GSU is the 
first hormonal subunit gene to be expressed within the developing pituitary, appearing 
in the ventral region of Rathke‟s pouch at e10.5 (40).  The distribution and timing of 
GSU promoter activation has been studied in transgenic mice using reporters linked 
to various portions of the GSU promoter.  A 381 base pair fragment of the murine 
GSU promoter is sufficient to direct gonadotrope and thyrotrope specific reporter 
expression within the developing pituitary; however, higher levels of expression are 
obtained with the use of a 4.6 kb promoter region that incorporates an upstream 
enhancer element (43).  One study using this 4.6 kb GSU promoter fragment showed 
reporter expression as early as e9.5 throughout the pituitary primordium (44).  The 
possibility of such early, promiscuous, or misregulated activation of this transgenic 
promoter fragment during development is important in relation to the studies described 
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in chapters 3 and 4 below, where in vivo genetic recombination was accomplished 
using this same 4.6 kb promoter to regulate expression of Cre recombinase. 
  
3.2 Developmental specification and differentiation of the gonadotrope lineage  
The developmental events underlying fate specification of the gonadotrope 
lineage remain largely unclear.  This is in contrast to other pituitary lineages such as 
the thyrotrope, somatotrope and lactotrope cells (the Pit-1 lineages) whose 
development and differentiation are dependent on expression of the POU domain 
containing transcription factor Pit-1 (45).  The orphan nuclear receptor steroidogenic 
factor-1 (SF1) is first expressed at e13.5 and is the first gonadotrope-specific marker 
to appear within the developing gland (46).  Onset of expression of SF1 is 
occasionally cited at the defining event in gonadotrope specification.  Indeed, pituitary 
specific depletion of SF1 led to impaired expression of the gonadotropins as well as 
the GnRHR, and secondary hypogonadism (47).  However, this phenotype was able to 
be rescued by administration of exogenous GnRH suggesting that while SF1 is 
necessary for gonadotrope function, it is not required for developmental specification 
or differentiation of the gonadotrope lineage (47).   
 The gonadotrope is the last of the anterior pituitary cell types to undergo 
terminal differentiation as marked by the relatively late onset of expression of the 
genes encoding the -subunits of FSH and LH.  The mechanisms underlying the 
timing of initial expression of these gonadotropin subunit genes are unknown.  
Activation of the murine FSH  promoter first occurs at approximately e17.5 while 
LH  biosynthesis commences approximately 24 hours later.  In conjunction with a 
cohort of relatively ubiquitous and cell type-non-specific transcription factors, SF1 
plays a key role in activation of the promoters for all of the genes that comprise the 
genetic signature of the gonadotrope ( GSU, FSH , LH , GnRHR), and is primarily 
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responsible for restricting expression of FSH , LH , as well as GnRHR to the 
gonadotrope (48). 
 
4. Molecular basis of the response of the gonadotrope to GnRH 
4.1 Experimental models used in the study of gonadotrope function 
 Studies of GnRH-activated signal transduction pathways in the gonadotrope 
have relied heavily on the T3-1 and L T2 murine gonadotrope-derived cell lines.  
These cell lines were generated through targeted expression of SV40 large T antigen 
in developing pituitary cells (49-51).  Both lines express the GnRHR as well as the 
GSU.  In addition, the L T2 cell line expresses the  subunit of LH, and may thus 
represent a somewhat more differentiated gonadotrope phenotype.  For the studies 
described in Chapters 2 and 4 below, T3-1 cells were used exclusively.   
Protocols for purification of gonadotropes from dispersed pituitary tissue and 
their propagation in primary culture have been described; however they are technically 
demanding and are not widely used (52).  However, due to the restricted pattern of 
expression of the GnRHR as well as the specificity of GnRH, many aspects of 
gonadotrope function, particularly transcriptional responses to GnRH stimulation, can 
be readily examined in primary cultures of mixed pituitary cells generated by 
enzymatic dispersal of fresh pituitary tissue.  Measurements of GnRH-induced 
changes in transcript levels in primary culture systems must be interpreted with 
caution, since expression of a gene of interest in cell types other than the gonadotrope 
will contribute to baseline transcript levels within an experimental unit, and will lead 
to underestimation of the effects of hormone stimulation on the subpopulation of 
gonadotropes within that unit.  This is relevant to the results described in Chapter 3 
where GnRH-induced increases in mRNA levels of Egr1, a transcription factor known 
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to be expressed in multiple pituitary cell types other than gonadotropes, were 
measured in mixed primary pituitary cultures. 
Finally, many transgenic models have been developed that shed light on the 
role of specific gene products within the pituitary.   Constitutive gene ablation may 
result in a phenotype that reflects primary pituitary dysfunction.  For example, despite 
its broad pattern of expression, mice lacking Egr1 display female infertility associated 
with a failure of LH production in the gonadotrope (53).  Alternatively, due to their 
more restricted pattern of expression, the promoters of genes encoding a number of the 
pituitary trophic hormones have been used to target transgene expression to the 
pituitary allowing conditional, Cre recombinase-mediated disruption of floxed alleles 
(54-56).  This approach is described in Chapters 3 and 4 where the GSU promoter 
was used to drive pituitary targeted expression of Cre recombinase, and subsequent 
Cre-mediated disruption of the ERK2 and Raf-1 genes.   
  
4.2 Structural and functional aspects of the GnRH receptor 
 The GnRHR is a member of the large G-protein coupled receptor (GPCR) 
superfamily.  Three forms of the GnRHR have been identified in vertebrates, 
designated types I, II, and III (57).  Three corresponding forms of GnRH (type I, II, 
and III) have also been identified (57).  The type I receptor is the predominant form 
expressed in the gonadotrope, and in some mammalian species including humans is 
also expressed in certain extra-pituitary tissues most notably the breast, gonads, 
prostate, and uterus (58).  The natural ligand for the type I receptor is type I GnRH; 
however type II GnRH may also engage and activate the type I receptor (59).  Indeed, 
in several mammalian species, including human and mouse, the type II GnRHR has 
been evolutionarily silenced at the genomic level by a frameshift mutation.  Thus, the 
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biological effects of GnRH II or its analogues are thought to be mediated by the type I 
receptor (60).   
The type I GnRHR was first cloned in 1992 from cDNA derived from the 
murine T3-1 gonadotrope-derived cell line (61, 62).  Subsequent cloning of 
GnRHR‟s from human, rat, sheep, pig, and horse showed that the receptor is highly 
conserved, with greater than 80% amino acid homology among these mammalian 
species (63).  The deduced amino acid sequence predicts a 327 amino acid (aa) 
receptor with seven transmembrane domains, a 35 aa amino-terminal extracellular 
domain with 2 putative glycosylation sites, and a conspicuously short 1-2 aa carboxyl-
terminal cytoplasmic domain.  An additional glycosylation site is predicted within the 
first extracellular loop (62, 63).  While the crystal structure of the GnRHR has not 
been determined, its homology with other members of the GPCR family, including 
rhodopsin, has allowed model-based predictions of the overall topology of the 
receptor, as well as the structural basis of its interaction with ligands (64).  Many of 
these predictions have been verified by site-directed mutagenesis studies in 
recombinant receptors expressed in cell culture systems.  For example, alanine 
substitution of asparagine residues 18 or 102 (predicted glycosylation sites) led to 
decreased receptor glycosylation, and while this had no effect on ligand affinity, 
overall receptor expression was decreased, indicating a role for glycosylation of these 
residues in receptor stability or appropriate membrane targeting (65).  Similar methods 
have identified critical residues involved in ligand binding within the second and 
seventh transmembrane domains, as well as the third extracellular loop (66-68) .  
Insight into the structural basis of the interaction of the receptor with its decapaptide 
ligand has facilitated the development of receptor antagonists, as well as high-affinity 
ligands that function as super-agonists (65).  Antide and buserelin (des-GLY
10
 [D-
Ser(t-But)
6
 ]-LH-RH Ethylamide) are examples of GnRHR antagonist, and super-
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agonist, respectively, that are commonly used in molecular and cellular studies of 
gonadotrope function.  Both compounds were used in the investigations described 
here. 
The lack of a carboxyl-terminal intracellular domain renders the mammalian 
type I GnRHR a structurally and functionally unique member of the GPCR family 
(63).  The C-terminal tail domain of the prototypical GPCR is an important target for 
phosphorylation, typically mediated by a G-protein coupled receptor kinase (GRK) 
(69).  C-terminal tail phosphorylation generates a docking site for members of the -
arrestin family of scaffolding proteins, which upon binding, mediate rapid 
desensitization and dynamin-dependent internalization of a receptor via clathrin-
coated pits (70).   Lack of a C-terminal tail implies that the GnRHR may be resistant 
to rapid desensitization and internalization, and this has been confirmed 
experimentally for this receptor in a variety of settings (71-74).  Domain swap studies 
in which the C-terminal tail of the thyrotropin-releasing hormone (TRH) receptor was 
fused to the C-terminus of the mammalian GnRHR rendered the receptor susceptible 
to rapid arrestin-mediated desensitization and internalization (75).  Exposure of 
gonadotropes to GnRH does lead to receptor internalization; however, this process 
occurs more slowly than with other GPCR‟s, and appears to be independent of 
dynamin (76).  Indeed, the GnRHR has been described as a “naturally-occuring 
internalization deficient mutant” GPCR (77).    
 Appropriate plasma membrane expression of the GnRHR is of obvious 
importance for responsiveness of the gonadotrope to GnRH.  In turn, surface 
expression of functional receptors requires proper intracellular folding, glycosylation, 
and trafficking of newly synthesized receptor proteins.  Naturally-occuring mutations 
have been described in the human GnRHR gene that lead to hypogonadotropic 
hypogonadism of variable clinical severity (21).  These mutations have been mapped 
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to various locations throughout the length of the GnRHR coding sequence.  Functional 
analysis of recombinant receptors harboring many of these mutations indicates that 
ligand binding and coupling to intracellular effectors are unimpaired, but that the 
mutant receptors undergo improper folding and either aberrant intracellular trafficking 
or premature degradation (22).  Loss of newly synthesized receptors due to stochastic 
processes of misfolding and premature degradation is common for some membrane 
receptors, and underscores the dynamic nature of receptor biosynthesis and recycling 
(78, 79).  In many instances, cell permeable ligand-mimetics may shift the equilibrium 
of this process in favor of effective receptor expression by improving the efficiency 
with which nascent receptors adopt a proper conformation during folding (80, 81).  
This has been shown for the GnRHR where treatment of cells with the GnRH-mimetic 
indole IN3 was able to establish GnRH responsiveness in cells expressing a variety of 
mutant receptors that otherwise underwent premature degradation (22).  This has 
stimulated interest in the mechanisms underlying appropriate plasma membrane 
targeting of the GnRHR as well as the development of pharmacological agents that 
would allow manipulation of cell surface receptor density by altering the efficiency of 
folding and trafficking. 
 
4.3 GnRH-induced signal transduction in the gonadotrope 
 The signaling events initiated by engagement of the GnRHR have been the 
subject of considerable investigation (82-85, 95, 97, 175, 176, 184).  As with other 
GPCR‟s, ligand binding induces a conformational change in the receptor that leads to 
dissociation and activation of a heterotrimeric G-protein generally involving the 
G q/11 subunit (85).  GTP loading of G q/11 leads to activation of phospholipase C , 
and subsequent elaboration of the second messengers, phophatidylinositol-3-
phosphate (IP3) and diacylglycerol (DAG).  DAG leads to activation of PKC isozymes 
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and contributes to a sharp rise in intracellular calcium concentration, which derives 
from both IP3-mediated release of intracellular calcium stores, as well as influx of 
extracellular calcium through L-type voltage gated channels (84).  These events are 
prerequisite for activation of mitogen-activated protein kinase (MAPK) activity, in 
particular the extracellular signal-regulated kinase (ERK) pathway (83).   
 
4.3.1 Membrane-associated signaling events 
 The delayed kinetics of GnRHR internalization underscore the importance of 
the plasma membrane as a platform for organization of the early signaling events that 
occur following ligand binding.  This is in contrast to other GPCRs such as the -
adrenergic receptor ( AR) that undergo rapid internalization and that may nucleate 
active signaling complexes on the surface of endosomes (86).   
 The GnRHR has been shown to couple to multiple G-proteins depending on 
cell type and experimental model; however, the predominant signaling events intiated 
by GnRHR occupancy reflect the activation of G q/11 family members (85).  G q/11 
comprises a group of pertussis toxin-insensitive palmitoylated GTP-binding proteins 
that lead to selective activation of the isoforms of phospholipase C.   
 Detailed structural and functional analysis of protein domains within PLC-  
indicate that these enzymes undergo constitutive and reversible membrane association 
mediated by the C-terminal region as well as the N-terminal plekstrin homology 
domain (87).   Activation of PLC  does not involve membrane recruitment.   Catalytic 
activity of PLC  is stimulated by interaction with GTP-loaded G q/11 subunits, and 
leads to the elaboration of IP3 and DAG within the plasma membrane.  PLC  also acts 
as a G q/11 GTPase activating protein (GAP) leading to negative feedback effects on 
the signaling input by stimulating hydrolysis of G q/11 bound GTP (88).   PLC  
isoforms are also present within the nucleus, where they catalyze a nuclear cycle of 
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inositol-phosphate (IP) turnover that has been shown to be important in cellular 
responses to various mitogenic stimuli (89).  Interestingly, nuclear PLC  is a direct 
ERK substrate, and ERK-mediated phosphorylation of S982 within the C-terminal 
domain is required for PLC  activation by Insulin-like Growth Factor 1 (IGF-1) (90).  
Of note, S982 resides within a regulatory region of the C-terminal domain that is also 
required for interaction with G q/11 (91).  Whether nuclear IP turnover plays any role 
in GnRH action, or whether GnRH-activated PLC isoforms are regulated by 
phosphorylation at the level of the plasma membrane is unknown. 
 In contrast to PLC , activation of PKC isoforms involves plasma membrane 
recruitment.  Three major classes of PKC have been characterized, namely the 
conventional, novel, and atypical PKCs (92).  All are activated through the synergistic 
effects of DAG and phosphatidylserine.  In addition, activation of the conventional 
PKCs requires calcium.   T3-1 cells express a variety of PKCs representing all 
classes including the , , , , and  isoforms (93, 94).  Fractionation experiments 
indicated that the and  isoforms may be the major PKCs activated by GnRH in 
these cells (94).  The phorbol ester PMA is a potent activator of all classes of PKC.  
Similarly, the pharmacological agent GF109203X (GFX) is a commonly used 
inhibitor of PKC activity that is active against all classes.   
 In T3-1 cells, PKC activity is required for ERK pathway activation by 
GnRH; however the mechanism underlying this requirement is unknown (95).  Raf-1 
kinase is widely believed to be the key upstream activator of the ERK signaling 
module in the gonadotrope, and direct activation of Raf-1 by PKC has been suggested 
as a mechanism by which GnRH-induced signaling events at the plasma membrane 
may link to an ERK cascade that ultimately converges on the nucleus (96, 97).  
Membrane recruitment is a critical step in the complex series of events that leads to 
Raf-1 activation; thus, recruitment and activation of Raf-1 by membrane-bound PKC 
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is an conceptually attractive scenario.  However, little evidence exists to support direct 
activation of Raf-1 by PKC.  Furthermore, the data presented in Chapter 4 raise 
significant doubt regarding the importance of Raf-1 itself in GnRH-induced ERK 
activation, either in T3-1 cells or in vivo.  The architecture of this portion of the 
GnRH signal transduction network, particularly the link between signaling activities at 
the plasma membrane and the ERK module, thus remain unclear. 
 
4.3.2 Membrane rafts and the GnRHR 
The membrane raft hypothesis 
 The fluid mosaic model of cellular membrane organization, originally 
proposed by Singer and Nicholson in 1972, describes the plasma membrane of cells as 
a homogenous fluid phase lipid bilayer containing numerous peripheral and integral 
membrane proteins, in which individual lipid molecules are essentially unconstrained 
with respect to their ability to diffuse laterally through the membrane (98).  
Subsequent investigations into the properties of model membranes composed of 
binary and ternary mixtures of lipids at defined molar ratios, as well as cellular 
membranes, has led to a contrasting model of the plasma membrane as a 
heterogeneous assembly of spatially and functionally distinct domains that may differ 
with respect to both lipid and protein composition (99-101).  This membrane raft 
hypothesis is predicated upon the notion that different lipid species within a membrane 
bilayer may differ in their affinities for each other and for membrane proteins, and that 
these differences in affinity may facilitate the formation of biochemically and 
biophysically distinct lipid domains within the membrane. 
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Definition of the membrane raft 
 Early descriptions of membrane rafts (often referred to as lipid rafts) were 
based on the observation that glycosylphosphtidyl-inositol (GPI)-anchored proteins 
remained insoluble when cells were homogenized at low temperature in the presence 
of the non-ionic detergent Triton X-100, and were consistently recovered in 
association with low-bouyant density membranes following sucrose density gradient 
centrifugation of cell homogenates (102).  Subsequent analysis of the composition of 
these detergent-resistant membranes (DRM‟s) showed that they were enriched in 
cholesterol and sphingolipids as well as numerous specific integral membrane proteins 
(103).  From these early characterizations of DRM‟s emerged the notion that the 
plasma membrane may be organized as a lipid bilayer containing discrete cholesterol 
and sphingolipid-enriched microdomains (lipid rafts) that serve as platforms for the 
recruitment of specific membrane proteins.  Perhaps due to the relative ease with 
which DRM‟s may be prepared from a variety of cell types, a largely operational 
definition of membrane rafts seems rapidly to have gained popularity in many areas of 
cell biology.  Indeed, hundreds of reports on the role of membrane rafts in various 
cellular contexts were published in ensuing years, many of which seem based on the 
assumption that DRM‟s provide a biologically meaningful representation of 
membrane domains as they exist within the plasma membrane of living cells.  As a 
caution against uncritical acceptance of this assumption, Lai proposed a definition of 
the membrane raft as “an unidentified floating object” (104).  Nevertheless, 
acceptance of this assumption appears to remain widespread. 
 A recent Keystone Symposium on Lipid Rafts and Cell Function was held at 
which the following definition of membrane rafts was proposed: “Membrane rafts are 
small (10-200 nm) heterogeneous, highly dynamic, sterol and sphingolipid enriched 
domains that compartmentalize cellular processes” (105).   
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Phase separation within model and cellular membranes 
 The temperature-dependent formation of biochemically and biophysically 
distinct lipid domains within model membranes composed of simple lipid mixtures is 
well established.  For example, when membranes composed of binary mixtures of 
lipids are brought to temperatures intermediate between the melting points of the 
individual lipid species, the lipids with the higher melting point may spontaneously 
aggregate into domains of solid phase within a surrounding milieu of fluid phase, or 
liquid disordered (ld), lipid (106).  In simple lipid mixtures, this phase separation is 
not abrupt, but occurs continuously over a range of temperatures (106).  Addition of 
cholesterol to binary lipid mixtures has been shown to broaden the range of 
temperature over which phase separation occurs following thermal fluctuations and to 
lead to the formation of a distinct lipid phase referred to the liquid ordered (lo) phase 
(107).  In the lo phase the acyl chains of individual lipid molecules assume an 
extended, closely packed, and highly ordered conformation akin to a solid phase, but 
retain high lateral mobility within the plane of the membrane, as in an ld phase (107).  
Cholesterol has been shown to be critical for the formation of the lo phase.  The rigid 
planar configuration of cholesterol may facilitate the extension of adjacent acyl chains 
and close lipid packing (108).  Cholesterol may also associate preferentially with 
sphingolipids, the large polar protruding head groups of which may help shield the 
hydrophobic ring structure of cholesterol from the surrounding aqueous environment 
(umbrella effect) (109).  Hydogen bonding between cholesterol and sphingolipids may 
also contribute to the nonuniform distribution of cholesterol throughout the membrane 
and the formation of cholesterol enriched lo domains (110). 
Large scale phase separation of persistent lo lipid domains may form in 
response to temperature changes, even in more complex vesicular membranes derived 
from the plasma membrane of living cells (111).  However, smaller and more transient 
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nanodomains have also been identified in model membranes of more complex 
chemical composition at physiologically appropriate temperatures (112). These 
observations suggest that while phase separation and formation of lo domains are 
likely to occur in cellular membranes, both their size and the time scales over which 
they exist are likely to be extremely small.  Indeed it has been proposed that the 
definition of the membrane raft be broadened to include highly transient molecular 
assemblies involving as few as 3 molecules with lifetimes of tens of milliseconds 
(113). 
 
Properties and functions of membrane rafts 
 The tight packing of lipids within lo domains creates a unique membrane 
environment for which integral and peripheral membrane proteins may show highly 
different affinities.  Rafts thus provide a theoretical mechanism for regulation of 
protein-protein interactions at the level of the plasma membrane through the 
partitioning of individual proteins into, or out of, regions of lo phase.   
 While the tendency of certain acylated cytoplasmic proteins, or GPI-linked 
exoplasmic proteins, to partition efficiently into regions of lo phase would seem 
predictable, experimental observations indicate that this often occurs only weakly.  For 
example, when the GPI anchored protein placental alkaline phosphatase (PLAP) was 
introduced into unilamellar vesicles containing coexisting lo and ld phases, the 
reporter protein actually showed preferential partitioning into regions of ld phase 
(114).  This occurred despite its reported tendency to partition into low-bouyant 
density DRM following cold detergent extraction (102).  However, antibody 
crosslinking of the PLAP markedly shifted its behavior within the membrane, leading 
to its preferential association with lo domains (114).  Similarly, in homogeneous 
model membranes containing the ganglioside GM1, large scale segregation of lo 
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membrane domains was induced in the absence of thermal fluctuations by external 
crosslinking of GM1 (115).  These observations are consistent with notion that 
membrane rafts may generally be extremely small and short-lived, but that specific 
extracellular stimuli that lead to crosslinking or clustering of membrane proteins may 
induce the formation of large scale and more persistent lo domains that in turn could 
act as platforms for the recruitment of specific proteins or the assembly of specific 
protein complexes (113).   
Perhaps the most substantial evidence in support of this general hypothesis 
comes from studies of T-lymphocyte activation.    Use of the phase sensitive 
fluorescent lipid reporter laurdan indicated that regions of lo phase are small and 
inconspicuous in non-stimulated T cells (116).  Occupancy of the T cell receptor 
(TCR) with antigen-MHC complex together with CD28 costimulation (the basic 
signals that drive T cell activation) leads to clustering of TCR-CD3-CD28 complexes.  
This receptor clustering is thought to be the driving force behind the regional 
condensation of plasma membrane around activated receptors into an lo phase, leading 
ultimately to the formation of a large membrane domain enriched in TCR and 
associated signaling complexes (the distal component of the immunological synapse).  
This regional membrane condensation was evidenced by a phase-dependent shift in 
laurdan fluorescence at sites of TCR activation (116).  Overall these observations 
point to a finely regulated interplay between lo membrane nano-domains, specific 
extracellular signals that may induce coalescence of these nanodomains into larger 
regions of lo phase through clustering or crosslinking of receptors, and raft associated 
recruitment of specific signaling complexes that may assemble in a stimulus-
dependent manner in the vicinity of activated receptors. 
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Controversies surrounding the role of membrane rafts in biological systems 
 Despite the large body of published work focused on the role of membrane 
rafts in various cell types, controversy continues to surround many aspects of the 
membrane raft hypothesis, including the size, lifespan, composition, function, and 
even the existence, of raft domains (104, 117).  Much of this controversy appears to 
reflect the technical difficulty involved in either isolation of raft domains from the 
plasma membrane of living cells or direct visualization of rafts in situ. 
 Several methods for purification of raft domains from cells have been 
described; most involve density gradient centrifugation of cell lysates prepared by 
extraction and mechanical homogenization of cells in the presence of low 
concentrations of a non-ionic detergent such as Triton X-100 (118).  Detergent-free 
methods have also been described by which cellular membranes may be fractionated 
on the basis of density alone (119, 120).  As with the results described in Chapter 2 
below, the association of specific proteins with low density membrane fractions is the 
fundamental readout for these experiments, and the tendency of a given protein to 
compartmentalize within a microdomain of the plasma membrane of a living cell is 
inferred therefrom.  These techniques are relatively simple and are commonly used; 
however they have several limitations.  Phase separation in membranes is highly 
influenced by temperature.  Nevertheless, standard fractionation techniques are 
typically performed at 4
o
C, with little regard for the ability of cold temperatures to 
induce membrane condensation or even protein precipitation.  Moreover, nonionic 
detergents have been shown to induce artifactual micron-scale segregation of domains 
from cellular membranes at low temperatures (121).  Parallel use of detergent-free 
fractionation methodologies may be warranted as a control for detergent artifacts. 
 An additional significant limitation of subcellular fractionation for study of 
membrane rafts is lack of temporal and spatial resolution.   Results of fractionation 
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studies may provide useful information regarding the general preference or affinity of 
a protein for a specific membrane environment.  However, from the point of view of 
membrane dynamics, these techniques are incapable of disclosing the time scales over 
which rafts may form and disperse in cells, nor can they capture the residence time or 
the rate of trafficking of a protein into or out of a membrane domain (113).  Similarly, 
fractionation methods generally yield micron scale fragments of protein-laden cellular 
membranes.  The resemblance of such large scale membrane condensations to the 
nanometer scale domains proposed to exist in situ is debatable.   
The formation of lo phase within membranes is dependent on cholesterol.  
Manipulation of cellular cholesterol levels has therefore become a widely used 
technique for assessing, at least indirectly, the association of a protein with raft 
domains.  Depletion of membrane cholesterol perturbs membrane domain 
organization, and loss of association of a protein with DRM or low density membranes 
following cholesterol depletion is often cited in support of that protein‟s inherent 
affinity for a lo membrane environment (122).  Cholesterol depletion is typically 
accomplished by exposure of cells to the compound methyl-  cyclodextrin (MBCD).  
MBCD is a cell-impermeable surface acting carbohydrate that efficiently extracts 
cholesterol from lipid bilayers by sequestration in a hydrophobic pocket.  Cholesterol 
depletion by MBCD is reversible through the exposure of cells to MBCD that has 
been presaturated with cholesterol, allowing for acute membrane cholesterol repletion, 
or over-repletion.  MBCD has become a commonly used tool for probing the function 
of membrane rafts in living cells; however, inference regarding the behavior or 
function of rafts based on cholesterol depletion experiments is also problematic (122).  
Cholesterol comprises approximately 30% of plasma membrane lipid on a molar basis, 
and up to 90% of total cellular cholesterol is contained within the plasma membrane 
(123).  While enriched within raft domains, cholesterol is also present within bulk ld 
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regions of plasma membrane and is susceptible to MBCD extraction from these 
regions as well as from rafts (122).  Cholesterol depletion may thus induce extensive 
structural and functional perturbations of the plasma membrane.  Acute cholesterol 
depletion is known to increase membrane permeability; indeed in our hands, exposure 
of T3-1 cells to MBCD led to rapid but reversible permeabilization within minutes as 
assessed by Trypan Blue staining (S. Bliss, unpublished data).  MBCD has also been 
shown to bind to phospholipids and may facilitate exchange of phospholipids between 
preexisting membrane domains (124).  Thus, while cholesterol depletion may be 
informative regarding the raft association of specific proteins, assessment of its effects 
on coordinated cellular activities such as signal transduction that may be sensitive to 
changes in overall cell membrane integrity clearly must be interpreted with caution.     
In lieu of biochemical approaches, numerous sophisticated biophysical 
techniques have been developed in recent years for direct characterization of 
membrane rafts in situ.  These include confocal microscopic imaging of cells treated 
with phase-sensitive membrane reporters, FRET analysis of protein or lipid 
juxtapositions within cellular or model membranes, single particle tracking, and high 
temporal resolution electron spin resonance (ESR) spectroscopic methods for 
evaluation of the residency time of lipids within specific domains (125-128).  These 
techniques have been instrumental in the development of the current view of 
membrane rafts as small and highly dynamic membrane heterogeneities that may 
nevertheless play important roles in signal transduction, especially through ligand-
dependent clustering and stabilization.   
 
Membrane rafts and the GnRHR 
 Previously, the GnRHR was shown to partition completely into low-bouyant 
density membrane fractions following sucrose density gradient centrifugation of T3-
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1 cell homogenates prepared both in the presence and absence of detergent, suggesting 
that the receptor may have an inherent preference for a lo membrane environment 
(129).  Following cholesterol depletion, cold detergent extraction solubilized the 
receptor; however, its association with low-density membranes was restored by 
cholesterol repletion.  Cholesterol depletion also blocked the ability of GnRH to 
activate the ERK pathway while ERK responsiveness to phorbol-ester induced 
activation of PKC was maintained.  Analysis of inositol phosphate production 
indicated that cholesterol depletion uncoupled the GnRHR-G-protein complex from 
PLC This blockade in signaling activity was also restored by cholesterol repletion 
(129).  ERK activation was also blocked by increasing cellular cholesterol levels to 
200% of baseline through exposure of cells to cholesterol-loaded MBCD without 
initial depletion (S Bliss, unpublished data).  These observations led to the hypothesis 
that the ability of the GnRHR to signal appropriately is affected by the biophysical 
properties of the plasma membrane, and may require association with lo plasma 
membrane microdomains (membrane rafts).    
FRET studies with fluorochrome labeled GnRHR showed that agonist 
treatment led to self-association (dimerization) of receptors and decreased lateral 
mobility of receptors within the membrane (130).  Receptor dimerization also 
occurred following treatment with antide; however, this receptor antagonist had no 
effect on lateral mobility of the receptor (130).  This suggests that agonist-induced 
receptor clustering may facilitate coupling of the receptor with the downstream 
intracellular signaling apparatus.  Consistent with this hypothesis, several key 
signaling intermediates known or presumed to play a role in the GnRHR-ERK 
pathway were also found to associate at least partially with low density membranes 
including G q/11, calmodulin, isoforms of the 14-3-3 family of adapter proteins, Raf-1, 
MEKs, and the ERKs themselves (129, 131).  The experiments described in Chapter 2 
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below were undertaken to examine in greater detail the association of ERKs with 
GnRHR-enriched plasma membrane microdomains and to further test the hypothesis 
that GnRH-induced ERK activation involves the assembly of a membrane-associated 
multiprotein signaling complex in proximity to the GnRHR. 
 
4.3.3 Calcium signaling in the gonadotrope 
 In the gonadotrope, GnRH induces a rapid biphasic elevation of intracellular 
calcium (132).  The initial sharp rise in cytosolic calcium reflects predominantly the 
release of calcium from intracellular storage depots, particularly the endoplasmic 
reticulum (ER).  Following this initial spike, a more sustained phase of calcium 
elevation occurs, due primarily to influx of extracellular calcium via L-type voltage 
gated channels (VGCC).  Release of intracellular calcium from the ER is triggered by 
IP3 through direct interaction with IP3 receptors on the surface of the ER.  Calcium 
influx through VGCC is dependent on the activity of PKC isozymes.   
 Calcium influx via VGCC has been shown to be uniquely required for ERK 
activation in the gonadotrope, although the mechanisms underlying this requirement 
remain unclear (83, 133).  In previous work from this laboratory, GnRH stimulation 
led to rapid calcium loading of the calcium sensing protein calmodulin, which was 
itself shown to be required for ERK activation independently of the calmodulin-
dependent protein kinase CamKII (131).  In vitro reconstitution experiments indicated 
direct calcium-dependent interaction between calmodulin and Raf-1 (131).  In 
addition, calmodulin was also recovered from low-density DRM following sucrose 
density gradient centrifugation of T3-1 cell homogenates, suggesting that calmodulin 
may serve as a link between VGCC calcium and the ERK pathway, and that this 
linkage may be regulated through association with membrane rafts (131).  The cellular 
effects of calcium signals have long been known to be highly compartmentalized 
29 
(microdomain calcium signaling) in a wide variety of excitable and nonexcitable cells 
(134).  Thus, while inconclusive, our observations raise the intriguing possibility that 
the contribution of VGCC calcium to GnRH-induced ERK activation in the 
gonadotrope represents a similarly compartmentalized event, possibly organized 
through association with plasma membrane rafts. 
 Recent studies have identified proline-rich tyrosine kinase 2 (Pyk2) as a 
calcium-dependent enzyme required for GnRH-induced ERK activation in both T3-1 
and L T2 cells.  In L T2 cells, Pyk2 was shown to act as a scaffold for the assembly 
of a signaling complex containing c-Src, Grb2, and Sos, and this complex was 
suggested to form a direct link between GnRH-induced calcium currents and canonical 
Ras-dependent activation of the ERK pathway (135).  Recent work from this 
laboratory also identified Pyk2 as a catalytic activity required for GnRH-induced ERK 
activation in T3-1 cells and showed that GnRH induces rapid phosphorylation of 
Pyk2 in mouse gonadotropes in vivo (136).  In agreement with previous results 
demonstrating a requirement for calmodulin for GnRH-induced ERK activation, this 
study documented a direct interaction between calcium-activated calmodulin and the 
catalytic domain of Pyk2 (131, 136). Calmodulin was further shown to be required for 
GnRH-induced Pyk2 phosporylation in mouse gondotropes in vivo.  Pyk2 thus 
appears to play a key role in linking VGCC-mediated calcium signals with the ERK 
pathway in gondotropes. 
 
4.3.4 GnRH-induced MAP kinase activation 
 The mitogen-activated protein kinase (MAPK) pathways are a highly 
conserved set of signal transduction cascades that mediate cellular responses to an 
enormous variety of environmental stimuli.  In mammals, there are 4 predominant 
MAPK pathways: the ERK, jun-N-terminal kinase (JNK), p38, and ERK5/Big MAP 
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kinase (ERK/BMK) pathways.  The basic organization of these pathways is similar, 
consisting of a multi-level phosphotransfer system.  Activation of the pathway begins 
with phosphorylation of an upstream MAP kinase-kinase kinase, which 
phosphorylates and activates an intermediate level MAP kinase kinase, which in turn 
phosphorylates and activates the terminal MAP kinase.  Activated MAP kinases 
phosphorylate numerous substrates throughout the cell including elements of the 
transcriptional machinery, chromatin components, cytoskeletal structures, and other 
downstream enzymes (137, 138).   
 In the gonadotrope, GnRH stimulation leads to activation of the ERK, JNK and 
p38 pathways (84).  Several studies link activation of these pathways to transcriptional 
regulation of the gonadotropin genes.  The role of ERK5/BMK in the gonadotrope has 
not been investigated.   
 
5. The ERK signaling pathway 
 The ERK signaling pathway is the most intensively studied and thoroughly 
characterized of the MAPK systems.  In its canonical form, the core element of the 
ERK pathway consists of a 3-level kinase cascade including the MAPKKK Raf-1, the 
MAPKK‟s MEK1 and 2, and the MAPK‟s ERK1 and 2 (139).  In addition to these 
core kinases, numerous scaffolding and adaptor proteins have been shown to play 
important roles in the functional organization of this pathway (140).    
The ERK pathway is involved in the transduction of signals emanating from a 
multitude of different cell surface receptors.  The best characterized of these are the 
receptor tyrosine kinases (RTKs).  Indeed, the ERK proteins were initially identified 
as kinase activities induced in cells by RTK ligands including a variety of mitogenic 
peptides and insulin (141, 142).  These ligands stimulate the ERK pathway through a 
classical mechanism involving activation of the low molecular weight GTPase Ras.  
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The ability of ERKs to mediate the proliferative effects of RTK ligands has been 
demonstrated in a variety of settings, and has been the focus of intense investigation in 
the areas of basic cell biology as well as drug discovery and anti-cancer therapeutics 
(143, 144).  The ERK pathway is also activated following engagement of many GPCR 
(145).  Agonists for these receptors include a wide variety of small molecules as well 
as numerous neurotransmitters, peptides hormones, cytokines, nucleotides and amino 
acids, ions, and lipids (146).  GPCRs are linked to a bewildering array of cellular 
functions.  While the ERK pathway has been shown to be important in mediating the 
mitogenic effects of many GPCR ligands, ERKs also play a role in the specific 
responses of some highly differentiated cells to certain agonists (146, 147).    
The ability of the ERK pathway to elicit dramatically diverse biological 
responses in different contexts points to complex and varied mechanisms of signal 
interpretation that have evolved in cells.  Early insights into ERK signal specificity 
came from studies of the PC12 rat pheochromocytoma cell line in which it was shown 
that sustained ERK activation induced by Nerve Growth Factor (NGF) led to neuronal 
differentiation while transient ERK activation following Epidermal Growth Factor 
(EGF) treatment elicited a non-differentiating proliferative response (148).  One 
established mechanism by which cells may interpret differences in ERK signal 
duration emerged from studies of the ERK-dependent immediate early response 
protein c-Fos.  As a component of the dimeric transcription factor AP-1, c-Fos is 
capable of coupling ERK pathway activity with the expression of a wide variety of 
genes.  c-Fos is rapidly upregulated following ERK activation; however, in the 
absence of post-translational modification, the newly synthesized protein undergoes 
rapid degradation.  ERK-dependent phosphorylation of the C-terminus of c-Fos 
stabilizes the protein, prolonging its half-life and allowing its nuclear accumulation 
(149).  C-terminal phosphorylation also targets the protein for secondary ERK-
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dependent phosphorylation of internal residues 325 and 331, which enhances its 
transcriptional activation function (149).  However, this only occurs under conditions 
of relatively sustained ERK activation.  These dual ERK-dependent phosphorylation 
events that sequentially stabilize and activate c-Fos provide an example of a simple 
but elegant mechanism by which cells may link ERK signals of variable duration with 
different transcriptional outputs.   
Protein-protein interactions mediated through defined docking domains are 
also important in the establishment of ERK signal specificity.  ERKs contain 2 key 
interaction domains: the common docking (CD) domain on the face of the protein 
opposite the catalytic site, and a separate interaction domain at the edge of the 
activation site (150, 151).  The former binds to cognate „D‟ domains of interactors 
such as ribosomal S6 kinases (RSK), MEK1/2, and certain MAP kinase phosphatases 
(MKPs). The latter binds to the „docking for ERK [Phe-X-Phe]‟ (DEF) domain of 
many ERK substrates including c-Fos and Egr1(150, 151).  Docking interactions are 
prerequisite for appropriate substrate recognition by ERKs and also guide the 
interaction of ERKs with various scaffolding and adaptor proteins.   These interactions 
may contribute to signal specificity by confining ERK activity to particular subcellular 
compartments.    For example, docking interactions underlie the nuclear translocation 
of activated ERKs that occurs in response to various stimuli (152, 153).  The 
MAPKKs MEK 1 and 2 can play an important role in this process.  The MEK proteins 
contain a nuclear export sequence that restricts them to the cytosol (154, 155).  Under 
resting conditions, stable associations between MEKs and inactive ERKs mediated 
through D domain-CD domain interactions may tether ERKs within the cytosolic 
compartment (154).  Upon pathway activation, however, the MEK-ERK association is 
destabilized allowing dissociation and nuclear translocation of active ERK.   
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In addition to their established tendency to undergo nuclear translocation, 
ERKs may also be recruited to extranuclear membranes, and may be activated within 
the context of membrane bound signaling complexes (156, 157).  The DEF domain 
containing protein kinase suppressor of ras (KSR) is a scaffold protein that has been 
shown to facilitate Ras-dependent activation of membrane targeted ERKs through 
nucleation of signaling complexes containing all the core kinases of the ERK pathway 
(158).  KSR has also been shown to bind G  dimers and to facilitate Ras-independent 
activation of membrane-associated ERKs following occupancy of certain GPCRs 
(159).  Docking interactions also underlie the organization of ERK signaling 
complexes by arrestins following desensitization and internalization of GPCRs 
(160).  Some data suggest that arrestin-associated complexes may serve to restrict 
activated ERKs to the cytosolic compartment thereby selectively targeting 
extranuclear substrates (160, 161).  Similarly, formation of focal adhesions may 
involve the recruitment, activation, and retention of ERKs at sites of adhesion through 
interactions with p125-FAK or Pyk2 (162).  The activity of this pool of ERKs may be 
restricted to highly compartmentalized phosphorylation of cytoskeletal components of 
the adhesion complex. 
 
5.1 Mechanisms of ERK activation by GPCR’s 
 In the classical paradigm of GPCR signaling, ligand binding stabilizes the 
receptor in an active conformation leading to nucleotide exchange of its G-protein  
subunit and the dissociation of the  subunit as well as the dimeric  subunit from the 
receptor.  The free  subunit then regulates the activity of various enzymatic effectors 
involved in the production of second messengers (163).  Historically, studies of GPCR 
signaling have emphasized the role of these receptors in highly differentiated cellular 
functions such as neurotransmission and excitation-contraction coupling.  However, in 
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recent years, appreciation of the role of GPCRs in cellular growth control has led to an 
interest in the mechanisms by which these receptors may activate established 
mitogenic pathways, in particular the ERK pathway (146).   
 The mechanisms of ERK activation by GPCRs vary considerably with both 
receptor and cell type.  In some settings, GPCRs have been shown to cause 
phosphorylation and activation of RTKs such as the epidermal growth factor receptor 
(EGFR) or the platelet-derived growth factor receptor (PDGFR) in a process referred 
to as transactivation (164).  The most widely cited mechanism of RTK transactivation 
is based on the phenomenon of ectodomain shedding.  According to this model, GPCR 
ligands lead to activation of ADAM family transmembrane matrix metalloproteinases 
(MMPs) through the activity of various intracellular effectors such as calcium, 
reactive oxygen species, G  dimers, PKC isoforms, and the non-receptor tyrosine 
kinases c-src and Pyk2.  MMPs in turn catalyze the proteolytic release of membrane 
bound RTK ligands leading to conventional ligand-dependent “outside-in” activation 
of RTKs and canonical Ras-dependent activation of the Raf-MEK-ERK cascade (165, 
166).   GPCRs may also drive ERK activation through second messenger-dependent 
enzyme systems.  For example, in the HEK293 cell model, activation of ERK through 
the endogenously expressed (2)-adrenergic receptor was shown to involve cAMP-
dependent activation of PKA, and subsequent activation of B-Raf via the small Ras-
family GTPase Rap-1 (167).  -arrestins have been shown to be capable of linking 
numerous GPCRs to the ERK module through nucleation of signaling complexes 
containing internalized receptors along with all the core components of the ERK 
pathway (160).  Finally, G  dimers may couple to the ERK pathway independent of 
their cognate -subunit through the direct or indirect activation of the activity of 
phosphatidylinositol-3-kinase (PI3-kinase) or PLC  (168).   
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5.2 Mechanisms of GnRH-induced ERK activation in the gonadotrope 
 In gonadotropes, GnRH stimulation leads to relatively transient activation of 
ERKs (84, 169).  Studies on the mechanism of GnRH-induced ERK activation in 
gonadotropes have yielded conflicting results depending on the model systems 
employed.  Nevertheless, some generalizations seem valid.  Unlike other GPCRs, the 
GnRHR is not phosphorylated following ligand binding and the lack of a C-terminal 
tail precludes direct interaction with -arrestins (72, 170).  Therefore arrestin-
mediated mechanisms of ERK activation are unlikely to apply.  In contrast, the 
requirement for extracellular calcium influx and activation of PKC isoforms for ERK 
activation has been thoroughly demonstrated (84, 133).  Previous work from this 
laboratory showed further that GnRH-induced ERK activation was blocked by 
inhibition of calmodulin (131).  Direct activation of Raf-1 by PKC is often cited as 
mechanism by GnRH may drive ERK pathway activation in a Ras-independent 
manner.  However, this hypothesis derives largely from a study in which PKC was 
shown to phosphorylate Raf-1 in vitro; in light of the complex nature of Raf-1 
activation, this hypothesis may be largely discounted (96).  Moreover, while Raf-1 is 
widely assumed to be the predominant upstream activator of the ERK pathway in 
these cells, experimental evidence in support of this is lacking.  Current views 
highlight the role of Raf-1 as an important regulator of apoptosis that is not required 
for ERK activation in all settings, and suggest that the alternative isoform B-raf may 
be of greater overall importance as a MAPKKK than Raf-1 (171).  Indeed, within the 
pituitary, activation of the ERK pathway in both corticotrope and somatotrope cells 
following stimulation with the GPCR ligands corticotropin-releasing hormone (CRH) 
or growth hormone-releasing hormone (GHRH) does not involve Raf-1, but proceeds 
through a pathway involving G s, PKA, Rap-1 and B-raf  (172, 173). 
36 
One report demonstrated the importance of EGFR transactivation through 
ectodomain shedding for GnRH-induced ERK activation in T3-1 cells (174).  
However, this may reflect a unique property of the cell clones used in those 
experiments as we have been unable to demonstrate EGF responsiveness in T3-1 
cells at any dose (MS Roberson & S Bliss, unpublished data).  Similarly, c-Src has 
been implicated as a link between the GnRHR and the ERK pathway through the 
activation of Ras (135, 175).  However, other reports indicate that GnRH-induced 
ERK activation is Ras-independent, and we have been unable to demonstrate 
phosphorylation of c-Src in T3-1 cells following exposure to GnRH (MS Roberson, 
unpublished data) (176).  Thus, the mechanisms by which the GnRHR couples to the 
ERK module remain unclear.  The molecular architecture of this region of GnRH 
signaling cascade would therefore seem to be a promising area of investigation. 
 
5.3 Importance of ERK signaling for gonadotrope function 
In gonadotropes, a substantial fraction of active ERK undergoes rapid nuclear 
translocation where it plays established roles in GnRH-induced transcriptional 
responses (169).  The immediate early gene response to GnRH stimulation was 
examined by microarray analysis in the L T2 cell line where 28 immediate early 
genes were shown to be significantly upregulated within 60 minutes of GnRH 
exposure (177).  The role of ERK signaling in the induction of several of these genes, 
including c-Fos, Egr1, and LRG21/ATF3, is established (169, 178, 179).  As a 
component of the dimeric transcription factor AP-1, c-Fos has been implicated in 
GnRH-induced expression of FSH , as well as in homologous upregulation of the 
GnRHR (180, 181).   Egr1 plays an established role in the transcriptional upregulation 
of LH , and also contributes to the expression of the dual specificity phosphatase 
MKP2/DUSP4 (182, 183).   ERKs have also been shown to contribute to GnRH-
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induced transcriptional upregulation of the GSU through putative phosphorylation of 
Ets family transcription factors associated with the GSU promoter (184).  ATF3 may 
also enhance expression of at least the human GSU through dimerization with c-Jun 
(178).  ERK signaling is thus linked to the expression of the full complement of genes 
(GnRHR, FSH , LH , GSU) that comprise the genetic signature of the gonadotrope.  
Whether ERK signaling contributes to the expression of other members of this 
immediate early gene repertoire in the gonadotrope remains to be determined.  The 
studies described in Chapter 4 below specifically address the role of the ERK pathway 
in mediating rapid GnRH-induced upregulation of the nuclear orphan receptor Nur77 
in the T3-1 cell line as well as in vivo. 
 
6. Summary and study aims 
 The mammalian reproductive axis is a finely regulated physiological system in 
which the gonadotrope plays a keys role.  The gonadotrope response to the oscillatory 
hypothalamic GnRH signal is mediated by the GnRH receptor, and interpretation of 
this stimulus involves the coordination of multiple intracellular signaling cascades.  
Recent evidence suggests that the biophysical properties of the plasma membrane may 
impact GnRH signaling by regulating interaction of the GnRHR with downstream 
signaling intermediates.  The ERK pathway plays an important role in the response of 
the gonadotrope to GnRH by mediating rapid transcriptional upregulation of a 
repertoire of immediate early response genes.  However, the differential roles of 
ERK1 and ERK2 in this context have not been addressed.  Moreover, the role of ERK 
signaling in the gonadotrope has been overwhelmingly examined in cell culture 
models, the physiological relevance of which has not been clearly established.  The 
studies described here had 3 major objectives: (1) to assess the association of ERKs 
with membrane rafts in gonadotropes, and to determine whether this association is of 
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regulatory significance for GnRH-induced ERK activation, (2) to define the 
requirement for ERK signaling for gonadotrope function in vivo using a genetic 
model, and (3) to examine the role of ERK signaling in mediating GnRH-induced 
expression of the immediate early response gene Nur77 in gonadotropes. 
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CHAPTER 2 
 
SIGNALING COMPLEXES ASSOCIATED WITH THE 
TYPE I GnRH RECEPTOR: COLOCALIZATION OF ERK2 AND 
               GnRH RECEPTOR WITHIN MEMBRANE RAFTS
* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Reprinted from Bliss SP, Navratil AM, Breed M, Skinner DC, Clay CM, Roberson 
MS. 2007, Mol Endocrinol, 21(2): 538-549.  With permission, Copyright 2007, The 
Endocrine Society. 
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SUMMARY 
Our previous work demonstrated that the type I GnRH receptor resides 
exclusively and constitutively within membrane rafts in αT3-1 gonadotropes, and that 
this association was necessary for the ability of the receptor to couple to the ERK 
signaling pathway.  G q, c-raf, and calmodulin have also been shown to reside in this 
compartment, implicating a raft-associated multiprotein signaling complex as a 
functional link between the GnRH receptor and ERK signaling.  In the studies 
reported here, we used subcellular fractionation and co-immunoprecipitation to 
analyze the behavior of ERKs with respect to this putative signaling platform.  ERK 2 
associated partially and constitutively with low-density membranes both in αT3-1 cells 
and in whole mouse pituitary.  Cholesterol depletion of αT3-1 cells reversibly blocked 
the association of both the GnRH receptor and ERKs with low-density membranes and 
uncoupled the ability of GnRH to activate ERK.  Analysis of the kinetics of recovery 
of ERK inducibility following cholesterol normalization supported the conclusion that 
re-establishment of the association of the GnRH receptor and ERKs with the 
membrane raft compartment was not sufficient for reconstitution of signaling activity.  
In αT3-1 cells, the GnRH receptor and ERK2 co-immunoprecipitated from low-
density membrane fractions prepared either in the presence or absence of detergent.  
The GnRH receptor also partitioned into low-density, detergent-resistant membrane 
fractions in mouse pituitary, and co-immunoprecipitated with ERK2 from these 
fractions.  Collectively, these data support a model in which coupling of the GnRH 
receptor to the ERK pathway in gonadotropes involves the assembly of a multiprotein 
signaling complex in association with specialized microdomains of the plasma 
membrane.   
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INTRODUCTION 
The complex signaling events initiated by engagement of the mammalian type 
I GnRHR (subsequently referred to as GnRHR) have been the subject of much 
investigation.  In gonadotropes, the GnRH-R couples to G q/11, leading to activation 
of phospholipase C , and subsequent elaboration of the second messengers, 
phophatidylinositol-3-phosphate (IP3) and diacylglycerol (DAG)(1).  DAG-dependent 
activation of PKC isozymes contribute to a sharp rise in intracellular calcium 
concentration, which derives from both IP3-mediated release of intracellular calcium 
stores, as well as influx of extracellular calcium through L-type voltage gated channels 
(2, 3).  GnRH also induces rapid activation of the mitogen activated protein kinase 
(MAPK) pathways, of which the extracellular signal-regulated kinase (ERK) pathway 
has been most thoroughly characterized.  In gonadotropes, activation of the ERK 
pathway has been linked to the expression of a complement of immediate early genes 
such as c-fos (4, 5), ATF-3 (6), and Per-1 (7), as well as several genes essential for 
gonadotrope function including the glycoprotein hormone  subunit ( -GSU) (8), the 
LH  subunit (5, 9), and a regulatory MAP kinase phosphatase (MKP2) (10).  Several 
requirements for ERK activation by GnRH have been defined, including influx of 
extracellular calcium through L-type voltage gated calcium channels (VGCC) (11), 
activation of PKC isozymes (12, 13), and calmodulin (14).  Nevertheless, the precise 
mechanism by which the GnRHR couples to the ERK pathway remains unclear.   
An important mechanism for regulation of signaling activity that has received 
widespread attention in recent years involves compartmentalization of signaling 
molecules through association with specialized low-density membrane microdomains 
termed membrane rafts (15-17).  These domains are cholesterol- and sphingolipid-rich 
regions of membrane that appear in many cell types to function as platforms for the 
assembly of multiprotein signaling complexes (18).
 
 Rafts are enriched in lipid species 
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with highly saturated acyl chains, particularly glycosphingolipids and sphingomyelin 
(19).  Interactions between sphingolipids and cholesterol contribute to the formation of 
a liquid-ordered (lo) phase.  The lo phase is described as a localized lipid environment 
in which the acyl chains of individual lipid molecules assume an extended, closely 
packed, and highly ordered conformation akin to a gel phase, but in which the lipids 
retain high lateral mobility within the plane of the membrane, as in a fluid phase (20).  
Liquid-ordered domains present a unique membrane environment for which integral 
and peripheral membrane proteins may show highly different affinities.  These 
domains thus provide a mechanism for regulation of protein-protein interactions 
through the partitioning of individual proteins into, or out of, lo regions.   
We have previously reported that the GnRHR resides constitutively and 
exclusively within a detergent-resistant, low-density membrane environment in αT3-1 
gonadotrope cells (21).  Cholesterol depletion shifted the receptor into a detergent-
soluble non-raft environment, and led to a reversible blockade of ERK activation by 
GnRH.  The GTP-binding protein G q/11, as well as c-raf, the putative upstream 
activator of the ERK pathway in these cells, co-localized with the receptor in low-
density membrane fractions suggesting that these membrane domains may be of 
functional significance in coupling the GnRHR to components of the ERK pathway 
(21).  To further explore this model, we now report the use of subcellular fractionation 
techniques to examine the behavior of the ERK proteins with respect to association 
with low-density membrane domains.  We find that ERKs 1 and 2 associate with low-
density domains of the plasma membrane in conjunction with the GnRHR in a 
constitutive and cholesterol-dependent manner, both in αT3-1 gonadotropes, as well as 
in whole mouse pituitary.  Membrane-associated ERKs are activated rapidly following 
exposure of cells to a GnRH agonist.  In addition, the GnRHR and ERKs co-
immunoprecipitate from low-density membrane preparations, lending further support 
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for our model of a raft-associated multiprotein signaling complex as a functional link 
between the GnRHR and the ERK signaling module.  
 
MATERIAL AND METHODS 
 
Cells, Antibodies, and Chemicals 
αT3-1 cells, an immortalized mouse gonadotrope cell line (generously 
provided by Dr. Pamela Mellon, University
 
of California, San Diego), were cultured as 
described previously (21).  Anti-ERK2 (sc-154-G), anti-G q/11 (sc-352), and 
horseradish peroxidase (HRP)-conjugated secondary antibodies were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA).  Secondary antibodies and FITC-
streptavidin used for immunohistochemistry were from Jackson Immunoresearch 
(West Grove, PA).  Anti-phospho-ERK1/2 antibody was from Sigma Chemical Co. 
(St. Louis, MO).  Anti-Flotillin-1 antibody was from BD Biosciences (San Jose, CA).  
Anti-EEA-1 antibody was from Upstate Biotechnology (Lake Placid, NY).  Anti-Ca 
pan α-1 antibody was from Alomone Labs (Jerusalem, Israel).  Anti-LH antibody was 
from A.C. Parlow and the National Hormone and Peptide Program sponsored by 
NIDDK. Anti-transferrin receptor antibody was purchased from Zymed laboratories 
(San Francisco, CA). Tissue-Tech OCT compound was from Miles Inc. (Elkhart, IN).  
HRP-conjugated streptavidin was from Vector Laboratories (Burlingame, CA).  The 
GnRHR antibody was raised in a rabbit against 20 amino acids of the second 
extracellular loop (aa193-aa212) of the ovine GnRHR. This sequence shows no 
overlap with any other receptor or peptide.  Buserelin (des-GLY
10
 [D-Ser(t-But)
6
 ]-
LH-RH Ethylamide;
 
referred to as GnRHa), methyl-β-cyclodextrin (CD), and 
cholesterol-loaded CD (CDChol), and all other chemicals were obtained from Sigma. 
In all experiments, GnRHa was used at 10 nM.  Alexa Fluor® 594 membrane raft 
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labeling kit (CTxB) was obtained through Molecular Probes (Eugene, OR). Glass 
bottom microwell dishes for confocal studies were obtained from Mat-Tek (Ashland, 
MA). Superfect transfection reagent was purchased from Qiagen (Valencia, CA). 
 
Confocal microscopy 
αT3-1 cells grown on glass bottom microwell dishes were transiently 
transfected with a GnRHR construct with a GFP fluorophore linked to the C-terminus 
for 48 hours. Following 48 hours of transfection, GM1 domains were labeled with 
Alexa Fluor® 594 CTxB at 4°C. Anti-CTxB antibody was then used to crosslink the 
CTxB labeled domains. Cells were fixed in 4% paraformaldehyde for 10 minutes at 
room temperature and then imaged. Imaging was done utilizing the 63X oil objective 
and the 488nm and 543nm laser lines of a Zeiss LSM 510 Meta confocal microscope. 
The
 
Alexa594 and GFP signals were acquired using multitrack mode
 
and no crosstalk 
between Alexa594 and GFP was observed.  Transferrin receptor (Tf-R) co-localization 
with GM1 was assessed in αT3-1 cells using the same Alexa Fluor® 594 CTxB 
staining approach described above. Following GM1 labeling, αT3-1 cells were fixed in 
4% paraformaldehyde for 10 min at room temperature. Cells were blocked in PBS 
containing 3% BSA and then incubated with anti-transferrin antibody overnight at 
4°C. The following day, cells were washed and labeled with an Alexa Fluor® 488 
conjugated anti-mouse secondary antibody for 1 hour. Cells were then imaged by 
confocal laser scanning microscopy (CLSM) as above. Quantitative analysis of 
fluorophore co-localization is expressed as a scatter diagram (50).  Identical images 
(co-localization) produce a clean diagonal line running from the bottom left to the top 
right. Differences between the images cause an irregular distribution in the scatter 
diagram.  
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Tissue Preparation and Immunohistochemistry 
Male mice were anesthetized with ketamine and transcardially perfused with 
100ml 1% sodium nitrite in 0.9% NaCl, followed by 200ml of fixative (4% 
paraformaldehyde, 15% saturated picric acid in 0.1M phosphate buffer (PB), pH 7.4) 
and then 100ml cryoprotectant (20% sucrose in 0.1M PB). Pituitaries were removed 
and stored in cryoprotectant overnight at 4
o
C. Tissue was embedded in Tissue-Tech 
OCT compound and frozen by immersion in liquid nitrogen-cooled isopentane. 
Sections (20µm) were mounted on Silane-coated slides and stored at -80C. 
Sections were washed (all washes 3 3 min in 0.01M PBS) and incubated (48 
h) in a solution containing a rabbit anti-GnRHR antibody (1:2000; 10% goat serum, 
0.3% Triton in PBS) as well as a horse anti-ovine LH antibody (1:5000). Sections 
were washed and immersed in biotinylated goat anti-rabbit IgG and goat anti-horse 
IgG linked to Texas Red (90 min; both at 1:200).  Following additional washing, 
sections were immersed in FITC-streptavidin (90 min; 1:200), washed, mounted and 
examined by conventional immunofluoresence microscopy. 
 
Cell Surface Biotinylation 
Cell surface biotinylation was performed using a commercial kit (Molecular 
Probes/Invitrogen, Carlsbad, CA) with minor modifications.  Biotin-XX-
sulfosuccinimidyl ester (Biotin-XX-SSE) was dissolved in DMSO at a concentration 
of 0.2 mg/mL and then diluted to a final concentration of 0.5 µg/mL in PBS.  T3-1 
cells were serum-starved in DMEM for 2 hours and then placed on ice.  Cells were 
washed twice with cold PBS and then incubated on ice for 15 minutes in 1 mL of 
Biotin-XX-SSE in PBS per 12cm
2
 of culture dish surface area.  Cells were then 
washed twice in cold PBS prior to collection. 
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Cell Fractionations 
To assess the specificity of cell-surface biotinylation, T3-1 cells
 
were grown 
to 80% confluence in 10 cm
2
 dishes, and surface biotinylated as described above.  
Cells were scraped into PBS and pelleted by centrifugation.  Cell pellets were 
resuspended in 500 µL of homogenization buffer (HB) containing 250 mM sucrose, 3 
mM imidazole, pH 7.4, 2 mM EDTA, and protease inhibitors.  A 50 µL aliquot of the 
whole cell suspension (representing 10% of the total input) was reserved.  The 
remaining suspension was incubated on ice for 10 minutes, homogenized in a glass 
dounce, and centrifuged for 10 minutes at 3,000 rpm.  The post-nuclear supernatant 
was collected, and centrifuged at 100,000 x g at 4
o
C for 30 minutes.  The resulting 
supernatant and pellet (representing cytosolic and total membrane fractions, 
respectively), as well as the input were boiled in SDS load buffer. 
Detergent-resistant, low-density membrane fractions were prepared essentially 
as described previously (21).  Briefly, αT3-1 cells were grown to 70-80% confluence 
in 15 cm
2
 dishes.  Following the treatments indicated, cells (~1.5 x 10
8
 per dish) were 
washed twice in cold PBS, and scraped into PBS with protease inhibitors.  Cells were 
pelleted by centrifugation and then resuspended in MES buffer (MBS) containing 25 
mM MES, pH6.5, 130 mM NaCl, and protease inhibitors to a final volume of 400 µL.  
The samples were adjusted to the indicated concentration of Triton X-100 and 
incubated on ice for 10 minutes.  Following dounce homogenization (20 strokes), the 
samples were mixed with an equal volume of 90% sucrose, placed in a 5 mL 
ultracentrifuge tube, and overlaid with a discontinuous gradient of sucrose in MBS 
consisting of 35% (3.7 mL) and 5% (500 µL) layers.  The gradients were centrifuged 
at 116,000 x g in a SW50.1 rotor for 20 hours at 4
o
C.  Low-density detergent resistant 
membranes were visible as a band of flocculent material at the 35-5% interface.  
Fractions (500 µL) were collected starting from the top of the gradient.  
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Detergent-free fractionations were performed as described previously (51) with 
minor modifications.   T3-1 cells (~4 x 10
8
 cells) were washed and scraped into PBS 
as described above.  Cells were pelleted by centrifugation and washed once in 5 mL 
cold HB.  Cell pellets were resuspended in 2.2 mL HB containing 50 µg/mL 
cycloheximide, and gently homogenized in a glass dounce (8 strokes).  Nuclei and 
unbroken cells were pelleted by centrifugation and 2 mL of the post-nuclear 
supernatant were collected and mixed with 2.4 mL of HB-sucrose containing 62% 
sucrose, 3 mM imidazole, pH 7.4, 2 mM EDTA, and protease inhibitors to achieve a 
final sucrose concentration in the sample of 40.6%.  The homogenate was transferred 
to a 13 mL ultracentrifuge tube, and overlaid with a discontinuous gradient of HB-
sucrose consisting of 35% (4 mL), 25% (3 mL), and HB (600 µL).  Samples were 
centrifuged in a SW41 rotor at 35,000 rpm, 4
o
C for one hour.  Translucent bands of 
material visible at each interface were collected, diluted four-fold in cold PBS, and 
repelleted by centrifugation at 100,000 x g for 30 minutes at 4
o
C.  Pellets were 
resuspended in SDS load buffer and boiled.         
Female B6/129 mice (8-20 weeks of age) were euthanized by CO2 
asphyxiation.  Pituitaries were collected and placed in DMEM containing 10% fetal 
bovine serum on ice.  Pituitaries were washed once in cold PBS and once in cold 
MBS, and homogenized as described above.  Animal use and experimental protocols 
for these studies
 
were approved by the Cornell University Institutional Animal
 
Care 
and Use Committee.  For whole pituitary fractionations, pituitaries (n=20) were 
resuspended in 400 µL cold MBS containing 0.1% Triton X-100, homogenized in a 
glass dounce (20 strokes), and subjected to discontinuous sucrose density 
centrifugation as described above for preparation of detergent-resistant low-density 
membranes. 
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Preparation of Cell Lysates, Immunoblotting, and Streptavidin Overlay Assays 
After the indicated treatments, cells were washed twice in cold PBS, and 
scraped into cold PBS containing 5 mM sodium vanadate, 0.2 mM 
phenylmethylsulfonyl fluoride, and 5 mM benzamidine.  Cells were pelleted by 
centrifugation and pellets were resuspended in a radioimmunoprecipitation
 
assay 
(RIPA) buffer containing 20 mM Tris-HCl (pH 8.0), 137
 
mM NaCl, 10% glycerol, 1% 
Nonidet P-40, 0.1% sodium dodecyl
 
sulfate (SDS), 0.5% deoxycholate, 2 mM EDTA, 
5 mM sodium vanadate,
 
0.2 mM phenylmethylsulfonyl fluoride, 5 mM benzamidine. 
Lysates were cleared by centrifugation and protein concentrations of
 
the lysates were 
determined by Bradford assay.  Protein samples were boiled for 5 minutes in SDS load 
buffer, resolved
 
by SDS-PAGE and transferred to polyvinylidene difluoride 
membranes
 
by electroblotting. Membranes were blocked with 5% nonfat dry
 
milk 
(NFDM) in TBST (10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.05%
 
Tween 20) and 
then incubated with primary and horseradish peroxidase (HRP)-conjugated secondary 
antibodies.  For streptavidin overlay assays, blots were blocked as described, and then 
incubated at room temperature for 1 hour in a 1:10,000 dilution of streptavidin-HRP in 
TBST.  Protein bands were visualized
 
using enhanced chemiluminescence according 
to the manufacturer‟s instructions (PerkinElmer, Boston, MA).   
 
Cholesterol Depletion and Repletion 
T3-1 cells were cultured in 6 cm
2
 dishes to 70-80% confluence.  Following 
serum starvation for 2 hours, cells were incubated in DMEM or DMEM containing 
2% methyl-β-cyclodextrin (CD) for the indicated times.  For cholesterol repletion, 
CD-containing media was exchanged for DMEM containing 0.5 mg/mL cholesterol in 
the form of cholesterol-loaded CD for the indicated times. Total cellular cholesterol 
was measured from 2 uL aliquots of clarified RIPA lysate using a commercial kit 
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(Amplex Red, Molecular Probes/Invitrogen, Carlsbad, CA) according to the 
manufacturer‟s instructions.   
 
Immunoprecipitation 
Aliquots (400 µL) of fractions containing suspensions of low-density 
membranes, or sucrose alone, were diluted in an equal volume of PBS and adjusted to 
0.01% Triton X-100.  Anti-GnRHR immune serum (IS, 25 µL), non-immune rabbit 
serum (NRS, 25 µL), or vehicle (PBS, 25 µL), were added, and the samples were 
rocked for 4 hours at 4
o
C.  Protein A/G agarose beads (30 µL) were added and the 
samples were rocked an additional hour at 4
o
C.  Beads were then washed 3 times in 
PBS with 0.01% Triton X-100, resuspended in 60 µL of SDS load buffer, and boiled. 
 
Statistical Analysis 
Data on cholesterol concentration were analyzed using a One-way Analysis of 
Variance with a Bonferoni post-hoc multiple comparisons test.  Significance for each 
pairwise comparison was determined at p< 0.01.    
 
RESULTS 
 
GnRHR colocalizes with the ganglioside GM1 in αT3-1 cell plasma membrane. 
Low-density membrane microdomains (membrane rafts) are enriched in the 
ganglioside GM1.  The B-subunit of cholera toxin (CtB) binds specifically to plasma 
membrane GM1 and has been used as a marker for GM1-enriched plasma-membrane 
subdomains in living cells (22).  We have reported biochemical data indicating that the 
GnRHR resides constitutively within low-density membrane domains in a cholesterol-
dependent manner (21).  To further characterize the tendency of the GnRHR to  
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Figure 2.1. GnRHR co-localizes with GM1 positive membrane domains in αT3-1 
cells.  A, αT3-1 cells transiently expressing a GnRHR-GFP fusion protein were 
stained with Alexa 594 conjugated CTxB and fixed. Confocal images of the separated 
fluorescence channels show membrane localization of the GnRHR-GFP (green 
channel) and Alexa 594 GM1 (red channel). Merged images show the overlay of the 
two flurophores.  αT3-1 cells were stained for GM1 using Alexa 594 CTxB. Cells were 
then fixed and immunostained for transferrin receptor using an Alexa 488 conjugated 
second antibody. Confocal images of the separated fluorescence channels show 
membrane localization of the TfR (green channel) and Alexa 594 GM1 (red channel). 
Merged images show the overlay images of the two flurophores. B, Using quantitative 
colocalization analysis,
 
the merged GnRHR-GFP and Alexa 594 GM1 image was 
computed and
 
expressed as a scatter diagram. Co-localization of fluorophores 
produces a clean diagonal line running from the bottom left to the top right indicating 
that GnRHR and GM1 are colocalized on the plasma membrane. In contrast, 
differences between fluorescence localization causes an irregular distribution in the 
scatter diagram indicating that TfR and GM1 display little colocalization. 
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partition into subdomains of the plasma membrane, we probed αT3-1 cells that stably 
express a GnRHR-GFP fusion protein with Alexa-594-conjugated CtB and examined 
the cells by laser confocal scanning microscopy (Figure 2.1).  GnRHR-GFP localized 
exclusively to the plasma membrane and co-localized with GM1-positive domains.  As 
a control, endogenously expressed transferrin receptor did not co-localize with CtB-
Alexa-594/GM1 positive membrane domains suggesting that GnRHR co-localization 
with GM1 was specific in this assay.  Consistent with our previous biochemical studies 
these data indicate that the GnRHR resides constitutively within regions of the plasma 
membrane marked by GM1. 
 
Anti-GnRHR immune serum binds specifically to its cognate epitope in both 
immunoblotting and immunohistochemical applications.   
The anti-GnRHR antibody used in these studies was raised against a conserved 
region of the second extracellular loop of the mammalian type I GnRHR.  To validate 
the performance of this antibody in the studies reported here, we treated αT3-1 cells 
with GnRHa (the GnRH agonist buserelin) for various time periods and examined 
whole cell lysates for GnRHR protein expression by immunoblot analysis.  As shown 
in Figure 2.2A, the GnRHR antiserum generated a predominant band of 
immunoreactivity of approximately 50 kD.  Consistent with previous reports of 
GnRH-induced upregulation of GnRHR in gonadotropes (23), the target of this 
antibody showed clear upregulation in response to GnRHa.  When used for 
immunohistochemical examination of sections of mouse pituitary, the same antiserum 
discretely marked a subpopulation of cells within the anterior lobe; co-staining with an 
antibody against LHβ subunit indicated nearly complete colocalization of GnRHR and 
LHβ immuno-fluorescence (Figure 2.2B).  These validation studies provide evidence  
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Figure 2.2. Validation of GnRHR antiserum.  A, αT3-1 cells were treated with 
GnRHa for the indicated times.  Whole cell lysates were analyzed by SDS-PAGE and 
immunoblotting using anti-GnRHR immune serum.  -actin was used as a loading 
control.  B, Histological sections of mouse pituitary were probed simultaneously with 
anti-GnRHR immune serum and an antibody against LH.  Sections were then 
incubated in fluorochrome-conjugated secondary antibodies, mounted, and examined 
by fluorescence microscopy.  PP = posterior pituitary; AP = anterior pituitary. 
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that this antibody recognizes both denatured and non-denatured conformations of its 
cognate epitope on the GnRHR with high specificity.  
 
ERK 2 associates constitutively with detergent-resistant, low-density membrane 
domains in αT3-1 cells. 
We previously reported that the GnRHR, G q/11, and c-raf, the putative 
upstream activator of the ERK signaling pathway in gonadotropes, associate 
constitutively with low-density, detergent-resistant membrane domains (DRMs) in 
αT3-1 cells (21).  Based on this data, we proposed that raft domains may play a key 
role in GnRH-induced ERK activation by serving as a platform for the association of 
key intermediates of this signaling pathway.  To further explore this model, we 
fractionated αT3-1 cells in the presence of 0.1% Triton X-100 and analyzed low-
density fractions for the presence of the ERK proteins.  A small proportion of total 
cellular ERK 2 partitioned constitutively into low-density fractions (Figure 2.3A).  
When the microsomal suspensions in the low-density fractions were re-homogenized 
and repelleted by high-speed centrifugation, ERK immunoreactivity appeared only in 
the membrane pellet, indicating that the ERK protein recovered in association with 
DRMs is indeed membrane-associated (data not shown).  Phosphorylated ERK was 
detected in the low-density fractions within 5 minutes of GnRHa administration, and 
the kinetics of activation of membrane-associated ERK appeared to parallel the 
kinetics of non-membrane-associated ERK. (Figure 2.3B).  Consistent with our 
previous results, the GnRHR as well as the G q/11 heterotrimeric G-protein subunit and 
the lipid raft marker flotillin-1 associated preferentially with the low-density fractions 
(Figure 2.3A).  As a further control, the membrane-associated α1 subunit of the L-type 
voltage gated calcium channel was not present in low-density fractions.  This latter  
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Figure 2.3 ERK2 associates with detergent-resistant, low-density membrane 
fractions in αT3-1 cells.  A, αT3-1 cells were homogenized in the presence of 0.1% 
Triton X-100 and subjected to discontinuous sucrose density gradient centrifugation.  
Fractions were collected from the top of the gradient and analyzed by SDS-PAGE and 
immunoblotting using antibodies against the GnRHR, G q/11, and ERK2, as well as the 
lipid raft marker flotillin-1, and the non-raft associated Cavpan α-1 calcium channel 
subunit.  B, Cells were treated with GnRHa or vehicle for the indicated times and 
fractionated as in A.  Fractions were collected and aliquots of low- and high-density 
fractions were analyzed by SDS-PAGE and immunoblotting using antibodies against 
phosphorylated ERK (p-ERK) and ERK2.     
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Figure 2.4. GnRHa stabilizes the association of ERK2 with detergent-resistant, 
low density membrane domains in αT3-1 cells.  Cells were treated with GnRHa or 
vehicle for 15 minutes and then homogenized in the presence of 1.0% Triton X-100.  
Homogenates were fractionated by discontinuous sucrose density gradient 
centrifugation and fractions were collected from the top of the gradient. Fractions were 
analyzed by immunoblot using an antibody against ERK2 (A) or phosphorylated ERK 
(p-ERK, B).  
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observation supports the specificity of the fractionation method, and provides a useful 
negative control for analysis of membrane rafts in gonadotropes.    
The DRMs analyzed in Figure 2.3 were isolated following homogenization of 
cells in the presence of 0.1% Triton X-100.  Under these conditions, the association of 
ERKs with low-density membranes was unaffected by administration of GnRHa (data 
not shown).  In contrast, homogenization of unstimulated cells in the presence of 1.0% 
Triton X-100 interrupted the association of ERKs with DRMs (Figure 2.4A).  
However, following 15 minutes of exposure to GnRHa, the association of ERKs with 
DRMs was rendered refractory to the effects of high detergent concentration (Figure 
2.4A),  Phosphorylated ERK was also detected in the low-density fractions of GnRHa 
treated cells following homogenization in the presence of the higher detergent 
concentration (Figure 2.4B).  This observation is consistent with the behavior of c-Raf 
under similar experimental conditions, and suggests that the signaling activity induced 
by GnRHR occupancy is capable of stabilizing interactions amongst the participants of 
a putative raft-associated signaling complex. 
 
ERK2 and the GnRHR associate preferentially with low-density membranes 
isolated in the absence of detergent.  
Resistance to detergent solubilization is an important operational characteristic 
of membrane rafts (24).  Indeed, sucrose density gradient centrifugation of cell 
homogenates prepared in the presence of low concentrations of non-ionic detergents 
remains the most common method for isolation of these membrane domains.  
However, controversy remains regarding the effects of detergents on cellular 
membranes, and some evidence suggests that detergent solubilization may itself 
enhance the ability of lipid bilayers to adopt a liquid ordered (lo) conformation (25).   
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Figure 2.5. In αT3-1 cells, GnRHR and ERK2 associate with low-density 
membrane domains isolated in the absence of detergent.  A, αT3-1 cells were 
surface biotinylated and separated into whole cell lysate (WCL), cytosolic (CYT), and 
crude membrane (CM) fractions.  Fractions along with non-biotinylated whole cell 
lysate were subjected to SDS-PAGE and analyzed by streptavidin overlay. Molecular 
weights are indicated in kD. B,C, cells were homogenized in a detergent-free buffer, 
and the post-nuclear supernatant was subjected to discontinuous sucrose density 
gradient centrifugation (40.6, 35, 25, 5%). Microsomal suspensions were collected 
from the upper (U), middle (M), and lower (L) interfaces of the gradient and the 
membranes were repelleted by centrifugation at 100,000 x g. Membrane pellets were 
electrophoresed and analyzed by streptavidin overlay (B) and immuno-blotting using 
antibodies against the indicated proteins (C).  
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To further assess the validity of our observations regarding the association of ERKs 
with DRMs, we adapted a technique based on sucrose density gradient centrifugation 
of post-nuclear supernatant for fractionation of subcellular membranes in the absence 
of detergent (26).  Using this method, Huber and colleagues describe clear separation 
of low-, intermediate- and high-density subcellular membrane fractions enriched in 
late endosomes/lysosomes, early endosomes and plasma membrane, respectively.  We 
reasoned that this method might simultaneously result in separation of low- and high-
density subdomains of plasma membrane, thereby providing a complementary method 
for detergent-free isolation of membrane rafts.  Initially, we used cell surface 
biotinylation to track the plasma membrane proteins during the fractionation.  
Consistent with previous reports (27), in the absence of cell surface biotinylation, 
streptavidin overlay assays revealed the presence of a small number of endogenously 
biotinylated proteins in αT3-1 whole cell lysates (Figure 2.5A).  Following cell surface 
biotinylation and separation of cell homogenates into cytosolic and total membrane 
fractions, streptavidin overlay assays revealed the majority of biotinylation within the 
membrane fraction, verifying the cell impermeability of the biotinylation reagent, and 
validating this assay for tracking of bulk plasma membrane during fractionation 
(Figure 2.5A).  Discontinuous sucrose density gradient fractionation of αT3-1 cell 
postnuclear supernatants following cell surface biotinylation revealed that the majority 
of plasma membrane localized to the high density fraction (35-40% sucrose interface, 
Figure 2.5B).  Microsomal suspensions retrieved from the middle fraction of the 
sucrose gradient (25-35% sucrose interface) were enriched in the early endosomal 
marker EEA-1 (Figure 2.5C).  However, both the GnRHR and the lipid raft marker 
flotillin-1 partitioned exclusively into this middle fraction, indicating that this 
technique allows effective separation of low-density subdomains of plasma 
membrane.  Both the ERKs as well as G q/11 associated with the lower density middle 
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fraction in a manner unaffected by GnRHa treatment (Figure 2.5C).  Following 
GnRHa treatment, phosphorylated ERK was similarly detected in the lower density 
middle fraction.  Immunoreactivity for the proteins examined was undetectable in the 
low-density upper fraction (data not shown).    
 
Both the association of ERK2 with low-density membrane domains as well as 
ERK inducibility by GnRHa are susceptible to perturbation of cellular 
cholesterol levels. 
Analysis of lipid behavior in model membranes indicates that lo domain 
formation is highly dependent upon cholesterol (28).  Cholesterol is also understood to 
be critically important in the formation of lipid raft domains in living cells (29).  We 
previously reported that, in αT3-1 cells,  depletion of cellular cholesterol led to a 
dissociation of the GnRHR from a detergent-resistant, low-density membrane 
environment as well as a reversible uncoupling of the ability of GnRH to activate the 
ERK pathway (21).  To further define the importance of cholesterol-dependent 
membrane organization for the function of this signaling pathway, we used a 
depletion/repletion strategy to define the kinetics of recovery of GnRH-induced ERK 
activation following cholesterol perturbation.  Exposure of cells to methyl-β-
cyclodextrin (CD) for 40 minutes resulted in a complete loss of both the GnRHR and 
the ERKs from DRMs (Figure 2.6A).  However, the association of the lipid raft 
marker flotillin-1 with DRMs was unaffected, indicating that cholesterol depletion did 
not promote complete solubilization of this membrane compartment (Figure 2.6A).  
Consistent with our previous results, CD exposure resulted in a significant decrease in 
cellular cholesterol to approximately 50% of control levels and led to a complete block 
of ERK activation by GnRH (Figure 2.6B).  Repletion of cholesterol by exposure of  
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Figure 2.6. Normalization of cellular cholesterol restores the association of ERK2 
with low-density membrane domains in αT3-1 cells following cholesterol 
depletion, but this is not sufficient to reconstitute cholesterol-dependent ERK 
inducibility by GnRH.  A, Cells were cultured in the absence (Control) or presence 
(Depletion) of methyl- -cyclodextrin (CD) for 40 minutes. Some cells were then 
incubated in media containing 0.5 mg/mL of cholesterol in the form of cholesterol-
loaded CD (CDChol) for 60 minutes (Depletion + repletion).  Cells were homogenized 
in the presence of 0.1% Triton X-100 and fractionated by discontinuous sucrose 
density gradient centrifugation.  Fractions were analyzed by immunoblot using anti-
GnRHR immune serum, or antibodies against ERK2 and the lipid raft marker Flotillin-
1.  B, Cells were subjected to cholesterol depletion and repletion as in (A).  Some 
samples were then incubated for the indicated times in cholesterol-free media (Media).  
Whole cell lysates were analyzed by immunoblot for phosphorylated and total ERK 
proteins.  Total cellular cholesterol measurements were normalized to total protein 
concentrations and are expressed as mean +/-SEM for 4 separate experiments. 
Asterices indicate significant differences from the control group (p<0.01) 
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cells to CD pre-loaded with cholesterol (CDChol) for 60 minutes normalized cellular 
cholesterol levels and led to reassociation of both the GnRHR and ERKs with DRMs 
(Figure 2.6A).  However, despite normalization or even mild elevation of total cellular 
cholesterol, ERK inducibility by GnRH was not restored for up three hours (Figure 
2.6B).  Moreover, exposure of αT3-1 cells to CDChol alone led to an approximately 3-
fold increase in cellular cholesterol levels and caused a block in ERK activation by 
GnRH that developed with highly similar kinetics (data not shown).  These results 
suggest that cholesterol homeostasis is critical for normal signaling through the 
GnRHR and implicate a complex process of dynamic membrane (re-)organization as 
an important regulatory feature in the functional re-establishment of the ERK pathway 
following perturbation of cholesterol homeostasis in cell membranes. 
 
GnRHR and ERK2 co-immunoprecipitate from low-density membrane domains 
in T3-1 cells. 
Our experimental results to date suggest the possibility that ERK activation 
following GnRHR occupancy may be initiated through the interaction of several 
signaling intermediates (G q/11, c-Raf, ERKs) that are compartmentalized in proximity 
to the GnRHR through association with low-density plasma membrane microdomains.  
However, our data do not rule out the possibility that co-fractionation of multiple 
signaling proteins in this pathway represents the isolation of a complex, mixed 
population of subcellular membrane compartments.  For example, many components 
of the ERK pathway have been shown in other systems to be assembled in association 
with endosomal membranes through interactions with specific scaffolds and adaptors 
(30, 31).  To further determine whether the GnRHR and ERKs associate with a 
common membrane environment within the raft compartment, we immunoprecipitated  
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Figure 2.7. GnRH receptor and ERK2 co-immunoprecipitate from low-density 
membrane fractions in αT3-1 cells. A, Cells were homogenized in the presence of 
0.1% Triton X-100 and fractionated through a discontinuous sucrose gradient.  
Fractions were collected and aliquots were analyzed by immunoblot using an antibody 
against ERK2.  B, GnRHR was immunoprecipitated from fraction 3 of the experiment 
in A (lanes 3-5) using anti-GnRHR immune serum (IS), nonimmune serum (NRS) or 
beads alone (Beads).  Control immunoprecipitations were performed in sucrose alone 
(lanes 6-8).  Whole cell lysate (WCL, 1 ug lane 1), 5% of the input for each IP (Input, 
lane 2) and the immunoprecipitates were analyzed by immunoblot using an anti-ERK2 
antibody.  C.   Cells were homogenized in the absence of detergent and fractionated by 
discontinuous sucrose density gradient centrifugation (40.6, 35, 25, 8%). GnRHR was 
immunoprecipitated from microsomal suspensions at the 25-35% sucrose interface 
using anti-GnRHR immune serum (IS), nonimmune serum (NRS) or beads alone 
(Beads). Whole cell lysate (WCL, 1 µg, lane 1), 5% of the input for each IP (Input, 
lane 2) and the immunoprecipitates (lanes 3-5) were analyzed by immunoblot using an 
anti-ERK2 antibody.   
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the GnRHR from low-density membrane suspensions and examined the 
immunoprecipitates for the presence of ERKs.  ERKs co-immunoprecipitated with the 
GnRHR from DRMs (Figure 2.7A and B), as well as from microsomal suspensions 
prepared in the absence of detergent (Figure 2.7C).  The reciprocal 
immunoprecipitations targeting ERK2 followed by immunoblot analysis for the 
GnRHR were uninformative due to a high level of non-specific signal arising from the 
heavy chain of the anti-ERK2 primary antibody. 
 
GnRHR associates with low-density membrane domains in whole mouse 
pituitary, and co-immunoprecipitates with ERK2 in mouse pituitary 
homogenates. 
Our data from αT3-1 cells strongly implicate low-density membrane 
microdomains in the regulation of ERK activation by GnRH.  To determine whether 
these domains may play a similar role in organization of this signaling pathway in 
differentiated gonadotropes in vivo, we examined DRMs from homogenates of whole 
mouse pituitaries.  The GnRHR partitioned into low-density DRMs in a manner 
similar to that observed in T3-1 cells (Figure 2.8A).  Flotillin-1 was present 
exclusively in the low-density fractions, while transferrin receptor was detected only 
in the high-density solubilized fractions (data not shown).  ERKs were also detectable 
in low density fractions from pituitary homogenates (Figure 2.8A).  Whole pituitary 
represents a diversity of cell types in which ERKs are ubiquitously expressed; thus the 
presence of ERKs within low-density fractions of pituitary homogenates does not 
provide evidence for cell type specificity regarding the association of ERKs with low-
density membranes.  To further determine whether ERKs associate with a low-density 
membrane compartment in gonadotropes, we immunoprecipitated the GnRHR from  
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Figure 2.8.  GnRHR and ERK2 co-immunoprecipitate from detergent-resistant, 
low-density membranes in whole mouse pituitaries.  A, whole mouse pituitaries 
were homogenized in the presence of 0.1% Triton X-100 and subjected to 
discontinuous sucrose density gradient centrifugation.  Fractions were collected from 
the top of the gradient and aliquots of each fraction were analyzed by immunoblot 
using anti-GnRHR immune serum and anti-ERK2 antibody. B, GnRHR was 
immunoprecipitated from fraction 3 of the same experiment using anti-GnRHR 
immune serum (IS), nonimmune serum (NRS) or beads alone (Beads). Whole cell 
lysate (WCL, 1 ug, lane 1), 5% of the input for each IP (Input, lane 2) and the 
immunoprecipitates (lanes 3-5) were analyzed by immunoblot using an anti-ERK2 
antibody.  
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DRMs of pituitary homogenates and examined the precipitates for the presence of 
ERKs.  Consistent with our observations in αT3-1 cells, ERKs co-immunprecipitated 
with the GnRHR indicating that these proteins associate with a common membrane 
environment in vivo (Figure 2.8B).  
 
DISCUSSION 
Subcellular compartmentalization of signaling proteins is now recognized as a 
mechanism by which signaling activity may be temporally and spatially regulated 
within the cell, or by which the activation of a given signaling pathway may be linked 
to a diversity of biological outcomes (32-34).  This has become particularly evident in 
the area of GPCR signaling.  While early studies of GPCR function focused on the 
role of activated G-protein α subunits in the generation of diffusible second 
messengers and modulation of ion conductances, current models emphasize the spatial 
segregation and trafficking of cell surface receptors amongst discrete subdomains of 
the plasma membrane, as well as the ability of internalized GPCRs to couple to 
diverse intracellular signaling cascades, including the ERK module of the MAPK 
system (35).  Consistent with these themes, we previously demonstrated that, unlike 
other GPCRs, the GnRHR partitions constitutively and exclusively into membrane 
rafts, and that this raft association was required for the ability of this GPCR to couple 
to the ERK pathway in the αT3-1 gonadotrope cell line (21).  The results described 
here expand upon these earlier findings and show that the GnRHR partitions into low-
density membrane domains in whole mouse pituitary as well in αT3-1 cells.  These 
results further support the use of this cell line as a model of GnRHR behavior in 
pituitary gonadotropes, and suggest that compartmentalization of the GnRHR into 
low-density membrane microdomains is of functional significance in vivo.   
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Following ligand activation, most GPCRs are rapidly phosphorylated, 
desensitized, and targeted for clathrin-mediated endocytosis through association with 
β-arrestins. (36).  Arrestins have also been shown to provide an important link 
between many GPCRs and the ERK pathway by nucleating specific signaling 
complexes on the surface of receptor-laden early endosomes (37-39).  However, the 
GnRHR is not phosphorylated following ligand binding, and does not associate with 
arrestins (40).  Furthermore, the delayed kinetics of GnRHR internalization suggests 
that GnRH-induced ERK activation occurs independently of receptor internalization 
(41).  Previously, we proposed a model in which coupling of the GnRHR to the ERK 
pathway involves, at least in part, the assembly of a raft-associated signaling complex 
consisting minimally of the GnRHR, G q, and c-Raf (21).  Our present confocal 
imaging data shows that the vast majority of the GnRHR population localizes to GM1-
enriched regions of the plasma membrane in αT3-1 cells.  Furthermore, we show that 
the GnRHR and ERKs co-immunoprecipitate from low-density membrane fractions 
both in αT3-1 cells as well as whole mouse pituitary.  These data demonstrate a close 
physical proximity between the GnRHR and ERKs at the level of the plasma 
membrane and provide further support for our model of a specific plasma membrane-
associated signaling complex as a link between the GnRHR and the ERK pathway in 
gonadotropes.  
In these studies, the behavior of the ERKs with respect to their association with 
low-density membrane domains was similar to our previous observations of c-Raf 
(21).  Both c-Raf and the ERKs partitioned constitutively and partially into low-
density membrane fractions, both in αT3-1 cells and in whole mouse pituitary.  In 
addition, these kinases were rapidly activated within this membrane compartment 
following GnRHa stimulation (21).  The small proportion of total cellular ERKs that 
partitioned into the low-density membrane compartment may reflect the overall small 
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size of this compartment, or may indicate a relative paucity of ERK docking sites 
within this compartment, dictated perhaps by the specific architecture of raft-
associated complexes.  Also, since signaling complexes are characterized by low-
affinity interactions, it is possible that dissociation and loss of some of these 
complexes from low-density membranes during homogenization and fractionation led 
to an underestimation of the proportion of ERKs that reside within this compartment 
in intact cells.  Like c-Raf, the association of ERKs with membrane rafts in resting 
cells was completely disrupted by homogenization of cells in higher concentrations of 
the non-ionic detergent Triton X-100.  Importantly, however, stimulation with GnRHa 
rescued the raft-association of ERKs, despite exposure of cells to higher detergent 
concentrations.  The biophysical basis for this increased resistance to detergent 
solubilization is unclear; however, the apparent increase in affinity of both c-Raf and 
ERKs for the low-density membrane compartment that is induced by GnRH argues 
that modulation of this membrane affinity is a specific biological effect of GnRHR 
activation.  Finally, unlike c-Raf, association of ERKs with low-density membranes 
was susceptible to cholesterol depletion, and was restored following cholesterol 
replenishment, in a manner that paralleled the GnRHR.  Interestingly, ERKs do not 
possess a defined lipid binding domain, and, to our knowledge, have not been shown 
to interact directly with membranes (42).  Loss of ERKs from the low-density 
membrane compartment under conditions of cholesterol depletion likely reflects the 
cholesterol dependence of an intermediate, membrane-associated adapter protein(s).  
Our analysis of the kinetics of recovery of ERK inducibility following cholesterol 
depletion and repletion indicated that normalization of total cellular cholesterol levels 
and restoration of the raft-association of the GnRHR and ERKs are not sufficient for 
reconstitution of signaling.  This temporal lag in recovery of signaling is consistent 
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with a requirement for reorganization of a raft-associated multiprotein signaling 
complex. 
While numerous methods for the study of membrane rafts have been reported, 
the most commonly used method for their isolation remains extraction of cells with 
low concentrations of a nonionic detergent, followed by fractionation of the cell 
homogenate by density gradient centrifugation.  However, studies of model 
membranes have raised concerns regarding the ability of non-ionic detergents to 
promote the formation of a cholesterol-dependent lo phase (24, 43).  To address these 
concerns, our previous work analyzed both DRMs as well as membrane fractions 
prepared using a detergent-free, carbonate-based method to demonstrate association of 
the GnRHR with low-density membranes (21).  Here we report the use of an 
additional complementary technique for fractionation of subcellular membranes in the 
absence of detergent.   This method was originally used for isolation of microsomal 
suspensions enriched in early endosomes (26).  Huber and colleagues have shown that 
early endosomes are largely separable from plasma membrane on the basis of 
differential buoyant density alone (30).  Since membrane rafts are distinguishable 
from bulk plasma membrane by their lower buoyant density, as well as their detergent-
resistance, we reasoned that this technique might allow separation of membrane rafts 
from bulk plasma membrane in the absence of detergent.  Indeed, our results with this 
method show that both the GnRHR and the lipid raft marker flotillin-1 partitioned into 
a low-density microsomal fraction that is enriched in early endosomes.  Using cell-
surface biotinylation to track the plasma membrane during the fractionation, our data 
indicate that the majority of plasma membrane partitions into a higher density fraction, 
consistent with the notion that the membrane raft domains occupied by GnRHR 
constitute a small proportion of the total plasma membrane in these cells.  
Interestingly, membrane-associated ERKs showed a preference for the lower density 
91 
fraction.  Since this low-density fraction represents a mixed population of endosomal 
and plasma membrane elements, we cannot exclude the possibility that a significant 
proportion of the ERKs that partitioned into this fraction were associated with 
endosomes.  Indeed assembly of signaling complexes on endosomes is a prominent 
feature of the organization of the ERK pathway (30, 44).  However, our ability to co-
immunoprecipitate the GnRHR and ERKs from this fraction indicates that at least 
some of the ERKs within this compartment are associated specifically with GnRHR-
enriched plasma membrane rafts.  The appearance of phosphorylated ERK within this 
fraction following GnRHa treatment further supports this conclusion.  Overall, these 
data corroborate our analyses of DRMs and lend further support to our model of a raft-
based GnRHR signaling platform. 
While our data provide evidence for the association of ERKs with plasma 
membrane rafts in gonadotropes, the functions and substrates of this membrane-
associated ERK are unknown.  In most cell types, including gonadotropes, a 
substantial portion of activated ERK undergoes nuclear translocation following 
activation; indeed, phosphorylation of nuclear substrates involved in transcriptional 
regulation is often considered the predominant endpoint of pathway activation.   
However, ERKs have also been shown to target a variety of extranuclear substrates 
including cytoskeletal regulatory proteins and cytoskeletal elements, proteins involved 
in intracellular membrane trafficking, proteosomal subunits, and translational 
regulators (45-47).  While the functional link between the ERK pathway and the 
activity of many of these substrates has not been thoroughly defined, a recent report 
indicated that the ERKs play a key role in the GnRH-induced upregulation of LH  
mRNA translation in L T2 cells through phosphorylation of specific elongation 
initiation factors (48).  As a further example of the complex and multifunctional 
organization of this pathway, it has been shown that mitogen-induced activation and 
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nuclear translocation of the ERK substrate p90RSK1 is preceded by its transient 
translocation to the plasma membrane via a mechanism that involves ERK interaction, 
but that is independent of ERK phosphotransferase activity (49).  This raises the 
interesting possibility that, in addition to their prominent role as kinases, activated 
ERK proteins may serve adapter roles under certain circumstances.  Given the small 
proportion of total cellular ERK that resides within the raft compartment in our 
studies, it seems unlikely that the totality of ERK activation that occurs within these 
cells takes place within the context of the raft-associated GnRHR signaling platform 
proposed in our model.  However, we are intrigued by the possibility that raft-
associated ERKs play a role in the cellular response to GnRH by targeting a specific 
subcellular complement of substrates.  Determination of the functional importance of 
raft-associated ERKs in gonadotropes will require identification of the molecular 
determinants required for association of these proteins with membrane rafts, as well as 
the composition of the protein complexes that form within this compartment.  
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CHAPTER 3 
 
ERK SIGNALING IN THE PITUITARY IS REQUIRED FOR FEMALE BUT NOT 
MALE FERTILITY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Reprinted from Bliss SP, Miller A, Navratil AM, Xie JJ, McDonough SP, Fisher PJ, 
Landreth GE, Roberson MS. 2009. Mol Endocrinol, accepted for publication. With 
permission, Copyright 2007, The Endocrine Society. 
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SUMMARY 
Males and females require different patterns of pituitary gonadotropin 
secretion for fertility.  The mechanisms underlying these gender-specific profiles of 
pituitary hormone production are not known; however, they are fundamental to 
understanding the sexually dimorphic control of reproductive function at the 
molecular level.  Several lines of evidence have suggested that the extracellular signal-
regulated kinases ERK1 and 2 are essential modulators of hypothalamic GnRH 
mediated regulation of pituitary gonadotropin production and fertility.  To test this 
hypothesis, we generated mice with a pituitary specific depletion of ERK1 and 2 and 
examined a range of physiological parameters including fertility.  We find that ERK 
signaling is required in females for ovulation and fertility, while male reproductive 
function is unaffected by this deficiency.  The effects of ERK pathway ablation on 
luteinizing hormone production underlie this gender specific phenotype, and the 
molecular mechanism involves a requirement for ERK-dependent upregulation of the 
transcription factor Egr1, which is necessary for LH  expression.  Together, these 
findings represent a significant advance in elucidating the molecular basis of gender 
specific regulation of the hypothalamic-pituitary-gonadal axis and sexually dimorphic 
control of fertility.  
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INTRODUCTION 
The mitogen-activated protein kinase (MAPK) signaling pathways comprise a 
conserved set of signal transduction modules that are activated in response to a variety 
of extracellular stimuli (1).  The extracellular signal-regulated kinase (ERK) pathway 
is the most thoroughly characterized of the MAPK systems and consists of a 3-level 
phosphorylation cascade which, in its canonical form, includes the MAPK-kinase-
kinase Raf-1, the MAPK-kinases MEK1 and 2, and the MAPK‟s ERK1 (MAPK3) and 
ERK2 (MAPK1).  Activated ERKs phosphorylate a multitude of targets throughout 
the cell, exerting broad regulatory influence over a wide range of processes including 
transcription, translation, cell cycle regulation, cytoskeletal remodeling, and apoptosis 
(1).   
ERK1 and 2 are generally thought to serve overlapping functions; however, it 
has also been demonstrated that ERK1 and 2 may play quite distinct roles in some 
differentiated cells (2).  In addition, the ERK1 null mouse is viable and fertile while 
the ERK2 null is embryonic lethal (3, 4).  Thus, ERK1 and 2 clearly serve highly 
divergent functions during development (5).  A genetic model that would allow for 
systematic analysis of the functions of ERK1 and 2 within specific cellular or 
developmental contexts is highly desirable; however, the embryonic lethality of the 
ERK2 null mouse necessitates a conditional approach to the ablation of ERK2, and 
has presumably hampered development of such a model. 
The pituitary gland is a complex endocrine organ that regulates many aspects 
of mammalian homeostasis.  The anterior pituitary is composed of several major 
hormone-producing cell types including thyrotropes that produce thyrotropin-
stimulating hormone (TSH); and gonadotropes that produce follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH).  TSH, LH, and FSH are heterodimeric 
hormones that have distinct β subunits but share a common α subunit ( GSU).  The 
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GSU is the first differentiated cell marker to appear during pituitary development 
(6).  Reporter assays suggest that the GSU promoter may become activated as early 
as e9.5 throughout the pituitary primordium; however, subsequent expression of 
GSU becomes restricted to thyrotropes and gonadotropes (7-9).   
Thyroptropes and gonadotropes play important roles in the regulation of 
metabolic and reproductive function, respectively.  Stimulation of these cells by the 
hypothalamic releasing hormones thyrotropin-releasing hormone (TRH) or 
gonadotropin-releasing hormone (GnRH) leads to synthesis and secretion of TSH by 
thyrotropes, and FSH and LH by gonadotropes.  The ERK pathway is activated in both 
thyrotropes and gonadotropes following stimulation by TRH or GnRH.  Little is 
known regarding the importance of the ERK pathway in thyrotropes.  In contrast, 
many studies suggest that ERK signaling is critical for the expression of several genes 
essential for the function of gonadotropes, including the GSU, LH , and a regulatory 
MAP kinase phosphatase (MKP2/DUSP4) (10-12).  Data supporting the importance of 
ERK signaling for gonadotrope function have been generated primarily through study 
of the T3-1 and L T2 gonadotrope-derived cell lines.  These cell lines have been 
useful tools in the molecular dissection of gonadotrope function; however, they are 
isolated from the complex endocrine environment of the living animal.  In light of the 
need for an in vivo model for study of the role of ERK signaling in the pituitary, we 
used Cre-LoxP technology to generate mice in which ablation of ERK1 and 2 were 
targeted to the GSU-expressing cells of the anterior pituitary.  Our results 
demonstrate that ERK signaling is required for fertility only in the female and provide 
new insight into the mechanisms underlying sexually dimorphic regulation of 
reproductive function.    
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MATERIALS AND METHODS 
Animals 
ERK1 null (ERK1
-/-
) and ERK2 floxed (ERK2
fl/fl
) mice have been described 
previously (33, 34).  GSU:CRE mice were purchased from Jackson Laboratories 
(Bar Harbor, ME).  Swiss Webster mice used as wild type controls were obtained from 
Taconic Farms (Germantown, NY). Rosa 26 reporter (R26R) mice were generously 
provided by Dr. Michael Kotlikoff (Cornell University, Ithaca NY).  Animals were 
handled in compliance with the Cornell University Institutional Animal Care and Use 
Committee.  For assessment of fertility, females were individually housed with males 
of proven fertility and examined daily for vaginal plugs.  Upon identification of a 
plug, females were isolated and observed for pregnancy.  Females in which vaginal 
plugs were not identified, or that failed to develop pregnancy after identification of a 
plug, were reintroduced to new males, for a total of 21 days of breeding opportunity.  
Following the breeding challenge, females were isolated for 14 days and then 
sacrificed and examined for pregnancy post mortem.  For superovulation, mice were 
injected intraperitoneally with either 5 IU pregnant mare serum gonadotropin (PMSG) 
or vehicle, followed in 48 hours by injection of 5 IU of either human chorionic 
gonadotropin (hCG) or vehicle.  After 72 hours, mice were sacrificed and ovaries were 
collected for histological examination.  Ovariectomy and castration were performed 
via ventral midline celiotomy under isoflurane anesthesia using standard aseptic 
conditions.   
 
Genotyping 
Genomic DNA was isolated from tail snips (3 mm), or an equivalent quantity 
of other tissues as indicated, using a commercial kit (Qiagen DNeasy, Valencia, CA) 
as per the manufacturer‟s instructions.  Routine genotyping of animals was performed 
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by PCR as previously described (5).  PCR for confirmation of recombination at the 
ERK2 locus was performed using primers „F‟: 5‟-AGCCAACAATCCCAAACCTG-
3‟, „5‟: 5‟-GCTGCCTAGAAACATGGAGCTGC-3‟, „7‟: 5- 
GCTCTTTAACCTCCACTGCCTAAGC-3‟, and „9‟: 5‟- 
GCCAGCTGCTCACACTTAGCAAAGC-3‟.  The identities of PCR products were 
confirmed by direct nucleotide sequencing for all founder animals.   
 
Histology, Immunohistochemistry, and Immunofluorescent labeling 
For histological examination, tissues were fixed in 10% formalin, embedded in 
paraffin, sectioned at 4µm, stained with hematoxylin and eosin (H&E) using standard 
histological technique, and examined by light microscopy.  In some studies, ovaries 
were serially sectioned and every 4
th
 section was examined microscopically for 
identification of luteal tissue.  
For ERK2 immunohistochemistry, sections were deparaffinized in xylene, 
rehydrated through EtOH dilution series to distilled H20.  Antigen retrieval was 
performed by boiling the slides in 0.01M Citrate buffer (pH 6.0).  Sections were 
washed in PBS, and blocked with 10% normal rabbit serum/10% nonfat dry milk in 
PBS for 20 minutes at room temperature.  Sections were then incubated in goat anti-
ERK2 primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:60 in 
PBS/1X casein (Vector Laboratories, Burlingame, CA), for two hours at 37
o
C.  
Sections were further washed in PBS, and incubated at room temperature for 20 
minutes with biotinylated rabbit-anti-goat IgG  (Invitrogen, Carlsbad, CA).  Sections 
were then treated with ABC reagent and diamino-benzidine as per the manufacturer‟s 
recommendations (Vector). 
For immunofluorescent co-labeling of ERK2 and LH , 5 μM pituitary sections 
were deparaffinized and rehydrated as described above.  Antigen retrieval and 
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incubation in anti-ERK2 primary antibody were also performed as above, substituting 
normal goat IgG at equivalent concentration (ug/mL) as negative control.  After 
incubation with biotinylated rabbit-anti-goat IgG and further washing, sections were 
incubated with Streptavidin Alexa Fluor  488 (Invitrogen) for 20 minutes at room 
temperature in the dark.  Stained slides were washed further with PBS and stored in 
distilled water overnight at 4
o
C.  On day two, sections were blocked with Fab 
Fragment goat anti-rabbit IgG H&L (Jackson ImmunoResearch, West Grove, PA) 
diluted 1:50 in PBS for 30 minutes at 37
o
C, and reblocked for 20 minutes with 10% 
goat serum/2Xcasein (Vector) in PBS.  Rabbit anti-LH  primary antibody (National 
Hormone and Peptide Program; NIDDK) was reconstituted in PBS at a concentration 
of 1 μg/μL, and applied at a 1:50 dilution for 2 hours at 37oC, substituting normal 
rabbit IgG (Vector) at an equivalent concentration (ug/mL) as a negative control.  LH  
was detected with Texas Red goat-anti-rabbit IgG H&L (Vector) at a 1:80 dilution in 
PBS for 20 minutes at room temperature in the dark.  Slides were washed and 
mounted in Vectashield DAPI (Vector).  Images were obtained on a Nikon E400 epi-
fluorescence microscope using the appropriate filters.   
 
Vaginal Cytology 
Vaginal lavage was performed with 30 μL of PBS and the effluent was used to 
make routine cytological smears.  Slides were fixed in methanol, and stained with 
Wright‟s stain.  Slides were examined by light microscopy and epithelial cells and 
leukocytes were differentiated on the basis of cell morphology. 
 
Serum hormone measurements 
 Immediately following euthanasia, mice were exsanguinated by cardiac 
puncture.  Blood samples were allowed to clot at room temperature for 2 hours and 
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were then centrifuged at 8,000 rpm for 10 minutes.  Serum supernatants were collected 
and stored at -80
o
C until assayed.   Total serum T4 concentrations were determined by 
ELISA using a commercial kit according to the manufacturer‟s instructions (Alpha 
Diagnostics, San Antonio, Texas) with samples run in duplicate.  Measurements of 
LH  and FSH  were performed by the University of Virginia Center for Research in 
Reproduction Ligand Assay and Analysis Core facility with samples run in singlet. 
 
Immunoblotting 
Tissues were homogenized in lysis buffer containing 20 mM Tris-HCl (pH 
8.0), 130
 
mM NaCl, 10% glycerol, 1% Nonidet P-40, 0.1% sodium dodecyl
 
sulfate 
(SDS), 0.5% deoxycholate, 2 mM EDTA, 5 mM sodium vanadate,
 
0.2 mM PMSF, 5 
mM benzamidine. Lysates were cleared by centrifugation and protein concentrations 
were determined by Bradford assay.  Protein samples were boiled for 5 minutes in 
SDS load buffer, resolved
 
by SDS-PAGE, and transferred to PVDF membranes
 
by 
electroblotting. Membranes were blocked with 5% nonfat dry
 
milk (NFDM) in TBST 
(10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.05%
 
Tween 20) and then incubated with 
specified antisera (anti LH , FSH  and TSH  from the National Hormone and Peptide 
Program; NIDDK; and anti-actin and horseradish peroxidase-conjugated secondary 
antibodies from Santa Cruz).  Protein bands were visualized
 
using enhanced 
chemiluminescence according to the manufacturer‟s instructions (PerkinElmer, 
Boston, MA).   
 
Pituitary Cell Primary Culture 
Mice were euthanized and pituitaries were placed in DMEM containing 10% 
FBS on ice.  Tissues were digested with agitation at 37
o
C for 10 minutes in DMEM 
containing 0.5 mg/mL each of collagenase and hyaluronidase (Sigma Chemical, St 
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Louis, MO).  Following tritiuration, tissue remnants were allowed to settle by gravity.  
The supernatant was removed and  the tissue pellet was resuspended in DMEM 
containing 0.25 mg/mL each of the same enzymes, and digested for an additional 10 
minutes.  Following a second round of tritiuration and sedimentation, the supernatants 
were combined.  Cells were washed once in DMEM containing 10% FBS, and plated 
in like medium on 15 mm diameter poly-L-lysine coated dishes at a density of 2 
pituitary equivalents per well.  Cells were maintained at 37
o
C in 5% CO2 for 12 hours 
before treatment.  
 
RNA isolation and Quantitative PCR 
Following the indicated treatments, total RNA was isolated from cultured cells 
or whole pituitaries using the RNeasy kit (Qiagen) according the manufacturer‟s 
instructions.  Reverse transcription was carried out in 40 μL reaction volumes using 
the High Capacity cDNA Archive Kit (Applied Biosystems, Carlsbad, CA).  Taqman 
primer-probe sets for mouse LH , GSU, FSH , GnRHR, TSH and Egr1, were 
purchased commercially (Applied Biosystems).  Amplification was performed under 
standard conditions using the ABI Prism 7500 Sequence Detection System.  Transcript 
levels were normalized to corresponding levels of -actin, and were calibrated to 
corresponding transcript levels represented in a pooled cDNA stock derived from wild 
type female mice, or to levels of the control group, as indicated.  
 
Data analysis 
Quantitative PCR and ELISA results were analyzed by t-test or one-way 
ANOVA.  Post hoc tests were performed with Bonferroni all-pairwise comparisons.   
All differences were considered significant at p<0.05. 
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RESULTS 
Generation and validation of the pituitary-targeted ERK1/2 double knockout 
mouse 
To define the physiological importance of ERK signaling in pituitary 
gonadotropes and thyrotropes, we began by generating mice with a conditional, 
pituitary-targeted ablation of ERK2.  Mice homozygous for a floxed mutation at the 
ERK2 locus (ERK2
fl/fl
), were crossed with GSU:Cre mice, in which Cre recombinase 
is expressed under the regulatory control of a 4.6 kb fragment of the murine αGSU 
promoter.  ERK2
fl/fl
, GSU:Cre mice were then mated to ERK1 null mice to generate 
ERK2
fl/fl
,ERK1
-/-
, GSU:CRE, hereafter designated DKO.  Pituitary-specific ERK2 
null males and females (with normal ERK1) were viable and fertile.  They were born 
at expected Mendelian frequencies, and were grossly and histologically unremarkable 
at 3 months of age (data not shown).  In contrast, at 3 weeks of age, DKO animals 
were represented at less than the expected frequency (expected: 0.5, observed: 0.24; 
n=327).  Within litters of neonates, some DKO animals were frequently identified 
either dead, or as unthrifty pups that failed to nurse and that died shortly after birth.   
 To validate the fidelity of GSU:Cre -mediated recombination, we crossed 
GSU:Cre males with Rosa26 reporter (R26R) females and assayed -galactosidase 
activity in tissue lysates from both Cre-expressing, and non-expressing offspring.  -
galactosidase activity was significantly increased in pituitary lysates from Cre-
expressing animals as compared with Cre-negative controls (Figure 3.1A).  
Differences in -galactosidase activity were not observed in lysates from other tissues 
(lung, kidney, heart and brain, Figure 3.1A and data not shown).  These data support 
the pituitary-enriched activity of the GSU:Cre.  Cre-dependent recombination 
specifically at the ERK2 locus was verified by PCR from ERK2
fl/fl
,CRE
+
 and 
ERK2
fl/fl
,CRE
-
 animals using primers flanking the floxed region of the ERK2 
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Figure 3.1. Validation of the ERK1/2 DKO mouse. (A) Pituitary-specific expression 
of the GSU-Cre was assessed by crossing the GSU-Cre transgenic male with R26R 
female mice and comparing Beta-galactosidase activity in tissue lysates from Cre-
expressing and non-expressing (control) offspring.  -gal activity in individual 
samples was followed over a 60 minute time course.  Symbols represent mean +/-SEM 
at each time point as measured in specified tissues from 3 animals. Asterices represent 
significant (p<0.05) differences between Cre-expressing and control samples at given 
time points. (B) Cre-mediated recombination at the ERK2 locus within the pituitary 
was detected by PCR using genomic DNA from the specified tissues.  For each 
sample, the forward primer designated „F‟ was paired individually with reverse 
primers labeled „5‟, „7‟, and „9‟ spanning the floxed genomic region as indicated in the 
schematic.  Lanes are labeled with the specified reverse primer used for the reaction.  
Molecular weight marker is shown in the left lane.  Equivalent results were obtained 
from males and females. (C) Cell type-specific loss of ERK protein in the ERK1/2 
DKO was determined by coimmunofluorescent labeling of pituitary sections from 
control (panels A-C) and DKO (panels D-F) male animals using FITC-conjugated 
antibodies against ERK1/2 and Texas Red-conjugated antibodies against LH .  ERK 
(A,D), LH  (B,E), and simultaneous visualization of both wavelengths (C,F) are 
shown.  Arrows indicate representative LH  positive cells with distinct lack of ERK 
labeling.  Bars, 100 uM. 
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locus (Figure 3.1B, schematic).  Products indicating excision of the floxed region of 
the ERK2 gene were only produced from pituitary genomic DNA of Cre
+
 individuals, 
indicating tissue-specific susceptibility of the ERK2 locus to Cre-mediated 
recombination (Figure 3.1B, left panel).  
Immunohistochemical co-labeling of pituitary sections from adult DKO and 
control animals using antibodies against ERK2 and LH  confirmed a high level of co-
localization between LH  and negative ERK labeling, indicating that ERK deficiency 
was relatively penetrant within the gonadotropes of DKO animals (Figure 3.1C).  
Immunohistochemical identification of TSHβ within ERK-deficient, LHβ negative 
cells in these sections confirmed the prediction that GSU-expressing thyrotropes 
were also rendered ERK-deficient within this line (data not shown).   Overall, these 
results support the fidelity of the compound genetic deletion within the adult DKO 
animals. 
  
Phenotypic characterization of the ERK1/2 DKO mouse   
DKO animals of both genders grew at the same rate as Cre
-
 littermate controls, 
and were grossly indistinguishable from controls from birth through 8 months of age 
(data not shown).  Test matings indicated that DKO males were fertile, while females 
showed no evidence of estrus cycle activity and did not mate.  To further assess 
estrous cycle activity, vaginal cytology was performed in control and DKO mice.  
Cyclic cytological changes indicative of estrous cycle activity were observed in 
control mice (Figure 3.2A).  In contrast, vaginal cytology in the DKO females showed 
a preponderance of polymorphonuclear leukocytes with occasional basal epithelial 
cells over the course of the study, consistent with anestrous behavior. 
Histological examination of a variety of tissues including the reproductive tract 
from DKO and control males revealed no abnormalities.  In contrast, ovaries from  
 111 
 
 
 
 
 
Figure 3.2. Assessment of estrous cycle activity in the ERK1/2 DKO mouse.  (A) 
Vaginal cytology was performed at 24 hour intervals by microscopic examination of 
Wright‟s stained vaginal lavage effluents.  One-hundred cells were counted and the 
percentage of epithelial cells at each time point was determined.  Data are shown for a 
single animal; however, similar results were obtained from 3 animals of each 
genotype.  (B) Hematoxylin and eosin stained histological sections of ovaries from 
control (panel A) and DKO (panel B) animals are shown.  A representative corpus 
luteum is indicated (CL) Bars in A and B, 200 M.   Microscopic sections from 
control (panel C), and DKO (panel D) ovaries were immunohistochemically stained 
using an antibody against ERK1/2.  Both control and DKO animals were ERK1 null, 
thus all specific labeling represents ERK2 protein.  Bars in C and D, 100 M. 
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DKO females contained follicles at various stages of maturation (primary through 
large antral follicles), but were specifically devoid of luteal tissue, while ovaries from 
control females were histologically unremarkable (Figure 3.2B, panels A and B). The 
combined data from cytological analysis of estrous cycle behavior and histological 
evidence of lack of luteal tissue within the ovary in DKO female mice supported the 
preliminary conclusion that the DKO mice were anovulatory.  To address whether the 
ovarian lesion in DKO animals may reflect promiscuous Cre expression and lack of 
ERK2 protein in the ovary, we examined ERK2 expression in ovaries from DKO and 
control females immunohistochemically.  Expression of ERK2 was observed in both 
DKO and control ovaries indicating that the anovulatory ovarian lesion was secondary 
to the primary pituitary defect (Figure 3.2B, panels C and D). 
 
ERK1/2 DKO mice are euthyroid 
Since GSU is expressed in thyrotropes as well as in gonadotropes, our model 
would predict fully penetrant Cre-dependent disruption of ERK signaling in the 
thyrotropes of DKO animals.  To evaluate thyroid function in these animals, we used 
quantitative PCR (qPCR) to measure whole pituitary content of TSH  mRNA in DKO 
and control animals.  Pituitary content of TSH  protein was examined by immunoblot 
analysis and T4 levels in serum were examined using an ELISA.  Pituitary TSH  
mRNA, TSH  protein in whole pituitary lysates or serum T4 concentrations did not 
differ between DKO and control mice (Figure 3.3).  These results confirm that DKO 
animals that survived to adulthood were euthyroid and effectively rule out thyroid 
dysfunction as a contributing factor to the anovulatory phenotype. 
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Figure 3.3.  Evaluation of thyroid function in the ERK1/2 DKO mouse.  (A) 
Relative transcript levels of TSH  from whole pituitaries of female control and DKO 
animals were determined by quantitative PCR.  Results were calibrated to levels of 
TSH  mRNA from pituitaries of randomly cycling female wild type mice.  Bars 
represent mean +/- SEM for 5 animals of each genotype.  Means were compared by 2-
tailed t-test. (B) Levels of TSH  in whole pituitary lysates from control and DKO 
animals were compared by immunoblot.  Actin is shown as a lane-loading control.  
(C) Serum levels of total T4 from randomly cycling wild type, control and DKO 
females were determined by ELISA.  Bars represent mean +/- SEM for 3 (wild type) 
or 11 (control and DKO) animals in the respective groups.  Means for control and 
DKO groups were compared by 2-tailed t-test.    
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Expression of LH  is reduced in pituitaries of ERK1/2 DKO animals 
The lack of luteal tissue in the ovaries of DKO females suggests that DKO 
females were anovulatory and implicates a gonadotropin deficiency in these animals.  
To test this, we used quantitative PCR (qPCR) to measure transcript levels of the  
gonadotropin subunits (LH , FSH  and GSU), as well as the GnRH receptor 
(GnRHR) in the pituitaries of DKO and control animals.  In females, LH  mRNA 
levels were significantly lower in DKO‟s as compared with randomly cycling control 
animals (Figure 3.4A).   In males, LH  levels were not statistically significantly 
different between DKO and control animals (Figure 3.4A).  Transcript levels of the 
other gonadotropin subunits, as well as the GnRHR did not differ between DKO and 
control animals for either gender (Figure 3.4A). 
To assess the effects of ERK deletion on pituitary stores of gonadotropin 
subunits, we examined pituitary lysates by immunoblotting using antibodies against 
LH  and FSH .  LH  was less abundant in pituitaries of DKO animals of both 
genders, as compared with controls, and was essentially undetectable in the pituitaries 
of DKO females (Figure 3.4B).  Levels of FSH  were similar between DKO and 
control animals of both genders (Figure 3.4B).   
 
The anovulatory phenotype of ERK1/2 DKO females is rescued by pharma-
cological superovulation 
Our histological findings and gene profiling data suggest that the anovulatory 
infertility in the DKO mice was a direct consequence of LH deficiency.  If correct, we 
reasoned that the ovaries of DKO females should remain capable of mounting an 
ovulatory response to an appropriate supra-ovarian gonadotropic stimulus.  To test 
this, we subjected DKO and control females to conventional pharmacological  
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Figure 4.  Basal expression of gonadotropin subunit and GnRHR genes in the 
ERK1/2 DKO mouse.  (A) Whole pituitary relative transcript levels of the specified 
genes were determined by quantitative PCR.  Results were calibrated to corresponding 
transcript levels in pituitaries of randomly cycling female wild type mice.  Bars 
represent mean +/- SEM for 5 animals of each gender and genotype.  Bars not sharing 
common letter designations represent mean values that are statistically significantly 
different (p<0.001).  (B)  Levels of LH  protein in whole pituitary lysates 
from control and DKO animals were compared by immunoblotting.  Actin is shown as 
a lane-loading control.  
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superovulation.  Corpora lutea were present in the ovaries of gonadotropin-treated 
DKO animals albeit at a frequency (number of corpora lutea/ovary) less than that  
observed in superovulated control females (Figure 3.5).  These results confirm the 
intrinsic ability of DKO ovaries to respond to an ovulatory signal. 
 
ERK signaling is required for the response of the gonadotropin subunits 
following gonadectomy 
Gonadal steroids regulate the expression of the gonadotropin subunit genes 
within the pituitary through negative feedback inhibition of GnRH release from the 
hypothalamus.  Accordingly, gonadectomy leads to increased expression of the β 
subunits of LH and FSH through disinhibition of the hypothalamic GnRH system (13, 
14).  To determine the role of ERK signaling in mediating the gonadotrope response to 
endogenous GnRH hyperstimulation, we subjected control and DKO mice of both 
genders to gonadectomy.  After 7 days, pituitary expression of the gonadotropin 
subunits and the GnRHR were assayed by qPCR.  Following gonadectomy, significant 
increases in LH  transcript levels were observed in control mice of both genders; 
however, the inductive effect of gonadectomy on LH  transcript levels was blocked in 
DKO‟s (Figure 3.6A and B, upper left panels).  In males, castration had no significant 
effect on FSH  transcript levels in either DKOs or controls (Figure 3.6A, upper right 
panel).   In contrast, ovariectomy led to an approximately 20-fold increase in FSH  
transcript levels in the control females (Figure 3.6B, upper right panel).  In DKO 
females, ovariectomy led to a more modest elevation in FSH  transcript levels, which 
did not reach statistical significance (Figure 3.6B, upper right panel).  Gonadectomy 
led to significant increases in αGSU transcript levels in both control males and 
females; however, this response was blocked in DKO animals of both genders (Figure 
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Figure 3.5.  Pharmacological superovulation rescues the anovulatory phenotype 
of the ERK1/2 DKO mouse.  Control and DKO females were injected 
intraperitoneally with vehicle or 5 units PSMG, followed in 48 hours by vehicle or 5 
units of hCG.  After 9 days, ovaries were collected and examined histologically.  
Ovarian sections from vehicle-treated (A,B) and superovulated (C,D) control (A,C) 
and DKO (B,D) animals are shown.  Arrows indicate corpora lute  
 
 
 
 
 
A B
C D
Control DKO
Saline
PMSG/hCG
CL
CL
CL
 121 
 
 
 
 
Figure 3.6.  ERK1/2 DKO animals of both genders fail to upregulate LH  
following gonadectomy.  Control and DKO animals were either castrated (Csx), 
ovariectomized (Ovx), or sham operated (sham).  After 7 days, pituitaries were 
collected and analyzed by qPCR for relative transcript levels of the indicated 
gonadotropin subunit genes and the GnRHR.  Data are shown separately for males (A) 
and females (B).  Results were calibrated to corresponding transcript levels in 
pituitaries of randomly cycling female wild type mice.  Bars represent mean +/- SEM 
for 6 males, or 7 females, per group, and represent pooled results from two separate 
experiments.  Bars not sharing common letter designations represent mean values that 
are statistically significantly different (p<0.001).  Note the differences in scaling of the 
Y-axis for the FSH  results in the female. 
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Figure 3.7.  Serum gonadotropin levels do not increase in DKO animals of either 
gender following gonadectomy.   Control and DKO animals were either castrated 
(Csx), ovariectomized (Ovx), or sham operated (sham).  After 7 days, animals were 
euthanized and serum levels of LH  and FSH  were determined by ELISA.  Data are 
shown separately for males (A) and females (B).  Bars represent mean +/- SEM for 6 
males, or 7 females, per group, and represent pooled results from two separate 
experiments.  Bars not sharing common letter designations represent mean values that 
are statistically significantly different (p<0.001). 
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3.6A and B, lower left panels).  Transcript levels of the GnRHR in males did not differ 
between either genotype or treatment, while in females, statistically significant but 
biologically insignificant differences were observed in GnRHR transcript levels 
between sham-operated control animals and all other groups (Figure 3.6 A and B, 
lower right panels).   
In parallel to the gene profiling results, serum levels of both LH  and FSH  
rose significantly following gonadectomy in control animals of both genders (Figure 
3.7A and B, left panels).  Baseline serum FSH  levels were not different between 
sham operated DKO and control animals of either gender.  In contrast, baseline serum 
levels of LH  were significantly lower in sham operated DKO‟s as compared to 
controls, and significant increases in serum LH  did not occur following gonadectomy 
in DKO animals of either gender.  These results support the conclusion that ERK 
signaling plays a critical role in mediating upregulation of both subunits of LH in 
response to GnRH stimulation in vivo.  
 
ERK-deficient gonadotropes fail to upregulate the immediate early response gene 
Egr1 following GnRH stimulation   
Early growth response factor-1 (EGR1) is a transcription factor encoded by an 
ERK-dependent immediate early gene that has been shown to play a key role in the 
transcriptional regulation of LH  (15).  To determine the effect of ERK ablation on 
the ability of gonadotropes to upregulate EGR1 in response to GnRH stimulation, we 
subjected control and DKO mice of both genders to gonadectomy and after 7 days, 
measured pituitary expression of Egr1 by qPCR.  In the control animals, mean Egr1 
transcript levels rose approximately 3-fold and 5-fold following gonadectomy in males 
and females, respectively; however, due to the high variability in transcript levels 
observed in the gonadectomized animals, these differences were not statistically  
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Figure 3.8.  ERK-deficient gonadotropes fail to upregulate the immediate early 
gene Egr1 in response to GnRH stimulation.  (A) Control and DKO animals of both 
genders were either gonadectomized (gonadectomy), or sham operated (sham).  After 
7 days, pituitaries were collected and analyzed by qPCR for relative transcript levels 
of Egr1.  Data are shown separately for males (left panel) and females (right panel).  
Results were calibrated to corresponding transcript levels in pituitaries of randomly 
cycling female wild type mice.  Bars represent mean +/- SEM for 6 animals per group, 
and represent pooled results from two separate experiments for each gender.  Bars not 
sharing common letter designations represent mean values that are statistically 
significantly different.  (B) Pituitaries from control and DKO animals were dispersed 
into primary culture (2 pituitaries/well) and treated for 20 minutes with vehicle or with 
100 nM of the GnRH agonist buserelin (GnRHa).  Relative transcript levels of Egr1 
and LH  were measured in each sample by qPCR.  Bars represent mean +/- SEM for 6 
wells representing pooled results from 2 separate experiments.  Data are shown 
separately for males (upper panels) and females (lower panels).  Bars not sharing 
common letter designations represent mean values that are statistically significantly 
different (p<0.05). 
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significantly different (Figure 3.8A).  No differences were observed in Egr1 transcript 
levels following gonadectomy in DKO animals of either gender (Figure 3.8A).   
Given the dynamic nature of the Egr1 transcriptional response to GnRH 
stimulation, we considered that the lack of statistically significant differences between 
the sham operated and gonadectomized control animals may reflect type II error.   
However, power analysis indicated that to achieve a power of 0.8 for detection of a 
fourfold difference in Egr1 transcript levels within the context of this experimental 
design would require sample sizes of 8 and 71 animals per group, for males and 
females, respectively.  To circumvent this limitation, we undertook an alternative 
strategy and measured Egr1 and LH  transcript levels by qPCR in primary pituitary 
cell cultures from DKO and control animals following stimulation with vehicle or the 
GnRH agonist buserelin (GnRHa).  We reasoned that this experimental approach 
would allow synchronization of experimental units with respect to the onset and 
duration of the GnRH signal in a manner that cannot be accomplished within our in 
vivo paradigm.  Baseline Egr1 transcript levels were significantly reduced in cells 
from DKO females as compared to controls (Figure 3.8B, lower left panel).  Egr1 
transcripts were significantly upregulated following GnRHa exposure in cells from 
control animals of both genders; however, upregulation of Egr1 mRNA was not 
observed in cells from DKO animals of either gender (Figure 3.8B, left panels).   LH  
transcripts were significantly reduced in cultures of vehicle-treated cells from DKO 
animals of both genders, as compared with controls.  Following GnRH stimulation, a 
statistically significant, but quantitatively negligible increase in LH  transcripts was 
observed in cells from control females.  Overall, the reduction in GnRH-induced Egr1 
transcription in ERK-deficient gonadotropes underscores a key mechanism linking 
ERK signaling to LH biosynthesis and highlights the unique importance of the ERK 
pathway for female fertility. 
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DISCUSSION 
Using a genetic approach, we show here that ablation of ERK1 and 2 in the 
anterior pituitary leads to infertility in females, but not males.  The anovulatory 
infertility in the ERK-deficient females in this study was associated with marked 
reductions in pituitary levels of LH .  Our studies on the pituitary response to 
gonadectomy indicate further that ERK-deficient gonadotropes are incapable of 
transcriptional upregulation of either LH  or GSU following pulsatile 
hyperstimulation by hypothalamic GnRH within the intact endocrine milieu of the 
living animal.  Thyroid function remained normal in animals with pituitary ERK 
deficiency suggesting that the function of the thyroid axis does not depend upon ERK 
signaling at the level of the thyrotrope. 
While our model reveals that ERK signaling is absolutely required for 
appropriate LH biosynthesis, our data also suggest that the ERK pathway may play a 
partial role in mediating transcriptional upregulation of FSH  in the female.   
Nevertheless, our observations of whole pituitary and serum FSH levels would suggest 
that overall expression of FSH  is largely ERK-independent.  Moreover, the presence 
of antral follicles in the ovaries of the DKO females, along with the absence of 
corpora lutea, strongly implicates LH deficiency as the primary cause of infertility in 
these animals, and further supports the relative ERK-independence of FSH 
biosynthesis.  This is further corroborated by the observation that the anovulatory 
phenotype was able to be rescued in the DKO females by administration of exogenous 
gonadotropin receptor ligands.  Our model thus confirms the ERK pathway as a 
dominant link between the activation of the GnRHR and LH  biosynthesis within the 
gonadotrope in vivo.  Gender differences in the transcriptional response of the 
gonadotropin subunits to GnRH stimulation have been reported previously (16-19); 
however, the sexually dimorphic nature of the requirement for the ERK signaling 
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pathway that is disclosed by our model is a novel observation that has not previously 
been appreciated.   
In contrast to the reproductive phenotype displayed within the adult DKO 
females, the majority of DKO‟s predicted to occur within this pedigree remained 
unaccounted for at 3 weeks of age.  The regular finding of dead DKO neonates 
suggests that pre- or perinatal mortality may represent a distinct phenotype resulting 
from pituitary-targeted disruption of the ERK pathway.  Perinatal mortality has been 
described following deletion of several genes that interfere with appropriate 
development of anterior pituitary cell lineages (20-22).  The pathophysiological basis 
of perinatal mortality has perhaps been most clearly defined in the Prop1 deficient 
mouse, in which severe congenital hypothyroidism secondary to hypoplasia of the 
Pit1-dependent thyrotrope lineage leads to surfactant deficiency and respiratory failure 
in neonatal pups (23).  Whether ERK signaling plays a role in thyrotrope development 
through modification of either the expression or function of Prop1 or Pit1 is unknown.  
However, as previously reported, some variability has been observed in the timing of 
onset and penetrance of GSU-Cre-mediated target gene recombination within the 
developing pituitary (24).   Therefore, it is intriguing to hypothesize that the perinatal 
mortality observed in our model may reflect early onset Cre expression within a subset 
of DKO animals, leading to more extensive loss of ERK activity throughout the 
pituitary primordium, and disruption of critical ERK-dependent processes of pituitary 
cell lineage specification.  Studies are currently underway to define the underlying 
mechanism of perinatal mortality within this model, and to clarify the role of the ERK 
pathway in development of the Pit1-dependent anterior pituitary cell lineages.     
The transcriptional regulation of LH  has been studied in a variety of 
experimental systems (15, 25, 26).  The LH  promoter contains binding sites for 
several transcription factors, including the zinc-finger transcription factor EGR1 (15, 
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27).  EGR1 has been shown to play a critical role in LH  transcription and appears to 
function primarily as an amplifier of LH  promoter activity, contributing to the 
responsiveness of the promoter to changes in the amplitude or pulse frequency of 
GnRH stimulation (26, 28).  Interestingly, despite the broad pattern of expression of 
EGR1, the predominant phenotype of the EGR1 null mouse consists of female 
anovulatory infertility associated with LH deficiency (29).  The phenotype of the 
female ERK DKO mouse reported here bears a striking similarity to that of the EGR1 
null, and the inability of ERK-deficient gonadotropes to upregulate EGR1 in response 
to GnRH stimulation indicates that ERK-dependent induction of EGR1 is a dominant 
mechanism by which GnRHR occupancy is linked to transcription of the LH  gene in 
vivo.  However, whether the LH deficiency in the ERK DKO is due solely to a failure 
of Egr1 induction, or whether the phenotype may also reflect a lack of ERK-dependent 
EGR1 phosphorylation is not clear.  For example, in one study, the GnRH-induced 
transcriptional activity of constitutively expressed Egr1 was attenuated in transiently 
transfected gonadotrope cells by treatment with the MEK inhibitor PD98059 (30).  
This observation raises the possibility that the ERK pathway may modulate LH  gene 
transcription at multiple levels involving not only gene induction but also direct 
phosphorylation of LH  transactivators such as EGR1.  Ultimately, full clarification of 
the role of ERK activation in LH biosynthesis will require more comprehensive 
genomic and proteomic approaches aimed at identification of the entire complement of 
ERK-dependent genes that are expressed in the gonadotrope, as well as relevant 
targets of ERK-dependent phosphorylation.     
In contrast to the females, ERK DKO males retained normal reproductive 
function and gonadal histology.  This observation provides further interesting 
comparison with the EGR1 null mouse as EGR1 null males are also reproductively 
competent (29).  However, despite their fertility, EGR1 null males did display Leydig 
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cell atrophy while testicular histology in the ERK-deficient males in this study was 
unremarkable (29).  The testicular lesion in the EGR1 null male undoubtedly reflects a 
more severe impairment of LH  production than in the ERK DKO.  Thus, despite the 
measurable decrease in pituitary LH  protein content in the DKO males in this study, 
production of LH in these animals was clearly sufficient to maintain normal testicular 
function and structure as well as fertility.  The inability of gonadotropes from ERK-
deficient males to upregulate EGR1 in response to GnRH stimulation suggests further 
that basal EGR1 expression is sufficient to support this level of LH  production.  
Overall, our data support a model in which the ERK pathway functions in both 
genders as a dominant link between the GnRHR and the Egr1 locus.  In turn, EGR1 
serves as a primary mediator of GnRH-induced upregulation of LH .  The gender 
difference in the requirement for ERK signaling in the gonadotrope would thus seem 
to reflect the relatively modest levels of LH that are required to support Leydig cell 
function in the male, as compared to the high levels of LH that are required for 
ovulation in the female.  Consistent with that notion, transcriptional regulation of the 
gonadotropin subunit genes is highly dependent upon the frequency of the pulsatile 
hypothalamic GnRH signal; rapid pulsatility favors LHβ production while slower 
GnRH pulsing appears to favor production of FSHβ (31).  Moreover, studies using the 
LβT2 cell model indicate that the ability of the gonadotrope to interpret variations in 
the GnRH interpulse interval may depend upon a functional ERK signaling module 
(32).  During the estrous cycle, regular variations occur in the frequency of GnRH 
pulsatility; pulsatility increases markedly during proestrus eventually leading to a 
preovulatory GnRH/LH surge and ovulation.  We propose that the ERK module plays 
a central role in the ability of the gonadotrope to respond to variations in the pulse 
pattern of the GnRH signal thereby linking changes in GnRH pulse frequency with the 
coordinated physiological outcomes associated with the female reproductive cycle.  
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The fact that males have no requirement for cyclic variations in GnRH pulsatility is 
consistent with our observations that steroidogenesis and spermatogenesis are 
unaffected by disruption of the ERK signaling pathway at the level of the 
gonadotrope.  
In summary, we have shown that ablation of the ERK signaling pathway in 
pituitary gonadotropes leads to infertility in female but not male mice.  Our data 
establish an essential role for the ERK pathway in mediating transcriptional 
upregulation of LH in the gonadotrope following GnRH stimulation in vivo, and lend 
insight into the molecular mechanisms underlying sexually dimorphic control of 
reproductive function. 
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CHAPTER 4 
 
 
ERK SIGNALING, BUT NOT C-RAF, IS REQUIRED FOR GONADOTROPIN-
RELEASING HORMONE (GNRH) INDUCED UPREGULATION OF NUR77 IN 
PITUITARY GONADOTROPES  
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SUMMARY 
Stimulation of pituitary gonadotropes by hypothalamic GnRH leads to the 
rapid expression of several immediate early genes that play key roles in orchestrating 
the response of the gonadotrope to the hypothalamic signal.  Elucidation of the 
signaling mechanisms that couple the GnRH receptor to this immediate early gene 
repertoire is critical for understanding the molecular basis of GnRH action.  Here we 
identify the orphan nuclear receptor Nur77 as a GnRH-responsive immediate early 
gene in T3-1 cells as well as in mouse gonadotropes in vivo.  Using a variety of 
molecular biological methods, we show that GnRH-induced transcriptional 
upregulation of Nur77 in T3-1 cells is dependent upon ERK signaling, but that 
neither activation of the ERK pathway, nor the transcriptional response of Nur77 to 
GnRH requires the activity of c-Raf.  In corroboration of these results, gonadotropes 
from mice with pituitary deficiency of ERK signaling failed to upregulate Nur77 
following GnRH stimulation.  In contrast, Nur77 responsiveness to GnRH was 
maintained in gonadotropes from mice with pituitary targeted ablation of c-Raf.  These 
results further clarify the role of ERK signaling in regulation of the GnRH-induced 
immediate early gene program in the gonadotrope, and shed new light on the complex 
functional organization of this signaling pathway in these cells.   
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INTRODUCTION 
In mammals, reproductive function is dependent upon the coordinated 
synthesis and secretion of the gonadotropins luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) by the pituitary gonadotrope.  Production of the 
gonadotropins is largely controlled by the hypothalamic decapeptide gonadotropin-
releasing hormone (GnRH).  GnRH is released in pulsatile fashion from the 
hypothalamus and acts through the gonadotropin-releasing hormone receptor 
(GnRHR), to stimulate biosynthesis of the gonadotropin subunits, as well as the 
GnRHR itself.  The signaling events initiated by the GnRHR coordinate the expression 
of a diverse set of immediate early response genes, several of which have been shown 
to regulate gonadotropin biosynthesis (1-4).  In the gonadotrope, as in most other cell 
types, early response genes play a critical role in linking a relatively transitory 
extracellular stimulus (the pulsatile GnRH signal) with more sustained changes in 
gene expression that underlie physiologically appropriate cellular responses to that 
stimulus (gonadotropin biosynthesis).  Elucidation of the signaling activities that link 
the GnRH signal with the immediate early gene repertoire is thus important for 
understanding the molecular basis of gonadotrope function. 
The ERK signaling pathway is rapidly activated by GnRH and ERK activity 
has been linked to the expression of several genes important for gonadotrope function 
including the gonadotropin subunit genes, as well as the dual specificity MAP kinase 
phosphatase MKP2/DUSP4 (1, 5-8).  ERK activity may also play a role in 
homologous regulation of the GnRHR (9).  Several ERK-dependent immediate early 
genes have been shown to play key roles in mediating the effects of GnRH, including 
Early growth response protein 1 (Egr1), c-Fos, and Activating transcription factor 3 
(ATF3) (1, 4-6). 
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Nur77 (NR4A1, NGFIB, NAK1, TR3) is an immediate early gene belonging to 
the NR4A family of orphan nuclear receptors.  Nur77 is rapidly upregulated in 
response to a wide range of extracellular signals and has been shown to play diverse 
and important roles as a transcriptional regulator in several cell types with high 
metabolic demands including neurons, skeletal and cardiac myocytes, hepatocytes and 
adipocytes (10-13).  Nur77 has also been shown to regulate the response of 
macrophages and endothelium to various pro-inflammatory cytokines and plays 
additional roles within the hypothalamic-pituitary-adrenal axis in the regulation of 
pro-opiomelanocortin gene transcription in pituitary corticotropes, as well as in 
adrenal and gonadal steroidogenesis (14-18).  Microarray analysis showed that Nur77 
was strongly upregulated by GnRH in the murine gonadotrope-derived L T2 cell line 
(19, 20).  Nur77 was also shown to be expressed in the less differentiated T3-1 
gonadotrope cell line; however, to our knowledge, the signaling mechanisms 
underlying GnRH induction of Nur77 have not been examined in detail either in this 
model or in vivo (21).  ERK activity has been shown to be important for agonist-
induced upregulation of Nur77 in several cell types (22-26).  Therefore, we set out to 
test the specific hypothesis that ERK signaling is required for GnRH-induced 
expression of Nur77 in the gonadotrope.  Our results establish Nur77 as an ERK-
dependent GnRH-responsive immediate early gene in vivo and shed unexpected new 
light on the functional organization of the ERK pathway in the gonadotrope. 
 
MATERIALS AND METHODS 
Cells, reagents, and animals: 
T3-1 cells were a generous gift from Dr. Pamela Mellon (University of 
California at San Diego, San Diego, CA) and were cultured as described previously 
(27).  NIH 3T3 cells were a gift from Dr. Joseph Wakshlag (Cornell University, 
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Ithaca, NY) and were cultured as described previously (28).  Primary antibodies 
against Nur77 (rabbit polyclonal), ERK2, c-Raf, B-raf and -actin, along with 
horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA).  Biotinylated anti-rabbit secondary 
antibody for immunocytochemistry was obtained from Vector Laboratories 
(Burlingame, CA).  Anti-phospho-ERK was from Sigma Chemical (St Louis, MO).  
Mouse monoclonal anti-Nur77 antibody was from Pharmingen (San Diego, CA).  
Rabbit anti-LH  antibody was from the National Hormone and Peptide Program; 
NIDDK.  Rat monoclonal anti-HA antibody was from Roche (Indianapolis, IN).  
Buserelin
 
(des-GLY
10
 [D-Ser(t-But)
6
]-LH-RH Ethylamide; referred to as
 
GnRHa), 
corticotrophin-releasing hormone (CRH), and the GnRHR antagonist antide, were 
from Sigma (St. Louis, MO).  All other pharmacological inhibitors were from 
Calbiochem (Gibbstown, NJ).   
The c-Raf floxed mouse and the ERK1/2 pituitary targeted compound 
knockout mouse have been described previously (29, 30).  GSU-CRE mice, in which 
Cre recombinase is expressed under regulatory control of a 4.6 kb fragment of the 
mouse GSU promoter, were purchased from Jackson Laboratories (Bar Harbor, ME).  
Swiss Webster mice used as wild type were purchased from Taconic Farms 
(Germantown, NY).  Animals were maintained and treated in compliance with the 
specifications of the Cornell University Institutional Animal Care and Use Committee.  
Genotyping of the c-Raf conditional knockout animals was performed by PCR using 
primers 5‟- AGCCGAGTCAGCAAATGCACTG – 3‟, and 5‟ – 
AGTAGTCTACGGCACGTTTACTAGG – 3‟.  Genomic analysis of Cre-dependent 
recombination at the c-Raf locus was performed by PCR using primers “Pr. F” 5‟-
AGCCGAGTCAGCAAATGCACTG-3‟, “Pr. 3” 5‟-
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TATCACCTGCCAGGAACCAACAAGC-3‟, and “Pr. 4” 5‟-
AAGCCAACACTGCTCACTGTGTGGC-3‟. 
 
Plasmid construction and transfection 
The pKH3 expression vector, containing three tandem copies of the 
hemaglutinin (HA) epitope tag, was a gift from Dr. Jun-lin Guan.  The Raf-CAAX 
expression vector was a gift from Dr. Linda Van Aelst (Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY).  An expression vector for the c-Raf-S375M 
catalytic mutant fused to GFP was a gift from Dr. Guillermo Romero (University of 
Pittsburgh, Pittsburgh, PA).  This mutant Raf cDNA was subcloned without the GFP 
coding sequence into pKH3 as a BamHI/EcoRI fragment using standard methods to 
generate pKH3-RafS375A.  To generate the Nur77 luciferase reporter, a 1566 bp 
fragment of the Nur77 proximal promoter was amplified by PCR from mouse genomic 
DNA using primers 5‟- GGTTAGTCTGCTGCACTGGTG – 3‟ and 5‟- 
AAGCTTCAGTCGCAGCCTGGTCC – 3‟ and subcloned as an SSTI-HindIII 
fragment into the luciferase expression vector Luclink2 using standard methods.  The 
c-Fos luciferase reporter has been described previously (31). The fidelity of all 
constructs was verified by direct nucleotide sequencing.  Transfections were 
performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the 
manufacturer‟s instructions.    
 
Immunocytochemistry and fluorescence microscopy 
For immunofluorescent co-labeling of ERK2 and LH , 5 μM pituitary sections 
were deparaffinized in xylene, rehydrated through EtOH dilution series to distilled 
H20.  Antigen retrieval was performed by boiling slides in 0.01M Citrate buffer (pH 
6.0).  Sections were washed in PBS, and blocked with 10% normal rabbit serum/10% 
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nonfat dry milk in PBS for 20 minutes at room temperature.  Sections were then 
incubated in polyclonal anti-Nur77 primary antibody diluted 1:10 in PBS/1X casein 
(Vector), for two hours at 37
o
C.  Sections were further washed in PBS, and incubated 
at room temperature for 20 minutes with biotinylated rabbit-anti-goat IgG 
(Invitrogen).  Normal rabbit IgG was used at equivalent concentration (ug/mL) as 
negative control.  After incubation with biotinylated donkey-anti-rabbit IgG and 
further washing, sections were incubated with Streptavidin Alexa Fluor  488 
(Invitrogen) for 20 minutes at room temperature in the dark.  Stained slides were 
washed further with PBS and stored in distilled water overnight at 4
o
C.  On day two, 
sections were blocked with Fab Fragment goat anti-rabbit IgG H&L (Jackson 
ImmunoResearch, West Grove, PA) diluted 1:50 in PBS for 30 minutes at 37
o
C, and 
reblocked for 20 minutes with 10% goat serum/2Xcasein (Vector) in PBS.  Rabbit 
anti-LH  primary antibody (National Hormone and Peptide Program; NIDDK) was 
reconstituted in PBS at a concentration of 1 μg/μL, and applied at a 1:50 dilution for 2 
hours at 37
o
C, substituting normal rabbit IgG (Vector) at an equivalent concentration 
(ug/mL) as a negative control.  LHb was detected with Texas Red goat-anti-rabbit IgG 
H&L (Vector) at a 1:80 dilution in PBS for 20 minutes at room temperature in the 
dark.  Slides were washed and mounted in Vectashield DAPI (Vector Laboratories, 
Burlingame, CA).  Images were obtained on a Nikon E400 epi-fluorescence 
microscope using the appropriate filters.   
 
Luciferase assay 
T3-1 cells were seeded onto 1.5 cm dishes at approximately 60% confluence 
and were transfected and treated as indicated within 24 hours of plating.  Media was 
removed and the cells were collected in 200 uL of 1X passive lysis buffer 
(Promega,Madison, WI).  Cells were lysed by 2 freeze-thaw cycles and the lysates 
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were clarified by centrifugation.  Protein concentration of the lysates was determined 
by Bradford assay, and lysates were adjusted to a concentration of 2 ug/uL.  Aliquots 
(50 uL, 100 ug) were assayed for luciferase activity as previously described.  Assays 
were run in triplicate for each treatment, and all experiments were repeated at least 
three times.    
 
siRNA 
Knockdown of c-Raf was performed in T3-1 cells by direct transfection of 
siRNAs.   To generate the siRNA‟s, an approximately 250 bp fragment from the 5‟ 
region of the c-Raf cDNA was generated by PCR using primers 5‟ – 
GCTTGGAAGACGATCAGC – 3‟ and 5‟ – TGCTGGGAACTAGCAGGC – 3‟.  
This PCR fragment was sequenced to ensure fidelity, and then used as a template for 
the generation of a pool of mixed siRNA‟s using a commercial kit according to the 
manufacturer‟s instructions (Dicer kit, Invitrogen, Carlsbad, CA)  Control siRNA‟s 
against LacZ were prepared in similar manner according to the kit instructions.  Cells 
were plated in 1.5 cm dishes at approximately 40% confluence and were transfected 
the next day for 4 hours with 100 ng of siRNA per dish using Lipofectamine 2000 
according to the manufacturer‟s instructions.  Transfections were then repeated the 
following day.  Treatments and preparation of lysates were performed 48 hours after 
the second transfection. 
 
Immunoprecipitation and immunoblotting 
For immunoblotting, cells were washed in cold
 
PBS and scraped into PBS 
containing 5 mM sodium vanadate,
 
0.2 mM phenylmethylsulfonyl fluoride, and 5 mM 
benzamidine.
 
Cells were pelleted by centrifugation, and pellets were resuspended
 
in 
lysis buffer containing 20 mM
 
Tris-HCl (pH 8.0), 140 mM NaCl, 10% glycerol, 1% 
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Nonidet P-40,
 
0.1% SDS, 0.5% deoxycholate, 2 mM EDTA, 5 mM sodium vanadate,
 
0.2 mM phenylmethylsulfonyl fluoride (PMSF), and 5 mM benzamidine. Lysates
 
were 
cleared by centrifugation and protein concentrations of
 
the lysates were determined by 
Bradford assay.  Protein samples
 
were boiled in SDS load buffer, resolved by SDS-
PAGE,
 
and transferred to polyvinylidene difluoride membranes by electroblotting.
 
Membranes were blocked with 5% nonfat dry milk in TBST (10 mM
 
Tris-HCl, pH 
7.5; 150 mM NaCl; 0.05% Tween 20) and then incubated with primary antibodies 
overnight in TBST with 5% milk.  Membranes were then washed in TBST and 
incubated in HRP-conjugated secondary antibodies for one hour at room temperature.  
After further washing, proteins were visualized using enhanced chemiluminescence
 
according to the manufacturer‟s instructions (PerkinElmer, Boston, MA).   
For immunoprecipitations, cells were washed and lysed as above, except that 
the lysis buffer was adjusted to 200 mM NaCl.  Aliquots of lysate containing 400 ug 
protein were adjusted to 5 mM
 
Tris-HCl (pH 8.0), 70 mM NaCl, 5% glycerol, 0.2% 
Nonidet P-40,
 
0.01% SDS, 0.1% deoxycholate, 1 mM EDTA, 5 mM sodium vanadate,
 
0.2 mM PMSF, and 5 mM benzamidine in a total volume of 400 uL.  Rabbit 
polyclonal anti-Nur77 antibody (2 ug/400 ug cellular protein) was added and the 
samples were rocked at 4
o
C overnight.  Protein A/G agarose (30 uL of 50% slurry per 
sample) was added and the samples were rocked at 4
o
C for an additional hour.  Beads 
were washed 3 times in wash buffer (5 mM
 
Tris-HCl [pH 8.0], 70 mM NaCl, 1% 
glycerol, 0.1% Nonidet P-40,
 
 0.01% SDS, 0.1% deoxycholate, 1 mM EDTA), and 
boiled in SDS load buffer.  Immunoprecipitates were blotted as described above.  
After blocking, membranes were incubated with mouse monoclonal anti-Nur77 
antibody at 1:1000 dilution in TBST with 5% milk overnight at 4
o
C.  Membranes were 
then washed and developed as described above. 
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Primary pituitary cell culture 
Immediately following euthanasia, pituitaries were collected into cold DMEM 
containing 10% FBS.  Pituitaries were digested at 37
o
C for 10 minutes in DMEM 
containing 0.5 mg/mL each of collagenase and hyaluronidase (Sigma Chemical, St 
Louis, MO).  Tissues were dispersed by repeated pipetting and tissue remnants were 
allowed to settle by gravity.  The supernatant was removed and adjusted to 20% FBS. 
Remaining tissue was resuspended in DMEM containing 0.25 mg/mL each of the 
same enzymes, and digested for an additional 10 minutes.  Following additional 
dispersal, the supernatants were combined.  Cells were washed in DMEM containing 
10% FBS, and plated in the same medium with Penicillin and Streptomycin on 10 mm 
diameter poly-L-lysine coated dishes at a density of 1 pituitary equivalent per well.  
Cells were maintained at 37
o
C in 5% CO2 overnight before treatment. 
 
RNA isolation and Quantitative PCR 
Total RNA was isolated using the RNeasy kit (Qiagen), according the 
manufacturer‟s instructions.  Reverse transcription was carried out using the High 
Capacity cDNA Archive Kit (Applied Biosystems, Carlsbad, CA).  Taqman primer-
probe sets for mouse Nur77, c-Raf, B-Raf, Egr-1, and -actin were purchased 
commercially (Applied Biosystems).  Amplification was performed under standard 
conditions using the ABI Prism 7500 Sequence Detection System.  Transcript levels 
were normalized to corresponding levels of -actin, and were calibrated to the control 
group within each experiment.  
 
Data analysis 
Data were analyzed using t-test or One-way Analysis of Variance.  Overall 
differences for t-test and ANOVA were considered significant at p<0.05.  Post hoc 
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tests involving comparison of multiple treatments against a control were performed 
using Dunnett‟s test.  All other post hoc tests were performed using Bonferroni‟s all 
pairwise comparisons.  Differences in post hoc pairwise comparisons were considered 
significant at p<0.05 per comparison. 
 
RESULTS 
Nur77 is upregulated with immediate early gene kinetics in both T3-1 cells and 
primary mouse gonadotropes following GnRHa stimulation 
Nur77 has been shown to be expressed in T3-1 cells; however, its 
responsiveness to GnRH stimulation has not been reported in this cell line (21).  To 
address this, T3-1 cells were exposed to the GnRH agonist buserelin over a 3-hour 
time course, and Nur77 upregulation was examined at the mRNA level by qPCR and 
at the protein level by immunoprecipitation and immunoblotting.   Nur77 transcripts 
were approximately 4-fold upregulated after one hour of GnRHa stimulation and 
returned to baseline levels within 4 hours (Figure 4.1A, left panel and data not shown).  
Nur77 protein levels were also robustly upregulated by GnRHa reaching maximal 
expression at approximately one hour of GnRHa stimulation (Figure 4.1A, right 
panel).  Induced Nur77 immunoreactivity appeared as multiple closely spaced bands 
on the immunoblot suggesting posttranslational modification of the induced protein.  
Consistent with previous reports, phosphatase treatment of the immunoprecipitates 
resolved the Nur77 immunoreactivity into a more uniform size of approximately 74 
kD (data not shown).  These results identify Nur77 as a GnRH-responsive immediate 
early gene in T3-1 cells and indicate that GnRHa-induced signaling activity in these 
cells leads to both induction and multi-site phosphorylation of Nur77. 
 Nur77 has been shown to be induced by CRH in pituitary corticotropes where 
it plays a role in the transcriptional upregulation of the pro-opiomelanocortin (POMC) 
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Figure 4.1. Upregulation of Nur77 in T3-1 and primary pituitary cells following 
stimulation with GnRHa.  A.  T3-1cells were exposed to the GnRH agonist 
buserelin for the indicated times and Nur77 mRNA levels were measured by qPCR 
(left panel).  Bars represent mean +/- SEM of 3 experimental units.  Asterices indicate 
significant differences (p < 0.05) from the zero time point.  The experiment was 
repeated 3 times with similar results.  B. Upregulation of Nur77 protein was also 
examined by immunoblotting (right panel).  Actin is shown as a lane loading control.  
B. Whole mouse pituitaries were dispersed into primary culture.  Following serum 
starvation, cultures were exposed to either GnRHa (left panel) or CRH (right panel) 
for the indicated time courses.  Nur77 mRNA levels were measured within each 
experimental unit by qPCR.  For each graph, bars represent mean +/- SEM for 6 
replicates representing pooled results from 2 separate experiments.  Asterices indicate 
significant differences from the 0-time point at p<0.05. 
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gene (24).  The corticotrope thus represents an established model of Nur77 
upregulation induced by activation of a G-protein coupled receptor.  To determine 
whether Nur77 is induced by GnRHa in primary mouse gonadotropes, and to compare 
its induction kinetics between gonadotropes and corticotropes, whole mouse pituitaries 
were dispersed into primary culture and then stimulated with either vehicle, GnRHa, 
or CRH.  GnRHa stimulation led to rapid and significant (approximately 4-fold) 
upregulation of Nur77 transcript levels within mixed primary pituitary cell cultures, 
the kinetic profile of which was highly similar to that observed in the T3-1 cell line 
(Figure 4.1B, left panel).   CRH stimulation led to a significant, but more modest 
(approximately 3-fold) increase in Nur77 transcript levels, with maximal expression 
observed following 60 minutes of agonist exposure (Figure 4.1B, right panel).  CRH-
induced Nur77 transcript levels returned to baseline within 120 minutes of agonist 
exposure, while the transcript upregulation induced by GnRHa was more sustained, 
remaining significantly elevated above baseline levels for at least 3 hours following 
agonist exposure (Figure 4.1B).   
 
Nur77 is expressed in mouse pituitary gonadotropes in vivo 
To assess the expression and subcellular localization of Nur77 in primary 
mouse gonadotropes, we examined pituitary sections from randomly cycling female 
mice using fluorescence immuno-colabeling of Nur77 and LH .  Nur77 was expressed 
in many cells throughout the anterior pituitary parenchyma and colocalized 
extensively with LH .  Within LH -positive gonadotropes, Nur77 was localized 
predominantly to the nucleus (Figure 4.2).   
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Figure 4.2. Nuclear localization of Nur77 in mouse pituitary gonadotropes in 
vivo.  Expression of Nur77 in gonadotropes in vivo was examined by 
immunofluorescent co-labeling of sections on mouse pituitary using a FITC-
conjugated antibodies against Nur77 and Texas Red-conjugated antibodies against 
LH .  Individual labelings of Nur77 and LH , and well as simultaneous visualization 
of both wavelengths (merge) and DAPI are shown.  White arrow indicates a 
gonadotrope that coexpresses LH  and Nur77 within the cytosolic and nuclear 
compartments respectively. 
 
LH Merge
DAPI Nur77
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GnRHa-induced upregulation of Nur77 in T3-1 cells is dependent on the 
classical calcium-PKC-ERK signaling pathway  
Having established Nur77 as a GnRH-responsive immediate early gene in 
T3-1 cells as well as differentiated gonadotropes, we next employed a cadre of 
pharmacological inhibitors of specific signaling events known to be induced by 
GnRH, and analyzed their effects on both GnRHa-induced Nur77 expression, and 
ERK activation in these cells.  As expected, pretreatment of cells with the GnRHR 
antagonist antide completely abrogated both ERK activation and Nur77 upregulation 
following GnRHa treatment (Figure 4.3A).  Inhibition of PKC isozymes with the 
agent GF109203X (GFX) similarly attenuated both Nur77 induction and ERK 
activation (Figure 4.3B).  Inhibition of both calmodulin and calcium flux through L-
type voltage gated calcium channels with the compounds W7 and nifedipine, 
respectively, completely blocked GnRH-induced Nur77 expression while reducing, 
but not abolishing, the ERK response (Figure 4.3C).  In contrast, inhibition of 
intracellular calcium fluxes with the intracellular calcium chelator Bapta-AM appeared 
to decrease Nur77 induction slightly, while having no effect on ERK activation 
(Figure 4.3C).  Pretreatment of cells with GW5074, an inhibitor of the catalytic 
activity of c-Raf, abolished the Nur77 response to GnRH stimulation (Figure4.3D).  
Surprisingly, however, c-Raf inhibition had no effect on GnRH-induced activation of 
ERK1/2 (Figure 4.3D).  Finally, inhibition of MEK1/2 with the specific inhibitor 
PD98059 significantly decreased GnRHa-induced Nur77 upregulation while 
predictably abolishing ERK activation (Figure 4.3E).  Together these results reinforce 
the requirement for ERK signaling for GnRH-induced Nur77 upregulation in T3-1 
cells, and provide further demonstration of the roles of PKC, extracellular calcium 
influx, and calmodulin in mediating the effects of GnRH action on this immediate 
early gene.  
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Figure 4.3.  Pharmacological analysis of Nur77 upregulation in T3-1 cells.  
Serum-starved T3-1 cells were pretreated for 30 minutes with either vehicle or the 
indicated pharmacological agents for 30 minutes.  Cells were then exposed to a time 
course (either 1 hour or 2 hours, as indicated) of GnRHa.  Lysates from cells exposed 
to a 2-hour time course of GnRHa were analyzed by immunoprecipitation followed by 
immunoblotting for Nur77 upregulation (upper portion of panels).  Actin levels within 
the lysates are shown as a control for the input of the immunoprecipitation.  Lysates 
from cells treated in parallel over a 1-hour time course were analyzed by imunoblot 
for levels of activated ERK (p-ERK, lower portion of panels).  Total ERK 
immunoreactivity is shown as a lane loading control for these samples.  Each 
experiment was repeated at least 3 times with similar results. 
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Our pharmacological data indicate that PKC activation, calcium, calmodulin, 
and ERK signaling are required for GnRH-induced upregulation of Nur77 in T3-1 
cells.  However, in this cell line, as in other systems, ERK activation itself has been 
shown to be dependent on PKC, calcium, and calmodulin (1, 27, 32-34).  Therefore, to 
determine if ERK signaling is sufficient for GnRHa-induced transcriptional 
upregulation of Nur77 in T3-1 cells, we utilized an expression vector encoding c-Raf 
fused to the CAAX membrane-targeting sequence from the small GTP-binding protein 
ras (Raf-CAAX).  Raf-CAAX associates constitutively with the plasma membrane 
where it drives sustained and high level activation of the ERK pathway independent of 
extracellular stimuli.   
Overexpression of Raf-CAAX in T3-1 cells led to robust and sustained 
phosphorylation of ERK1/2 (Figure 4.4A).  Cells were then transfected with a 
luciferase reporter containing 1,566 bp of the mouse Nur77 proximal promoter 
(Nur77-luc).  In addition, some cells were transfected with either pCMV-Raf-CAAX 
or the empty control vector (pCMV).  Following transfection, cells were exposed to 
either vehicle or the MEK inhibitor PD98059, followed by treatment with either 
vehicle or GnRHa as indicated.  GnRHa stimulation led to robust activation of the 
Nur77 luciferase reporter; however, this effect was significantly reduced by 
pharmacological inhibition of ERK signaling (Figure 4.4B, left panel).  Significant 
increases in Nur77 luciferase reporter activity were not observed following 
transfection of Raf-CAAX alone (Figure 4.4B, left panel).  To verify the ability of 
Raf-CAAX to drive a transcriptional response in these cells, we repeated the 
experiment using a c-Fos luciferase reporter (c-Fos-luc).  GnRHa induced a significant 
increase in the activity of the Fos-luc reporter which was largely abrogated by 
inhibition of MEK1/2.  Raf-CAAX also induced a significant increase in 
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Figure 4.4.  ERK signaling is required, but not sufficient, for GnRH-induced 
transcriptional upregulation of Nur77 in T3-1 cells.  A. T3-1 cells were 
transfected for 4 hours with increasing quantities (0.25, 1.0, or 2.5 ug) of Raf-CAAX 
expression vector.  After an additional 4 hour incubation in complete media, cell 
lysates were analyzed by immunoblot for levels of activated ERK1/2 (p-ERK).  Total 
ERK (T-ERK) and actin immunoreactivity are shown as lane loading controls.  B. 
T3-1 cells were transfected with a Nur77-luciferase reporter (Nur77-luc, left panel) 
or a c-Fos-luciferase reporter (C-Fos-luc, right panel).  In addition, some cells were 
transfected with empty control vector or a Raf-CAAX expression vector to drive 
hormone-independent activation of the ERK pathway.  Cells were pretreated or not as 
indicated with the MEK inhibitor PD90859 (PD), and/or the GnRH agonist buserelin.  
Bars represent mean +/- SEM normalized luciferase activity of 3 experimental units.  
Bars with different letter designations represent mean values that are statistically 
significantly different at p<0.05.  C. T3-1 cells were pretreated or not with PD98059, 
or were transfected with empty vector or Raf-CAAX as indicated, and were then 
treated with either vehicle or GnRHa as in (A).  Bars represent mean +/- SEM 
endogenous Nur77 (left panel) or Egr1 (right panel) transcript levels as measured by 
qPCR.  Bars with different letter designations represent mean values that are 
statistically significantly different at p<0.05.  These experiments were repeated at least 
3 times with similar results. 
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Fos-luc activity, demonstrating the ability of Raf-CAAX to activate an ERK-
responsive promoter (Figure 4.4B, right panel).   
To assess the effect of ERK signaling on the endogenous Nur77 gene in T3-1 
cells, we treated cells as described above, and then measured Nur77 transcript levels 
by qRT-PCR.  The inductive effect of GnRHa on Nur77 transcript levels was blocked 
by pharmacological inhibition of the ERK pathway (Figure 4.4C, left panel).  
Consistent with our observations on the Nur77 luciferase reporter, overexpression of 
Raf-CAAX had no effect on endogenous Nur77 transcript levels in these cells (Figure 
4.4B, left panel).  To assess the ability of Raf-CAAX to induce transcriptional 
upregulation of an endogenous gene in these cells, we also measured transcript levels 
of the ERK responsive immediate early gene Egr1 in these samples.  Treatment with 
GnRHa led to an approximately 27-fold increase in Egr1 transcript levels within one 
hour; however, this induction was largely blocked by inhibition of MEK1/2 (Figure 
4.4C, right panel).  Raf-CAAX led to a more modest (approximately 10-fold) 
elevation in Egr1 transcript levels over empty vector treated controls.  This effect did 
not achieve statistical significance in the context of a one-way ANOVA with post-hoc 
all pairwise comparisons; however, this likely reflects type II error.  Collectively, 
these results indicate that ERK signaling is required, but not sufficient, for GnRHa-
induced transcriptional upregulation of Nur77 in T3-1 cells. 
 
Pharmacological inhibition of c-Raf does not inhibit GnRHa-induced activation 
of ERK1/2 in T3-1 cells 
Our pharmacological experiments yielded the unexpected finding that 
phosphorylation of ERK1/2 is unaffected by pretreatment of T3-1 cells with the c-
Raf inhibitor GW5074.  This raises the intriguing hypothesis that GnRH-induced  
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activation of the ERK pathway may in fact be independent of c-Raf catalytic activity.  
To test this further, we treated both T3-1 cells and NIH-3T3 mouse fibroblasts with 
either PD98059 or a range of doses of GW5074, and evaluated the response of the 
ERK pathway to treatment with either GnRHa or the classical receptor tyrosine kinase 
ligand epidermal growth factor (EGF).  We chose the NIH-3T3 cell line as a control 
for this experiment since these cells represent a model in which growth factor induced, 
c-Raf-dependent ERK activation was initially characterized (35).  Predictably, 
PD98059 abolished the ERK response to both GnRHa and EGF in T3-1 and 3T3 
cells, respectively (Figure 4.5).   Pretreatment of T3-1 cells with GW5074 over a 
dose range of 1-10 uM had no effect on GnRHa-induced ERK activation (Figure 4.5, 
left panel).  Consistent with previous reports (36), exposure of T3-1 cells to higher 
concentrations of GW5074 (>10 uM) led to GnRHa-independent ERK activation (data 
not shown).  In contrast, EGF-induced ERK activation in NIH 3T3 cells was markedly 
inhibited by GW5074 at doses in excess of 1 uM (Figure 4.5, right panel).  These 
results confirm the activity of this pharmacological agent, and lend further support to 
the hypothesis that GnRHa-induced ERK activation does not require the catalytic 
activity of c-Raf.   
 
Neither overexpression of a dominant negative catalytic mutant of c-Raf, nor 
siRNA-mediated knockdown of c-Raf expression, inhibits GnRHa-induced 
activation of ERK1/2 in T3-1 cells 
The inhibitor GW5074 has been a useful pharmacological screening tool to 
assess the role of c-Raf in various cellular processes.  However, like many 
pharmacological agents, its specificity can be difficult to verify in any given 
experimental setting.  To circumvent this difficulty, and further examine the role of   
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Figure 4.5.  Comparative effects of c-Raf inhibition on GnRH- and EGF-induced 
ERK activation in T3-1 and NIH-3T3 cells.   Serum-starved T3-1 cells (left 
panel), or NIH-3T3 cells (right panel) were pre-treated for 30 minutes as indicated 
with either vehicle, PD98059, or increasing concentrations (1, 5, or 10 uM) of the c-
Raf inhibitor GW5074.  Cells were then exposed to either vehicle, GnRHa or EGF for 
10 minutes.  Cell lysates were analyzed by immunoblot for levels of activated ERK (p-
ERK).  Total ERK immunoreactivity (T-ERK) is shown as a lane loading control.  
Experiments were performed at least three times with similar results. 
 
 
 
 
 
GnRHa      - +     - +    - - - +    +    +
p-ERK
T-ERK
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p-ERK
T-ERK
EGF           - +     - +    - - - +    +    +
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c-Raf in mediating GnRH-induced ERK activation, we employed the complementary 
strategies of dominant-negative c-Raf overexpression, and c-Raf knockdown using 
RNA interference.  T3-1 cells and NIH 3T3 cells were transiently transfected with 
increasing doses of an expression construct encoding an HA-tagged catalytically 
inactive form of c-Raf (Raf-S375M).  Cells were then stimulated with either vehicle or 
GnRHa ( T3-1 cells), or vehicle or EGF (  cells and ERK phosphorylation 
was examined by immunoblot.  Dose-dependent expression of the recombinant protein 
was verified by immunoblot against c-Raf and HA.  Consistent with our 
pharmacological data, GnRHa-induced ERK activation in T3-1 cells was unaffected 
by overexpression of Raf-S375M at any dose (Figure 4.6A, left panel).  In contrast, 
even within this transient transfection paradigm, modest inhibition of EGF-induced 
ERK activation in NIH 3T3 cells was observed at the highest dose of Raf-S375M 
overexpression (Figure 4.6A, right panel).   
In some cellular models, RNAi-mediated decreases in cellular c-Raf protein 
levels have been shown to cause proportional decreases in ERK activation following 
agonist treatment (37).  To determine whether suppression of c-Raf protein in T3-1 
cells affects the ability of GnRHa to activate the ERK pathway, we transiently 
transfected cells with increasing doses of siRNA‟s against either c-Raf or LacZ 
mRNA.  Cells were then stimulated with either vehicle or GnRHa and ERK 
phosphorylation was examined by immunoblot.  Levels of c-Raf, as well as B-Raf 
were also assessed by immunoblot to verify specificity of knockdown of the target Raf 
isoform.   c-Raf siRNA resulted in significant reductions in cellular c-Raf protein, with 
no comparable reduction in levels of B-Raf (Figure 4.6B).  GnRHa-induced ERK 
activation was again unaffected by the decrease in c-Raf protein levels.  Together, 
these data support the conclusion that c-Raf is not required for GnRH-induced 
activation of the ERK pathway in gonadotropes.   
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Figure 4.6.  Effects of c-Raf dominant negative overexpression and siRNA-
mediated c-Raf knockdown on GnRH-induced ERK activation in T3-1 cells.  A. 
T3-1 cells (left panel) or NIH-3T3 cells (right panel) were transfected with 
increasing doses of an expression vector encoding an HA-tagged dominant-negative c-
Raf (pKH3-Raf-S375A).  Following transfection, cells were serum-starved, and then 
stimulated with either vehicle or GnRHa for 10 minutes.  Cell lysates were analyzed 
by immunoblot for levels of activated ERK (p-ERK).  Total ERK immunoreactivity 
(T-ERK) is shown as a lane loading control.  Lysates were also analyzed for 
immunoreactivity against Raf-1 and the HA epitope tag.  B.  T3-1 cells were 
transfected with increasing doses of siRNA targeting either c-Raf, or the LacZ coding 
sequences.  Following transfection, cells were serum-starved, and then stimulated with 
either vehicle or GnRHa for 10 minutes.  Cell lysates were analyzed by immunoblot 
for levels of activated ERK (p-ERK).  Total ERK immunoreactivity (T-ERK) is shown 
as a lane loading control.  Lysates were also analyzed for immunoreactivity against B-
Raf to assess isoform specificity of the anti-c-Raf siRNA.   These experiments were 
performed at least three times with similar results. 
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Generation and validation of a pituitary specific c-Raf knockout mouse. 
The data presented here support use of the T3-1 cell line as a model for study 
of the mechanisms of GnRH-induced Nur77 expression in the gonadotrope.  However, 
to further corroborate our results, we sought to develop an in vivo model by which to 
compare the roles of c-Raf and ERK activity in mediating the Nur77 transcriptional 
response to GnRH.  Previously, we described generation of a transgenic mouse model 
with pituitary targeted ablation of ERK1 and 2 that resulted in female infertility due to 
LH deficiency (30).  Using a similar genetic approach, we generated mice with 
pituitary-targeted conditional ablation of c-Raf (c-Raf conditional knockout, c-Raf 
CKO).  We examined a range of physiological parameters in c-Raf CKO animals, 
including fertility, to establish the role of c-Raf for gonadotrope function in vivo, and 
then specifically asked whether c-Raf is required for GnRH-induced transcriptional 
upregulation of Nur77 in vivo. 
 Mice homozygous for a floxed mutation at the c-Raf locus (c-Raf
fl/fl
), were 
crossed with GSU:Cre mice, in which Cre recombinase is expressed under the 
regulatory control of a 4.6 kb fragment of the murine αGSU promoter.  Cre-dependent 
recombination at the c-Raf locus was assessed by PCR in c-Raf
fl/fl
,CRE
+
 and c-
Raf
fl/fl
,CRE
-
 animals using primers flanking the floxed region of the c-Raf locus 
(Figure 4.7A, schematic).  Products indicating excision of the floxed region of the c-
Raf gene were only produced from pituitary genomic DNA of Cre
+
 individuals, 
indicating tissue-specific susceptibility of the c-Raf locus to Cre-mediated 
recombination (Figure 4.7A, left panel). 
 To further verify this transgenic model, we compared pituitary transcript levels 
of c-Raf in c-Raf
fl/fl
,CRE
+
 and c-Raf
fl/fl
,CRE
-
 animals using quantitiative PCR (qPCR).  
Transcript levels of c-Raf were significantly lower in Cre-expressing animals as  
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Figure 4.7.  Validation of the pituitary targeted c-Raf conditional knockout 
mouse.  A. Cre-mediated recombination at the c-Raf locus within the pituitary was 
detected by PCR using genomic DNA from the specified tissues.  For each sample, the 
forward primer designated „Pr. F‟ was paired individually with reverse primers labeled 
„Pr. 3‟ and „Pr. 4‟ spanning the floxed genomic region as indicated in the schematic.  
Lanes are labeled with the specified reverse primer used for the reaction.  Molecular 
weight marker is shown in the left lane.  Equivalent results were obtained from males 
and females.  B. Whole pituitary transcript levels of c-Raf and B-Raf were measured 
by qPCR in control and CKO animals.  Bars represent mean +/- SEM from 5 animals 
per group.  Means were compared by 2-tailed t-test with p values indicated.  C. Litter 
sizes from matings between control or CKO animals were compared by 2-tailed t-test 
(left panel).  Bars represent mean +/- SEM of 9 litters per group.  Body weights were 
compared between control and CKO animals from 2 weeks through 6 weeks of age 
(right panel).  Points represent mean +/- SEM of body weights from the same 5 
animals from each group.  Data are shown for females; however similar results were 
obtained for males. 
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compared with Cre-non-expressing controls (Figure 4.7B, left panel).  In contrast, B-
Raf transcript levels were not significantly different between c-Raf CKO and control 
mice (Figure 4.7B).  The degree of reduction in c-Raf transcript levels is consistent 
with the fact that only a minority of cells within the pituitary express the GSU and 
would be expected to be rendered c-Raf deficient in this model.  These data further 
support the fidelity of the genetic perturbation in this model.   
 Pituitary-specific c-Raf null males and females were viable and fertile.  They 
were born at expected Mendelian frequencies, grew at the same rate as control 
littermates and were grossly and histologically indistinguishable from either control 
littermates or wild type mice at adulthood (Figure 4.7C, right panel and data not 
shown).  Litter sizes from matings between control animals were not significantly 
different from litter sizes from matings between CKO animals (Figure 4.7C, left 
panel).  These observations support the conclusion that c-Raf is not required for the 
function of differentiated gonadotropes in vivo. 
 
Basal and GnRHa-induced transcriptional upregulation of Nur77 in primary 
mouse gonadotropes requires ERK signaling but is independent of c-Raf 
To address the requirements for c-Raf and ERK activity for GnRH-induced 
expression of Nur77 in vivo, we dispersed whole pituitaries from mice with pituitary 
deficiency of c-Raf, ERK1/2, or their respective control littermates into primary 
culture and stimulated the cells with either GnRHa or CRH.  Nur77 transcript levels 
were then measured in the cultures by qPCR.  In pituitary cell cultures from mice with 
pituitary deficiency of c-Raf, both GnRHa and CRH led to significant increases in 
Nur77 transcript levels which were indistinguishable from the response of the controls 
(Figure 4.8A).  CRH stimulation led to significant increases in Nur77 transcript levels  
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Figure 4.8.  GnRHa- or CRH-induced transcriptional upregulation of Nur77 in 
primary mixed pituitary cell cultures from mice with pituitary-targeted ablation 
of either c-Raf, or ERK1/2.  A. Whole pituitaries from mice with GSU-CRE-
mediated pituitary-specific disruption of c-Raf (c-Raf conditional knockout, c-Raf 
CKO) were dispersed into primary culture.  Following serum starvation, cultures were 
exposed to either vehicle, and GnRHa or CRH for 60 minutes.  Nur77 mRNA levels 
were measured within each experimental unit by qPCR.  Bars represent mean +/- SEM 
for 9 replicates representing pooled results from 3 separate experiments.  Bars with 
different letter designations represent mean values that are statistically significantly 
different at p<0.05.  B. Whole pituitaries from mice with pituitary-specific compound 
ablation of ERK1 and 2 (ERK1/2 double knockout, ERK1/2 DKO) were dispersed 
into primary culture and treated as in (A).  Bars represent mean +/- SEM for 6 
replicates representing pooled results from 2 separate experiments.  Bars with different 
letter designations represent mean values that are statistically significantly different at 
p<0.05. 
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in both control mice and mice with pituitary deficiency of ERK1/2 (Figure 4.8B, right 
panel).  In contrast, while GnRHa stimulation induced significant increases in Nur77  
transcript levels in control mice, this inductive effect of GnRHa was completely 
blocked in ERK deficient pituitary cells (Figure 4.8B, left panel).  Together, these  
results establish Nur77 as a GnRH-responsive, ERK-dependent immediate early gene 
in the gonadotrope, and indicate further that c-Raf is not an obligate intermediary in 
the GnRH-ERK signaling pathway in vivo. 
 
DISCUSSION   
Using both cellular and in vivo models, we show here that the orphan nuclear 
receptor Nur77 is rapidly and robustly upregulated in gonadotropes following GnRH 
stimulation.  Activation of the ERK signaling pathway is required, but not sufficient 
for Nur77 induction both in the T3-1 gonadotrope cell model, and in vivo.  
Consistent with the observation that c-Raf kinase is not required for GnRH-induced 
transcriptional upregulation of Nur77, our data reveal further that c-Raf is not the 
primary MAPKKK of the ERK pathway within these cells.   In these studies, the 
kinetics and magnitude of Nur77 induction were highly similar between the T3-1 cell 
line and primary pituitary gonadotropes. This contrasts with a recent report 
demonstrating sustained expression of Nur77 in the L T2 cell line following GnRH 
stimulation (38).  The overall correspondence between T3-1 cells and primary 
gonadotropes supports the validity of this cell line as a model for study of GnRH-
induced Nur77 expression in the gonadotrope.     
While perhaps controversial within the context of GnRH signaling, our 
observations on the c-Raf independence of ERK pathway activation in the 
gonadotrope are consistent with many contemporary reports on the cellular functions 
of c-Raf (39-41).  C-Raf dependent activation of the ERK pathway remains a widely 
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accepted paradigm, yet a growing body of evidence indicates that MEK kinase activity 
is not a primary function of c-Raf.  Gene ablation studies showed that c-Raf deficient 
mice die at approximately e10.5 of gestation due to widespread apoptosis; however, 
growth factor induced ERK activation remained unimpaired in c-Raf-deficient 
embryonic stem cells, suggesting that the developmental defect in these mice was 
unrelated to the loss of a critical MEK kinase (42). Moreover, the lethal phenotype in 
the c-Raf deficient mouse was rescued by reintroduction of a catalytically inactive 
form of c-Raf showing that the requirement for c-Raf during development is 
independent of its MEK kinase activity (43).  Recent reports using conditional targeted 
gene ablation approaches indicate instead that c-Raf may serve a primary role as a 
negative regulator of apoptosis in vivo (29, 41, 44, 45).  The mechanism underlying 
downregulation of sensitivity to apoptotic stimuli has been linked to direct c-Raf 
mediated inhibition of the proapoptotic proteins ASK1 or MST2 (41, 46).  In our 
examination of mice with pituitary targeted ablation of c-Raf, we found no differences 
in gonadotrope numbers between c-Raf deficient animals and littermate controls (data 
not shown).  Thus, targeted ablation of c-Raf in pituitary gonadotropes appears to have 
no effect on cellular phenotype.  However, gonadotropes are highly differentiated 
postmitotic cells that do not undergo apoptosis during the course of their functional 
life.  In addition, given the critical importance of these cells for reproductive function, 
it may be reasonable to speculate that they have evolved robust and multifaceted 
resistance to apoptotic stimuli.  Therefore, the antiapoptotic activity of c-Raf may be 
dispensible within this specific cell lineage.   
Our studies using the compound GW5074 showed that inhibition of c-Raf 
activity had no effect on either GnRH-induced ERK activation, or on transcriptional 
upregulation of Nur77 in T3-1 cells.  Interestingly, however, upregulation of Nur77 
at the protein level was largely abrogated by c-Raf inhibition.  It is possible that this 
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represents a non-specific effect of the GW5074 compound on translational processes.  
Alternatively, this observation may point to a role for c-Raf in translational regulation 
in these cells.  Indeed, GnRH-induced upregulation of the immediate early gene c-Fos 
at the protein level in T3-1 cells was unaffected by GW5074 pretreatment (S Bliss, 
unpublished data).  Recently, the translational regulator eukaryotic elongation factor 
1A (eEF-1A) was identified as a target of c-Raf-mediated phosphorylation (44).  
Inhibition of c-Raf activity led to a decrease in interferon-induced eEF-1A 
phosphorylation which accelerated the ubiquitination and proteosomal degradation of 
eEF-1A.  In turn, downregulation of eEF-1A was associated with increased cellular 
sensitivity to the pro-apoptotic effects of interferon-  (44).  This study points to an 
additional mechanism by which c-Raf may antagonize apoptosis.  More broadly, the 
identification of eEF-1A as a c-Raf substrate discloses an intriguing link between c-
Raf catalytic activity and the translational apparatus of the cell.  This is consistent with 
a previous report that indicated that stimulation of cap-dependent translation by GnRH 
in T3-1 cells was partially dependent on ras (and presumably, therefore, c-Raf) but 
was not dependent on ERK signaling (47).  Whether c-Raf catalytic activity is 
uniquely required for GnRH-induced translational upregulation of Nur77 in these cells 
is currently being investigated.   
 Our results indicate that upregulation of Nur77 in T3-1 gonadotropes is 
dependent on both PKC and calcium.  These findings are consistent with previous 
reports demonstrating calcium and PKC dependence of Nur77 in a variety of cell types 
(23, 24, 34, 48).  In T lymphocytes, an established model in which Nur77 is strongly 
upregulated following stimulation of the T cell receptor (TCR), calcium and PKC 
function as parallel signaling pathways with synergistic effects on Nur77 promoter 
activation (49).  PKC increases Nur77 promoter activity by targeting the transcription 
factor Jun-D.  Jun-D binds constitutively to AP-1-like (NAP) sites of the Nur77 
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promoter and under resting conditions, represses the Nur77 promoter through 
recruitment of the corepressor Menin and an mSin3A-HDAC complex (50).  
Activation of PKC leads to phosporylation of Jun-D, dissociation of the Menin-
corepressor complex, and recruitment of p300 HAT activity to the promoter (50).  
Importantly, PKC-dependent phosphorylation of Jun-D in this setting is mediated 
specifically by the ERK pathway (50).  In luteinized ovarian cells, induction of Nur77 
by the arachidonic acid metabolite prostaglandin F  was also shown to be dependent 
on calcium/calmodulin and ERK1/2-mediated phosphorylation of Jun-D; however, in 
these cells, ERK activation itself was shown to be dependent on calcium/calmodulin 
(34).  Activation of the ERK pathway has similarly been shown to be dependent on 
PKC, extracellular calcium/calmodulin in T3-1 gonadotropes (1, 27, 32, 33).  Thus, 
while the molecular mechanisms of Nur77 promoter activation in gonadotropes await 
precise clarification, it seems reasonable to hypothesize that ERK-dependent 
phosphorylation of Jun-D may play a key role.  In support of this hypothesis, both the 
expression and the transcriptional activity of Jun-D were previously shown to 
upregulated by GnRH in the T3-1 cell line (51). 
 Nur77 has been shown to serve a variety of physiological roles in different 
cells types, but functions most commonly as a transcriptional regulator.  Monomeric 
Nur77 binds to a consensus octanucleotide response element (NGFI-B-response 
element, NBRE) consisting of sequence AAAGGTCA and may function as a 
transcriptional activator or repressor (12, 48, 52, 53).  Nur77 may also dimerize with 
other members of the NR4A family (Nor-1 or Nurr1) and bind to a bipartite target 
DNA motif, the Nur response element (NurRE) (54).   We have demonstrated the 
ability of GnRH stimulation to activate multimers of NBRE and NurRE in T3-1 cells 
with equal efficiency (S Bliss and MS Roberson, unpublished observations).  
Alternatively, Nur77 may dimerize with RXR and bind to a DR5 element in a retinoic 
 174 
 
acid-dependent manner (54, 55).  A recent genomic analysis revealed 483 genes in the 
human genome that possess an NBRE within their proximal promoter, highlighting the 
possibility that Nur77 may exert broad transcriptional regulatory influence in various 
contexts (56).  Clarification of the physiological role(s) of Nur77 has been confounded 
by the observation that Nur77 deficient mice are viable and fertile and display only 
relatively subtle phenotypic abnormalities associated with dysregulation of central 
dopaminergic neuronal pathways (10).  However, a high degree of functional 
redundancy between Nur77 and the closely related NR4A family member Nor-1 may 
underlie the disparities between reported gene regulatory roles of Nur77 and the lack 
of overt phenotypic abnormalities in the Nur77 deficient mouse (57, 58).  Elucidation 
of physiologically relevant targets of Nur77 in the gonadotrope will likely require a 
genetic approach involving tissue-specific compound deletion of both Nur77 and Nor-
1.    
In conclusion, our data establish Nur77 as an immediate early response gene 
strongly induced by GnRH in gonadotropes in vivo.  Analysis of the signaling 
activities required for upregulation of Nur77 in these cells demonstrate that activation 
of the Nur77 promoter is dependent on calcium, PKC, and ERK signaling.  In 
addition, these results indicate that activation of the ERK pathway following GnRH 
receptor occupancy in gonadotropes is independent of c-Raf, and point to a possible 
alternative role for c-Raf in regulation of translation in these cells. 
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  The functional organization of the vertebrate HPG axis, and the central role of 
the gonadotrope in the regulation of reproductive function have been appreciated for 
several decades (1-5).  Historically, experimental studies of HPG axis function have 
emphasized the use of live animal models in which specific experimental 
manipulations are linked to relatively broad physiological outcome parameters such as 
fluctuations in plasma hormone levels, or measureable changes in reproductive 
behaviors or fertility.  This general approach is perhaps best exemplified by the work 
of Ian Clarke who developed a method of chronic surgical cannulation of the 
hypophyseal portal vessels in sheep allowing high frequency sampling and 
biochemical analysis of hypophyseal portal blood (6, 7).  This seminal work clarified 
the importance of the pulsatile nature of hypothalamic GnRH secretion and its link to 
oscillations in plasma levels of the gonadotropins, as well as the fundamental role of 
gonadal steroids in negative feedback regulation of the activity of the HPG axis.   
In contrast to whole animal physiological approaches to the study of the HPG 
axis, research into the molecular mechanisms underlying gonadotrope function has 
relied heavily upon use of the established T3-1 and L T2 gonadotrope cell lines (8-
16).  Certainly, neither the complex pulsatile nature of the GnRH signal, nor the 
integrated feed-forward or feedback endocrine regulatory mechanisms at play in the 
living animal can be satisfactorily modeled in these simple cell systems.  Nevertheless, 
over the past 20 years, these cell lines have proven to be useful tools for examination 
of the molecular basis gonadotrope function.  More recently, dramatic expansion of 
the availability of genetically modified mice has provided an opportunity to integrate 
these approaches, and to test specific hypotheses regarding the molecular mechanisms 
underlying gonadotrope responsiveness to GnRH within a physiologically relevant 
whole animal model.  The work described in this dissertation has emphasized such 
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complementary use of basic cellular and in vivo models in the investigation of the role 
of ERK signaling in gonadotrope function. 
 
Membrane rafts and the GnRHR 
Appropriate cell surface expression of the GnRHR by gonadotropes is 
obviously essential for GnRH action.  Previous work has demonstrated that certain 
forms of hypogonadotropic hypogonadism may result from aberrant intracellular 
trafficking and lack of appropriate expression of the receptor (17, 18); however, 
results published by the lab of Dr. Colin Clay in collaboration with this lab provided 
the first evidence that GnRHR function may be further regulated at the level of the 
plasma membrane through its association with cholesterol-enriched membrane 
microdomains (19).  The data presented in Chapter 2 of this dissertation indicate that 
the biophysical properties of the plasma membrane are important for the ability of the 
GnRHR to couple to the ERK module, and suggest that membrane rafts may play a 
role in facilitating the assembly of a plasma-membrane associated GnRHR-ERK 
signaling complex.  The composition of this signaling complex warrants more 
systematic investigation.  Mass spectrometry has been useful for identification of raft-
associated proteins as well as for identification of individual components of native 
protein complexes purified by immunoprecipitation or affinity chromatographic 
techniques (20-23).  Our ability to immunoprecipitate the GnRHR from a low-density 
membrane environment following cell fractionation suggests that a similar strategy 
may be useful for elucidation of the composition of signaling complexes that associate 
with membrane rafts in conjunction with the GnRHR.   
   It is notable that the constitutive and ligand-independent association of the 
GnRHR with low-density membrane rafts is atypical of GPCRs generally.  Most 
GPCRs show partial constitutive association with membrane rafts, and in many cases, 
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agonist treatment causes a significant change in the tendency of a receptor to partition 
into, or out of, a low-density membrane environment (24, 25).  Whether the GnRHR 
has an intrinsic biophysical preference for a lo membrane environment, or whether its 
behavior is dependent upon specific protein-protein interactions is not entirely clear; 
however, domain swap studies indicated that the absence of the C-terminal tail does 
not itself lead to constitutive raft association of the receptor (19).  Ultimately the 
GnRHR may represent an interesting and unique model for study of the biophysical 
mechanisms underlying the partitioning of GPCRs into lo lipid environments. 
 
The requirement for ERK signaling for gonadotrope function in vivo  
The ability of the GnRHR to activate the ERK pathway and the role of ERK 
signaling in various aspects of gonadotrope function have been convincingly 
demonstrated in the T3-1 and L T2 gonadotrope cell lines (10, 15, 26-31).    The 
data presented in Chapter 3 corroborate the importance of the ERK pathway for 
gonadotrope function and establish the ERK pathway a major mediator of the effects 
of GnRH on LH  transcription in vivo.   However, our results further disclose an 
interesting gender difference in the requirement for ERK signaling for fertility.  The 
female-specific nature of this requirement has not previously been recognized and 
highlights value of this genetic approach to the study of the molecular basis of 
gonadotrope function.  Whether the gender-specific nature of the requirement for ERK 
signaling in the gonadotrope represents simply a differential requirement for LH itself 
between males and females, or whether there exists a more intrinsic gender difference 
in the requirement for ERK signaling for LH  transcription is not clear.  However, the 
generation and characterization of this model would appear to provide a useful tool 
with which to address the mechanisms underlying this gender-specific phenotype.   
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While our data indicate that the major phenotypic impact of gonadotrope-
targeted ERK ablation reflects deficient Egr-1 upregulation and failure of LH  
transcription, it is likely that phosphorylation of numerous substrates is impaired in the 
ERK-deficient gonadotrope.  Identification of these substrates promises to shed light 
on finer aspects of the function and regulation of these cells.  Indeed, in agreement 
with previous work (32), transcriptional upregulation of the -GSU is impaired in the 
ERK-deficient gonadotrope, yet the gonadal histology in these animals would indicate 
that this defect does not result in an overt phenotype.  Generation of this model of 
pituitary ERK deficiency brings identification and in vivo validation of additional and 
perhaps previously unrecognized ERK substrates and ERK-dependent genes well 
within reach, through either comprehensive genomic or proteomic techniques, or 
candidate target approaches.   
 
Nur77 in the gonadotrope 
Using a candidate gene approach, we show in Chapter 4 of this dissertation 
that Nur77 is a component of the immediate early gene program induced by GnRH in 
the gonadotrope.  The hypothesis that Nur77 is a GnRH-induced immediate early gene 
that plays a role in gonadotrope function evolved from previous observations that this 
orphan nuclear receptor is upregulated in the L T2 cell line following GnRH 
stimulation (33), as well as reports describing the role of Nur77 in activation of the 
proopiomelanocortin promoter in pituitary corticotropes (34).  The data in Chapter 4 
constitute the first account of the signaling mechanisms involved in mediating Nur77 
upregulation in either the T3-1 cell line or in differentiated gonadotropes in vivo.  
Use of our pituitary-specific ERK deficient mice confirms that Nur77 is an ERK 
dependent GnRH-responsive immediate early gene in vivo.   
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Our observations regarding the c-Raf independence of GnRH-induced ERK 
pathway activation raise interesting questions regarding the functional organization of 
the ERK pathway as well as the role(s) of c-Raf in these cells.  Reports in the literature 
on GnRH signaling frequently cite c-Raf as the canonical upstream MAPKKK of the 
ERK module in the gonadotrope (29, 30, 32, 35, 36); however scrutiny of this 
literature reveals little to no experimental evidence to support this notion.  GnRH 
stimulation does appear to induce raid phosphorylation and enhanced catalytic activity 
of c-Raf in gonadotropes (30, 37).  Therefore, it seems reasonable to hypothesize that 
c-Raf may play some role as a MAPKKK in these cells, perhaps in parallel with 
separate and sufficient pathway(s) linking the GnRHR to the ERK module.  Given the 
importance of ERK signaling for female fertility, it is perhaps not surprising that 
multiple redundant mechanisms of GnRH-induced ERK activation may have evolved.  
As with the pituitary-specific ERK deficient mouse, the pituitary-targeted c-Raf 
deficient model may provide a useful tool for further investigation of the role of c-Raf 
in the gonadotrope. 
 While our data on the upregulation of Nur77 in the gonadotrope provide 
insight into the signaling events that mediate the induction of this gene, the biological 
functions of Nur77 in these cells remain to be determined.  Interestingly, the proximal 
promoters of both the GSU and the GnRHRcontain monomeric Nur77 response 
sequences (NBRE), making these genes attractive candidates for evaluation as Nur77 
targets.  Indeed, preliminary observations from this lab indicate that overexpression of 
recombinant Nur77 in T3-1 cells led to the modest but significant dose-dependent 
activation of a luciferase reporter containing a 600 bp fragment of the proximal 
GnRHR promoter (S Bliss, unpublished observations).  This poses the intriguing 
possibility that Nur77 may play a role as a low-level transcriptional activator of this 
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important gonadotrope gene.  Attempts to clarify the role of Nur77 in the gonadotrope 
are ongoing. 
 
Summary 
The ERK signaling pathway is an important component of the intracellular 
signal transduction systems that mediate the effects of GnRH in the gonadotrope.  By 
combining basic cellular and genetic approaches, the studies presented here broaden 
our understanding of the importance of ERK signaling for the function of 
differentiated gonadotropes, and raise new questions regarding the organization of this 
pathway in these cells.  It is hoped that this incremental contribution to the broader 
field of gonadotrope biology may facilitate the development of more effective 
strategies for management of reproductive dysfunction. 
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